0001493152-23-012553.txt : 20230417 0001493152-23-012553.hdr.sgml : 20230417 20230417163547 ACCESSION NUMBER: 0001493152-23-012553 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230417 DATE AS OF CHANGE: 20230417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDONOVO THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001528172 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 452552528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55453 FILM NUMBER: 23824383 BUSINESS ADDRESS: STREET 1: 6320 CANOGA AVENUE STREET 2: 15TH FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 BUSINESS PHONE: (800) 489-4774 MAIL ADDRESS: STREET 1: 6320 CANOGA AVENUE STREET 2: 15TH FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 FORMER COMPANY: FORMER CONFORMED NAME: Hanover Portfolio Acquisitions, Inc. DATE OF NAME CHANGE: 20110920 FORMER COMPANY: FORMER CONFORMED NAME: Hanover Portfoliio Acquisitions, Inc. DATE OF NAME CHANGE: 20110817 10-K 1 form10-k.htm
0001528172 false FY 2 0001528172 2022-01-01 2022-12-31 0001528172 2022-06-30 0001528172 2023-04-17 0001528172 2022-12-31 0001528172 2021-12-31 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2022-12-31 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2021-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2021-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2021-12-31 0001528172 2021-01-01 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2020-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2020-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2020-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2020-12-31 0001528172 us-gaap:CommonStockMember 2020-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001528172 ENDV:SubscriptionReceivableMember 2020-12-31 0001528172 us-gaap:RetainedEarningsMember 2020-12-31 0001528172 2020-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2021-12-31 0001528172 us-gaap:CommonStockMember 2021-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001528172 ENDV:SubscriptionReceivableMember 2021-12-31 0001528172 us-gaap:RetainedEarningsMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001528172 ENDV:SubscriptionReceivableMember 2021-01-01 2021-12-31 0001528172 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001528172 ENDV:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001528172 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-12-31 0001528172 us-gaap:CommonStockMember 2022-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001528172 ENDV:SubscriptionReceivableMember 2022-12-31 0001528172 us-gaap:RetainedEarningsMember 2022-12-31 0001528172 ENDV:HanoverPortfolioAcquisitionsIncMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember 2022-12-31 0001528172 us-gaap:WarrantMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2021-12-31 0001528172 us-gaap:WarrantMember 2021-12-31 0001528172 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001528172 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2022-01-01 2022-12-31 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2022-01-01 2022-12-31 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-01-01 2021-12-31 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-01-01 2021-12-31 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2022-12-31 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2022-12-31 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2021-12-31 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2021-12-31 0001528172 us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2022-12-31 0001528172 us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2022-12-31 0001528172 us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2021-12-31 0001528172 us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2021-12-31 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-12-31 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-12-31 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2022-01-01 2022-12-31 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2021-01-01 2021-12-31 0001528172 us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0001528172 us-gaap:RoyaltyMember 2021-01-01 2021-12-31 0001528172 ENDV:RioGrandeNeurosciencesIncMember 2017-12-01 2017-12-31 0001528172 ENDV:NonRelatedPartiesMember 2022-12-31 0001528172 ENDV:FormerRelatedPartyMember 2022-12-31 0001528172 ENDV:OnePromissoryNotesMember 2022-12-31 0001528172 ENDV:OnePromissoryNotesMember 2022-01-01 2022-12-31 0001528172 ENDV:OnePromissoryNotesMember srt:MinimumMember 2022-12-31 0001528172 ENDV:OnePromissoryNotesMember srt:MaximumMember 2022-12-31 0001528172 ENDV:SevenFixedRateMember 2022-01-01 2022-12-31 0001528172 ENDV:FixedRatedNotesMember 2022-12-31 0001528172 ENDV:PastMaturityMember ENDV:FixedRatedNotesMember 2022-12-31 0001528172 ENDV:EighteenFixedRateMember 2022-12-31 0001528172 ENDV:SixteenFixedRateMember 2022-01-01 2022-12-31 0001528172 ENDV:EighteenFixedRateMember 2022-09-30 0001528172 ENDV:FixedRatedNotesMember 2022-01-01 2022-12-31 0001528172 ENDV:ConvertibleNotesMember 2022-12-31 0001528172 ENDV:OneVariableNoteMember 2022-12-31 0001528172 ENDV:EightFixedPromissoryNotesMember 2021-12-31 0001528172 ENDV:EightFixedPromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:FixedRatedNotesMember 2021-12-31 0001528172 ENDV:PastMaturityMember ENDV:FixedRatedNotesMember 2021-12-31 0001528172 ENDV:ThirteenFixedRatePromissoryNotesMember ENDV:UnrelatedPartiesMember 2021-12-31 0001528172 ENDV:NineFixedRatePromissoryNotesMember ENDV:UnrelatedPartiesMember 2021-12-31 0001528172 us-gaap:GainLossOnDerivativeInstrumentsMember ENDV:TwoPromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:OnePromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:ConvertibleNotesMember 2021-12-31 0001528172 ENDV:ConvertibleNotesMember ENDV:PastMaturityMember 2021-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember 2022-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember srt:MinimumMember 2022-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember srt:MaximumMember 2022-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember 2022-01-01 2022-12-31 0001528172 ENDV:NotesPayableMember ENDV:RelatedPartyMember 2022-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember 2021-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember srt:MinimumMember 2021-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember srt:MaximumMember 2021-12-31 0001528172 ENDV:NotesPayableMember ENDV:FormerRelatedPartyMember 2021-01-01 2021-12-31 0001528172 us-gaap:PrivatePlacementMember 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2015-08-01 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2022-12-31 0001528172 us-gaap:PrivatePlacementMember 2021-12-31 0001528172 ENDV:RioGrandeNeurosciencesIncMember us-gaap:IntellectualPropertyMember 2021-12-31 0001528172 ENDV:IntellectualPropertyRightsMember 2021-12-31 0001528172 ENDV:PreferredStockDesignatedMember 2022-12-31 0001528172 ENDV:SeriesAAMember 2022-12-31 0001528172 ENDV:PreferredSeriesBMember 2022-12-31 0001528172 ENDV:PreferredSeriesCMember 2022-12-31 0001528172 ENDV:PreferredSeriesDMember 2022-12-31 0001528172 ENDV:UndesignatedMember 2022-12-31 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-21 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2022-12-31 0001528172 ENDV:SeriesAAPreferredStockMember 2021-12-31 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-06 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001528172 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-21 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2020-01-28 2020-01-29 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2022-01-01 2022-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2019-11-11 0001528172 us-gaap:CommonStockMember 2022-09-26 2022-09-27 0001528172 2022-09-27 0001528172 2022-09-26 2022-09-27 0001528172 us-gaap:CommonStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001528172 ENDV:OneInvestorMember 2022-01-01 2022-12-31 0001528172 ENDV:PurchaseAgreementMember 2022-01-01 2022-12-31 0001528172 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001528172 ENDV:PromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:SecuritiesPurchaseAgreementMember 2021-01-01 2021-12-31 0001528172 ENDV:ConversionOfSeriesCPreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SettlementOfDebtMember 2021-01-01 2021-12-31 0001528172 ENDV:FormerRelatedPartyMember 2021-01-01 2021-12-31 0001528172 ENDV:ConsultingAgreementMember 2021-01-01 2021-12-31 0001528172 ENDV:IndependentContractorMember srt:MinimumMember 2022-01-01 2022-12-31 0001528172 ENDV:IndependentContractorMember 2022-12-31 0001528172 ENDV:IndependentContractorAgreementMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember 2020-12-31 0001528172 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001528172 ENDV:StockOptionsMember 2021-01-01 2021-12-31 0001528172 ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember ENDV:PriceRangeOneMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember ENDV:PriceRangeOneMember 2022-12-31 0001528172 ENDV:StockOptionsMember ENDV:PriceRangeTwoMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember ENDV:PriceRangeTwoMember 2022-12-31 0001528172 ENDV:StockOptionsMember ENDV:PriceRangeThreeMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember ENDV:PriceRangeThreeMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 us-gaap:WarrantMember 2020-12-31 0001528172 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001528172 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001528172 us-gaap:WarrantMember ENDV:PriceRangeOneMember 2022-01-01 2022-12-31 0001528172 us-gaap:WarrantMember ENDV:PriceRangeOneMember 2022-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2022-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2021-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2022-01-01 2022-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2021-01-01 2021-12-31 0001528172 ENDV:BlueRidgeConsultingLLCMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001528172 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001528172 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001528172 ENDV:BlueRidgeConsultingLLCMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001528172 ENDV:OneOfficerAndExecutiveMember 2022-12-31 0001528172 ENDV:OneOfficerAndExecutiveMember 2021-12-31 0001528172 ENDV:FormerPresidentMember 2022-12-31 0001528172 ENDV:FormerPresidentMember 2021-12-31 0001528172 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ENDV:OneSignificantCustomersMember 2022-01-01 2022-12-31 0001528172 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ENDV:TwoSignificantCustomersMember 2022-01-01 2022-12-31 0001528172 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ENDV:OneSignificantCustomersMember 2021-01-01 2021-12-31 0001528172 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ENDV:TwoSignificantCustomersMember 2021-01-01 2021-12-31 0001528172 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember ENDV:SupplierMember 2022-01-01 2022-12-31 0001528172 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ENDV:TwoCustomersMember 2021-01-01 2021-12-31 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2023-01-01 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember ENDV:ConsultingAgreementMember 2023-01-01 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-01-01 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember ENDV:SettlementAgreementMember 2023-01-01 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember ENDV:PurchaseAgreementMember 2023-01-01 2023-04-17 0001528172 us-gaap:SubsequentEventMember us-gaap:CommonStockMember srt:BoardOfDirectorsChairmanMember 2023-01-01 2023-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission file number: 000-55453

 

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   45-2552528

State or other jurisdiction of

incorporation or organization

  

(I.R.S. Employer

Identification No.)

     

6320 Canoga Avenue, 15th Floor

Woodland Hills, CA

   91367
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (800) 489-4774

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934: None.

 

Securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934:

 

Title of each class   Trading Symbol(s)   Name of principal U.S. market on which traded
Common stock, par value $0.0001   ENDV   OTCMKTS

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large-accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large-accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting common stock held by non-affiliates of the registrant was $1,128,567 as of the last business day of the fiscal quarter ended June 30, 2022, based on the closing price $0.0090 per share for the common stock on such date as traded on the OTCQB.

 

As of April 17, 2023, the registrant had 270,285,405 shares of common stock, par value $0.0001 per share, outstanding.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  PART I  
Item 1. Business. 4
Item 1A. Risk Factors. 10
Item 1B. Unresolved Staff Comments. 10
Item 2. Properties. 10
Item 3. Legal Proceedings. 10
Item 4. Mine Safety Disclosures. 10
     
  PART II  
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 11
Item 6. Selected Financial Data. 11
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 11
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 16
Item 8. Financial Statements and Supplementary Data. 17
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 40
Item 9A. Controls and Procedures. 40
Item 9B. Other Information. 43
     
  PART III  
Item 10. Directors, Executive Officers, and Corporate Governance. 43
Item 11. Executive Compensation. 45
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 46
Item 13. Certain Relationships and Related Transactions, and Director Independence. 46
Item 14. Principal Accounting Fees and Services. 47
     
  PART IV  
Item 15. Exhibits, Financial Statement Schedules. 48
     
SIGNATURES 50

 

2
 

 

FORWARD-LOOKING STATEMENTS

 

When used in this Report, the words “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “intend,” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding events, conditions and financial trends which may affect the Company’s future plans of operations, business strategy, operating results, and financial position. Such statements are not guarantees of future performance and are subject to risks and uncertainties and actual results may differ materially from those included within the forward-looking statements for various reasons.” Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required under federal securities laws and the rules and regulations of the United States Securities and Exchange Commission, the Company does not undertake, and specifically declines, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions, or otherwise.

 

This Report contains certain estimates and plans related to us and the industry in which we operate, which assume certain events, trends, and activities will occur and the projected information based on those assumptions. We do not know all of our assumptions are accurate. In particular, we do not know what level of acceptance our strategy will achieve, how many acquisitions we will be able to consummate or finance, or the size thereof. If our assumptions are wrong about any events, trends, or activities, then our estimates for future growth for our business also may be wrong. There can be no assurances any of our estimates as to our business growth will be achieved.

 

3
 

 

PART I

 

Item 1. Business.

 

Overview

 

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine.

 

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

 

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

 

Corporate History

 

Our predecessor company, Hanover Asset Management, Inc. was incorporated in November 2008 in California. For the purpose of reincorporating in Delaware, we merged with a newly incorporated successor company, Hanover Portfolio Acquisitions, Inc., in July 2011 under which we continue to operate.

 

IP Resources International, Inc. began operations on September 1, 2011, and was formally incorporated on October 17, 2011.

 

Reverse Acquisition

 

On March 14, 2012, we entered into a Share Exchange Agreement (“Agreement”) with IPR and certain of its shareholders. Under the Agreement, each participating IPR shareholder exchanged all of their issued and outstanding IPR common shares totaling 33,234,294, free and clear of all liens, and $155,000 for Company common shares equal to 1.2342 times the number of IPR shares being transferred to the Company for a total of 410 of our shares. The $155,000 was not paid at closing. The Company recorded the $155,000 as acquisition payable. IPR agreed to make payments of up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company.

 

As a result of the Agreement, the former shareholders of IPR, immediately post-acquisition owned approximately 89% of the Company and its officers and directors constituted the majority of the officers and directors of the Company. Since the shareholders, officers, and directors of IPR have control of the Company, the acquisition constitutes a reverse acquisition, so IPR was the accounting acquirer, and we were the accounting acquiree. For legal purposes, we are the legal parent and IPR is the legal subsidiary.

 

Acquisition of Aviva Companies Corporation

 

On April 2, 2013, the Company entered into an Acquisition Agreement (the “Acquisition Agreement”) with (i) The Aviva Companies Corporation (“Aviva”) and (ii) all of the shareholders of Aviva (the “Shareholders”) pursuant to which the Company acquired all of the outstanding shares of Aviva in exchange for the issuance of 60 shares of our common stock, par value $0.0001 per share to the Shareholders (the “Share Exchange”). As a result of the Share Exchange, Aviva became a wholly owned subsidiary of the Company.

 

Other than in respect to the transaction, there is no material relationship among Aviva’s stockholders and any of the Company’s affiliates, directors, or officers. We are not currently actively pursuing the development of the Aviva Companies Corporation.

 

4
 

 

Acquisition of WeHealAnimals, Inc.

 

On November 16, 2013, the Company entered into an Acquisition Agreement (the “Acquisition Agreement”) with (i) WeHealAnimals, Inc. (“WHA”) and (ii) the sole shareholder of WHA (the “Shareholder”) pursuant to which the Company acquired all of the outstanding shares of WHA in exchange for the issuance of 3 shares of our common stock, par value $0.0001 per share and $96,000 to the Shareholder (the “Share Exchange”). As a result of the Share Exchange, WHA became a wholly owned subsidiary of the Company and all of the equity of WHA including its and its sole shareholder’s intellectual property became the property of the Company. This obligation was fully paid on December 15, 2015, through the issuance of 350 shares of stock to Shareholder. WHA is a Nevada corporation with intellectual property in the fields of biotechnology, including its biologics and time-varying electromagnetic frequencies with potential applications on people and animals that management believes can be developed to the benefit of the Company and its shareholders. WHA’s sole shareholder was formerly Chairman and Chief Scientist of Regenetech, Inc. Regenetech was acquired by a company that wanted its technology, biomolecules grown in microgravity, for use in cosmetics. WHA’s sole shareholder left Regenetech with exclusive rights to this proprietary square wave form technology and stem cell technologies, including the patents and patent applications relating thereto.

 

Other than in respect to the transaction, there is no material relationship between WHA’s sole stockholder and any of the Company’s affiliates, directors, or officers.

 

Acquisition of Rio Grande Assets

 

On December 22, 2017, we acquired intellectual property and other assets (the “RGN Assets”) from Rio Grande Neurosciences, Inc. (RGN). The price was $4,500,000 of which we paid $3,000,000 in cash and delivered a $1,500,000 secured promissory note due November 30, 2018, and security agreement. Before such note was due, the note was assigned to Eagle Equities, LLC (“Eagle”) its due date was extended to November 30, 2019, and it was made convertible into our common stock at a price related to our common stock’s market price at the time of conversion. The maturity date was then extended to December 31, 2021. The RGN Assets relate to RGN’s PEMF portfolio of intellectual property, including 27 issued patents with foreign patent protection covering the therapeutic use of PEMF as well as the treatment of various central nervous system disorders. We intend to initiate and fund future clinical trials to evaluate the further use of PEMF in the treatment of central nervous system disorders, including traumatic brain injury, post-concussion syndrome, stroke, and multiple sclerosis. However, no assurance can be given that we will be successful in these endeavors or that the results of any tests will indicate further development of the RGN Assets.

 

The PEMF assets acquired include SofPulse®, a portable, disposable PEMF device with a CE Mark and an FDA 510(k) clearance for the treatment of post-surgical pain and edema in addition to medical reimbursement for the treatment of chronic wounds. Endonovo Therapeutics has begun the commercialization of the PEMF assets through marketing and the creation of various sales channels and distribution agreements.

 

Present Development Plans

 

We are currently a biotechnology company developing bioelectronic devices and cell therapies for regenerative medicine and a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices.

 

The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company’s non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

 

5
 

 

These bioelectronics devices are also commonly referred to as “electroceuticals.” These products are part of an emerging field termed “Bioelectronic Medicine,” that seeks to harness electrical signals in nerves and cells to alter the course of diseases and conditions. Whereas our competitors are primarily using implantable electrical nerve stimulators, we are developing devices that are not implantable and use electromagnetic pulses to deliver electrical stimulation to cells and tissues. We are developing these bioelectronic devices for the treatment of inflammatory conditions in tissues and vital organs with a concentration on vascular diseases and ischemia/reperfusion injuries.

 

The Company is negotiating with a major distribution partner in order to initiate the marketing of SofPulse® in South and Central America. Additionally, the Company is currently engaged in distribution discussions with recognized distribution partners in Australia, Europe, and various Southeast Asian markets. SofPulse® is completing the final stages of receiving regulatory clearance in Taiwan through Endonovo’s distribution partner Evermed Medical Enterprise, Ltd. Final Taiwan FDA approval is expected to be completed in the second half of 2023.

 

On December 13, 2022, the Company announced the launch of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options. The Endonovo Telehealth platform will provide direct-to-consumer sales of prescription uses of their SofPulse® Pulsed Electro Magnetic Fields (PEMF) medical device proven to reduce opioid use. This initiative is in the early stages and has not to date generated revenue.

 

Possible Additional Line of Business

 

The Company recently entered into a program to expand its operations through a program of acquisition of specialty construction and facilities maintenance companies. On September 27, 2022, the Company executed a definitive purchase agreement with Western Star Concrete LLC, a Texas concrete construction company located in the Dallas, Texas area. No consideration was transferred, or shares issued with respect to the definitive purchase agreement as of December 31, 2022. There have been no changes to this date.

 

The Company plans to initiate a spin-off of its medical device assets to SofPulse, Inc., a new Company, which was formed by Endonovo and will be transferred to our President and Chief Commercial Officer of the Company’s medical division, Ira Weisberg. Ira Weisberg will be responsible for running SofPulse, Inc. independently from Endonovo and will develop commercialization initiatives through sales and marketing channels for SofPulse, Inc. utilizing the SofPulse® medical assets.

 

Intellectual Property:

 

SofPulse: We have 29 issued patents with foreign patent protection covering the therapeutic use of tPEMF as well as the treatment of various central nervous system disorders. Additionally to date, we have filed seven patent applications in the U.S. through the U.S. Patent and Trademark Office (USPTO) and four international patent applications in the E.U., China, South Korea and Japan covering our Time-Varying Electromagnetic Field (TVEMF) technology, the production of biomolecules, the creation of an allogeneic mesenchymal stem cell product a treatment for chemical and radiation injuries, production of stem cell secretome and a method of treating tissues and organs using our TVEMF technology. To date, we have been granted one U.S. Patent (U.S. Patent No. 9,410,143) issued on August 9, 2017, covering the production of human biomolecules using our TVEMF technology. We will continue to seek to strengthen our portfolio of intellectual property by filing additional patents around uses of our core technologies.

 

Our business strategy is aimed at building value by positioning each of our technologies and therapies to treat specific diseases that lack effective treatment, post-operative pain and edema, or whose current standard of treatment involves invasive procedures and/or potentially harmful side effects. We anticipate updating and refining the business strategy as new medical and/or clinical advancements are made as a result of extensive research and development. In general, the component functions of the business model are to:

 

  ● Commercialize our FDA cleared technology through direct sales, distributors, and licensees;
     
  ● License our technologies;
     
  ● Develop additional medical indications for our medical devices;

 

6
 

 

  ● Develop additional non-invasive, medical technologies;
     
  ● Conduct pre-clinical and clinical human studies for FDA Approval of our medical devices and cell therapies;
     
  ● Acquire subsidiaries under the parent company, Endonovo Therapeutics, to assist in the development and distribution of medical technologies;
     
  ● Incrementally invest, market, and refine acquired and developed medical technologies and therapies.

 

Industry Overview

 

Bioelectrical Medicine within the Healthcare Industry

 

The healthcare industry is one of the world’s largest and fastest-growing industries. Consuming over 10 percent of Gross Domestic Product (GDP) of most developed nations, health care can form an enormous part of a country’s economy.

 

As of 2016, 91.1% of residents had health protection in the United States, either through their employer or bought individually. During 2016, healthcare costs reached $3.3 trillion, or $10,348 per person. The share of U.S. GDP devoted to healthcare was 17.9% of U.S. Gross Domestic Product (GDP), the largest of any country in the world. Specifically, the cost of pharmaceuticals in the United States is the highest on the planet. It is expected that Healthcare’s share of U.S. GDP will continue its upward trend, reaching 20 percent of U.S. GDP by 2025. Globally, by 2040, Healthcare spending is expected to exceed $18 Trillion annually.

 

Bio-Electrical Medicine is a $17.2 Billion sector of the Healthcare Industry growing at more than a 11% CAGR estimated to exceed $35.5 Billion by 2025, according to Grand View Research. Bioelectric medicine is at the forefront of technological revolution in medical sciences. As opposed to the pharmaceutical industry, bioelectric medicine has a different treatment therapy that is based on electrical pulses instead of drugs to trigger the body’s recovery capabilities. Bioelectric medicine develops nerve stimulating and sensors activation technologies to regulate biological functions and treat diseases by combining bioengineering, neuroscience, molecular medicines and electronics. These technologies may change the future of therapies for wide range of diseases.

 

On the basis of type of device, the global Electroceuticals®/Bioelectrical Medicine Market is classified into two major classes:

 

  Ø Implantable Electroceuticals® Devices, and
     
  Ø Non-invasive Electroceuticals® Devices.

 

BioElectric Medicine vs. Drug Therapies

 

Over the past 15 years, long-acting and extended-release opioids have been used to treat open wounds, post-operative wounds and chronic pain. These opioids are normally administered at high doses and over long treatment durations particularly in the United States, resulting in a drastic increase in the number opioid-tolerant individuals and a prescription opioid abuse epidemic. Endonovo offers an alternative, non-opioid treatment through its Electroceuticals® systems: The Company’s SofPulse® system is a medical device/designed to rapidly reduce post-operative swelling/edema, pain and to treat and accelerate the recovery of chronic wounds through the use of tPEMF. Chronic pain therapy via tPEMF works by relieving the underlying cause of pain – inflammation.

 

Drug therapies remain the standard of care for a broad range of medical conditions, including high blood pressure, chronic pain, autoimmune diseases, and psychiatric disorders. Management believes that bioelectronic medicine has developed as a viable alternative for the treatment of many disorders.

 

7
 

 

Normally, our nervous systems send signals to our tissues and organs to suppress inflammation, a phenomenon known as the inflammatory reflex. But sometimes, this system does not work properly, with malfunctions resulting in diseases like rheumatoid arthritis and inflammatory bowel disease. Traditionally, doctors have treated these diseases using drugs designed to suppress inflammation, such as infliximab (trade name Remicade) or adalimumab (Humira). But these drugs are expensive. Plus, they don’t work for everyone, often come with nasty side effects, and in some rare cases, they can even kill.

 

Current Product Being Sold – SofPulse®

 

 

 

In clinical trials, the SofPulse® device has proven to reduce mean pain scores by nearly 300% and inflammation by 275% thereby improving and reducing recovery time. Additionally, active patients have experienced a 2.2-fold reduction in narcotic use. The SofPulse® delivers tPEMF to enhance post-surgical recovery, naturally. Since the SofPulse® is non-invasive and non-pharmacologic, there are no known side effects and no potential for overdose or dependency AND no effects on healthy tissue.

 

How the SofPulse® Works

 

SofPulse® delivers low intensity microcurrents of energy directly to the procedure site, to enhance recovery, by increasing the amount of naturally occurring Vascular Endothelial Growth Factor (VEGF), thereby increasing the physiological process through which new blood vessels form from pre-existing vessels (Angiogenesis). Within hours/days, the Fibroblast Growth Factor (FGF) enhances, thereby increasing the production of Collagen/Granulation (within days) and Transforming Growth Factor (TGF-β) accelerating Remodeling in the body within days/weeks. This device reduces inflammation and speeds/improves the healing process. The natural healing process allows patients to get back to life faster with lowered use of narcotics. A surgeon places and activates SofPulse® immediately after a procedure. The SofPulse® can be placed over a surgical dressing or clothing and can easily be applied and/or removed in many cases by the patient themselves. The length of time the device is used will vary depending on the type of procedure.

 

8
 

 

 

 

The SofPulse® allows patients to get back to an active life faster with less use of narcotics.

 

  Ø Immediately Usable and Effective - Single use patient device applied immediately after surgery.
  Ø Easy to Use - SofPulse® can easily be applied and or removed, including in many cases by the patient themselves
  Ø Automated Dosing - Device is activated automatically or can be used as needed
  Ø Versatile - The product comes as a single device or dual device to accommodate different surgical procedures

 

Manufacturing

 

Our SofPulse® device is manufactured for us by ADM Tronics, Inc. in an FDA approved facility in Northvale, New Jersey.

 

Sales & Marketing

 

Endonovo’s strategy is to establish relationships with third parties, such as sales organizations, distributors, and marketing coordinators, that assist us in developing, marketing, selling, and implementing our products. In addition, Endonovo is establishing an aggressive presence in the social media ecosystem in order to initiate direct to consumer sales.

 

We believe that strategic and technology-based relationships with consumers, ambulatory surgical centers and medical facilities are fundamental to our success. We have forged numerous relationships with medical device distributors to enhance our combined capabilities. This approach enhances our ability to accelerate market penetration, accelerate the pace of our sales growth and solidify relationships.

 

We have a variety of marketing programs designed to create brand awareness and market recognition for our product offerings and for sales lead generation. Our marketing efforts include attending and presenting at healthcare related conferences, advertising, content development and distribution, public relations, social media publication of technical and informative articles in industry journals and sales training.

 

9
 

 

In addition, our strategic partners augment our marketing and sales campaigns through seminars, trade shows and joint public relations and advertising campaigns. Our customers and strategic partners provide references and recommendations that we often feature in external marketing activities.

 

The Company is also developing a wide-ranging list of brand ambassadors to bring focus and to increase awareness of the benefits of SofPulse® into the consumer markets.

 

Endonovo also is utilizing Key Opinion Leaders (KOLs) and Scientific Advisory Board Members (SABs) within the medical community to develop a sales-channel recommendation to other physicians/surgeons.

 

Competition

 

The pain management market is intensely competitive, highly fragmented and characterized by rapidly changing technology and drugs. We currently compete with other medical device manufacturers as well as pharmaceutical companies that have developed drugs many which are considered addictive.

 

Employees

 

The Company does not have any employees. However, we have retained approximately nine (9) individuals as independent contractors that are involved in business development, sales, and administrative functions.

 

Item 1A. Risk Factors.

 

Not applicable because we are a smaller reporting company.

 

Item 1B. Unresolved Staff Comments.

 

Not applicable because we are a smaller reporting company.

 

Item 2. Properties.

 

We have one office located in Southern California. We believe such office is adequate for our present needs.

 

Item 3. Legal Proceedings.

 

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of December 31, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

10
 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock trades on the OTCQB under the symbol “ENDV”. The OTCQB is a quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter (“OTC”) equity securities. An OTCQB equity security generally is any equity that is not listed or traded on a national securities exchange. Our stock is thinly traded, and a robust, active trading market may never develop. The market for the Company’s common stock has been limited, volatile, and sporadic.

 

Price Range of Common Stock

 

The following table shows, for the periods indicated, the high and low closing prices per share of our common stock as reported by the OTCQB quotation service.

 

   Closing Price 
   High   Low 
         
Year Ended December 31, 2021          
First Quarter  $0.10   $0.02 
Second Quarter  $0.04   $0.02 
Third Quarter  $0.06   $0.01 
Fourth Quarter  $0.04   $0.02 
           
Year Ended December 31, 2022          
First Quarter  $0.02   $0.02 
Second Quarter  $0.02   $0.01 
Third Quarter  $0.01   $0.01 
Fourth Quarter  $0.02   $0.01 

 

Approximate Number of Equity Security Holders

 

As of April 14, 2023, there were approximately 424 stockholders of record. Because shares of our common stock are held by depositaries, brokers and other nominees, the number of beneficial holders of our shares is substantially larger than the number of stockholders of record.

 

Dividends

 

Holders of our common stock are entitled to receive dividends if, as and when declared by the Board of Directors out of funds legally available. We have never declared or paid any dividends on our common stock. We intend to retain any future earnings for use in the operation and expansion of our business. Consequently, we do not anticipate paying any cash dividends on our common stock to our stockholders for the foreseeable future.

 

Item 6. Selected Financial Data.

 

Not applicable because we are a smaller reporting company. 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. The information and financial data discussed below is only a summary and should be read in conjunction with the historical financial statements and related notes contained elsewhere in this 10-K. The financial statements contained elsewhere in this 10-K fully represent the Company’s financial condition and operations; however, they are not indicative of the Company’s future performance. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this 10-K.

 

11
 

 

Cautionary Notice Regarding Forward Looking Statements

 

The information contained in Item 2 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

 

This filing contains a number of forward-looking statements which reflect management’s current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this filing other than statements of historical fact, including statements addressing operating performance, events, or developments which management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, adequacy of funds from operations, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “may,” variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

 

Readers should not place undue reliance on these forward-looking statements, which are based on management’s current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this filing. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in prior filings, in press releases and in other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Critical Accounting Policies and Estimates

 

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below.

 

Impairment of Other Intangible and Long-Lived Assets

 

The Company accounts for its intangible assets under the provisions of ASC 350, “Intangibles - Goodwill and Other”. In accordance with ASC 350, intangible assets with a definite life are analyzed for impairment under ASC 360-10-05 “Property, Plant and Equipment” and intangible assets with an indefinite life are analyzed for impairment under ASC 360 annually, or more often if circumstances dictate. The Company performs its annual simplified impairment test in the fourth quarter of each year. The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value.

 

12
 

 

Use of estimates

 

Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. The significant estimates were made for the fair value of common stock issued for services, with notes payable arrangements, in connection with note extension agreements, and as repayment for outstanding debt, in estimating the useful life used for depreciation and amortization of our long-lived assets, in the valuation of the derivative liability, and the valuation of deferred income tax assets. Actual results and outcomes may differ from management’s estimates and assumptions.

 

Recently Issued Accounting Pronouncements

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company’s financial statements.

 

Results of Operations Year Ended December 31, 2022, vs. Year Ended December 31, 2021

 

   Year Ended December 31,   Favorable     
   2022   2021   (Unfavorable)   % 
                 
Revenue  $135,355   $73,105    62,250    85.2 
Cost of revenue   9,990    14,985    4,995    33.3 
Gross profit   125,365    58,120    67,245    115.7 
                     
Operating expenses   3,389,705    2,284,667    (1,105,038)   (48.4)
                     
Loss from operations   (3,264,340)   (2,226,547)   (1,037,793)   (46.6)
                     
Other expense   (15,210,495)   (878,347)   (14,332,148)   (1,631.8)
                     
Net loss  $(18,474,835)  $(3,104,894)  $(15,369,941)   (495.0)

 

Revenue

 

Revenue of the Company’s SofPulse® product during the current year increased by $62,250 or 85.2% compared to the previous year.

 

Revenues for sales of our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. During the year ended December 31, 2022, the Company also recognized $113,620 in royalty/licensing revenue from a former related party.

 

We anticipate that revenue will increase in future periods as the roll out of the SofPulse® product continues. The Company is looking to partner with global participants in the medical device market to spur its expansion. The Company expects such investment alternatives to include partnerships, joint ventures, distribution, and licensing agreements for the PEMF medical technology. The Company also look to expand on current initiatives with the Department of Defense, the Department of Veterans Affairs, and other surgical and pain management markets.

 

Cost of Revenue

 

Cost of revenue decreased by $4,995 or 33.3% from the previous year to $9,990 during the current year compared to $14,985 during the previous year. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue. It is anticipated that cost of revenue will increase in future periods as the roll out of the SofPulse® product continues.

 

13
 

 

Operating Expenses

 

Our operating expenses increased by $1,105,038 or 48.4% to $3,389,705 in 2022 compared to $2,284,667 in 2021. The operating expenses were comprised primarily of consulting fees, professional fees, and stock-based compensation. This change was due primarily to an increase in stock-based compensation of approximately $1.2 million.

 

Depreciation and Amortization

 

We incur depreciation and amortization expenses for costs related to our patents. Our depreciation and amortization expense was $646,912 in 2022 compared to $648,492 in 2021. The Company has not impaired its finite-lived intangible as of December 31, 2022 and 2021.

 

Other Expense

 

Other expense was $15,210,495 in 2022 compared to $878,347 in 2021. Other Expense includes interest expense, change in fair value of derivative liability, amortization of debt issuance cost, gain on extinguishment of debt and make-good expense.

 

The increase in other expense during our fiscal year 2022 was primarily the result of re-valuation of the derivative liability embedded in the convertible notes issued with variable conversion rates. The Change in fair value of the Company’s derivative liability resulted in an expense of $14 million in 2022 compared to a gain of approximately $41,000 in 2021, resulting from changes to the inputs to the fair value option pricing model. The Company also incurred an increase in interest expense of approximately $380,000 and approximately $225,000 of additional expenses attributed to the make good provision embedded in the fixed rate convertible notes, offset by an increase of approximately $340,700 of gain from debt extinguishment in 2022.

 

Liquidity and Capital Resources

 

   As of December 31,   Increase 
   2022   2021   (Decrease) 
Working Capital               
                
Current assets  $15,822   $94,855   $(79,033)
Current liabilities   33,381,760    17,701,710    15,680,050 
Working capital deficit  $(33,365,938)  $(17,606,855)  $15,759,083 
                
Long-term debt  $79,825   $79,825   $- 
                
Stockholders’ deficit  $(32,180,319)  $(15,774,324)  $16,405,995 

 

   For Years Ended December 31,   Increase 
   2022   2021   (Decrease) 
Statements of Cash Flows Select Information               
                
Net cash provided (used) by:               
Operating activities  $(678,838)  $(986,584)  $(307,746)
Financing activities  $593,000   $1,059,100   $(466,100)

 

   As of December 31,   Increase 
   2022   2021   (Decrease) 
Balance Sheet Select Information               
                
Cash  $98   $85,936   $(85,838)
                
Accounts payable and accrued liabilities  $8,869,451   $7,078,283   $1,791,168 

 

14
 

 

Since January 2022 and through December 31, 2022, the Company has raised approximately $0.6 million in equity and debt transactions. These funds have been used to advance the operations of the Company, build its bio-medical platform, and general corporate development. Our accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. However, the Company has incurred substantial losses. Our current liabilities exceed our current assets and available cash is not sufficient to fund the expected future operations. The Company is raising additional capital through debt and equity securities to continue the funding of its ongoing operations and fund the various business initiatives. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from sales and future license agreements, and also in February 2023 secured a reseller agreement with Academy Medical, Inc., a Service-Disabled Veteran-Owned Small Business, thereby providing priority procurement benefits to the Company. The relationship with Academy Medical is intended ensure availability of SofPulseâ to the Veterans Health Administration (VHA) and Department of Defense (DoD). To date no revenue has been realized under this contract. The Company is also continuing its efforts to raise capital through the sale of its common stock and has engaged an Investment Banker to raise additional capital. Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. Our cash on hand at December 31, 2022 was less than $1,000. This will not be sufficient to fund operations if additional capital is not raised. The Company raised an aggregate of $0.225 million through the sale of equity and debt securities since January 1, 2023, through the date of this report.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K, obligations under any guaranteed contracts or contingent obligations. We also have no other commitments, other than the costs of being a public company that will increase our operating costs or cash requirements in the future.

 

Seasonality

 

Management does not believe that our current business segment is seasonal to any material extent.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

We do not have in effect any compensation plans under which our equity securities are authorized for issuance.

 

15
 

 

Unregistered Sales of Equity Securities

 

During the year ended December 31, 2022, we issued the following unregistered equity securities:

 

Number of       
Common Shares  Source of    
Issued  Payment  Amount 
25,850,000  Conversion of notes and accrued interest  $517,000 
2,428,777  Settlement of debt  $46,147 
66,500,000  Services  $1,316,900 
3,450,000  Commitment shares  $46,793 
15,000,000  Issuance for cash  $142,000 
25,500,000  Conversion of preferred stock  $- 

 

The above issuances were exempt from registration pursuant to Section 4(2), and/or Regulation D promulgated under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance of securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a Smaller Reporting Company (“SRC”) and are not required to provide the information under this item.

 

16
 

 

Item 8. Financial Statements and Supplementary Data.

 

ENDONOVO THERAPEUTICS, INC.

AND SUBSIDIARIES

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm (PCAOB ID No: 468) 18
Consolidated Balance Sheets for December 31, 2022 and 2021 20
Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021 21
Consolidated Statements of Stockholders’ Deficit for the Years Ended December 31, 2022 and 2021 22
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021 24
Notes to Consolidated Financial Statements for the Years Ended December 31, 2022 and 2021 25

 

17
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders

Endonovo Therapeutics, Inc. and Subsidiaries

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Endonovo Therapeutics, Inc. and Subsidiaries (the Company) as of December 31, 2022 and 2021, and the related statements of operations, shareholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes to the consolidated financial statements (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Explanatory Paragraph – Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has continued to incur significant operating losses and negative cash flows from operations, during the year ended December 31, 2022, and has negative working capital at December 31, 2022. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

18
 

 

Instruments with Embedded Conversion Features

 

Description of the Matter

 

As discussed in Note 1 to the Consolidated Financial Statements, the Company issues instruments with embedded conversion features. Some of these embedded conversion features result in a derivative liability that is measured at fair value.

 

Auditing derivative liability is complex and highly judgmental due to the variability and uncertainty associated with the Company’s assessment of estimates used in calculating the value of the derivative liability. Changes in these estimates would have a significant effect on the valuation of the derivative liability and the related change in fair value of derivative liability.

 

How We Addressed the Matter in Our Audit

 

To test the derivative liability, our audit procedures included, among others, evaluating the appropriateness of the Company’s accounting policy for instruments with embedded conversion features and the estimates and assumptions used in calculating the fair value of the derivative liability. We evaluated whether the methods used to calculate the fair value of the derivative liability were applied consistently. We also tested the completeness and accuracy of the underlying data used for the fair value measurement.

 

/s/ Rose, Snyder & Jacobs LLP

 

We have served as the Company’s auditor since 2008.

 

Encino, CA

April 17, 2023

 

19
 

 

Endonovo Therapeutics, Inc. and Subsidiaries

Consolidated Balance Sheets

As of December 31,

 

   2022   2021 
ASSETS          
Current Assets:          
Cash  $98   $85,936 
Accounts receivable, net   -    944 
Prepaid expenses and other current assets   15,724    7,975 
Total current assets   15,822    94,855 
           
Patents, net   1,265,444    1,912,356 
Total assets  $1,281,266   $2,007,211 
           
LIABILITIES AND SHAREHOLDERS’ DEFICIT          
Current Liabilities          
Accounts payable and accrued liabilities  $884,195   $658,463 
Accrued interest   3,542,650    2,528,459 
Deferred compensation   4,442,606    3,891,361 
Notes payable, net of discounts of $10,587 and $75,800 as of December 31, 2022 and 2021, respectively   7,041,145    7,055,030 
Notes payable – former related party   112,100    126,100 
Derivative liability   17,359,064    3,442,297 
Total current liabilities   33,381,760    17,701,710 
           
Other long term liabilities   79,825    79,825 
Total liabilities   33,461,585    17,781,535 
COMMITMENTS AND CONTINGENCIES, note 8   -    - 
Shareholders’ deficit          
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at December 31, 2022 and December 31, 2021   25    25 
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized and 600 issued and outstanding at December 31, 2022 and December 31, 2021   1    1 
Series C convertible preferred stock, $0.0001 par value, 8,000 shares authorized, 738 shares issued and outstanding at December 31, 2022 and December 31, 2021   -    - 
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized and 50 and 305 issued and outstanding at December 31, 2022 and December 31, 2021, respectively   -    - 
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; and 213,227,538 and 74,498,761 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively   21,322    7,449 
Additional paid-in capital   42,919,086    40,663,187 
Stock subscriptions   (1,570)   (1,570)
Accumulated deficit   (75,119,183)   (56,443,416)
Total shareholders’ deficit   (32,180,319)   (15,774,324)
Total liabilities and shareholders’ deficit  $1,281,266   $2007,211 

 

See accompanying summary of accounting policies and notes to consolidated financial statements.

 

20
 

 

Endonovo Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Operations

For the Years Ended December 31,

 

   2022   2021 
         
Revenue  $135,355   $73,105 
Cost of revenue   9,990    14,985 
Gross profit   125,365    58,120 
           
Operating expenses   3,389,705    2,284,667 
Loss from operations   (3,264,340)   (2,226,547)
           
Other income (expense)          
Change in fair value of derivative liability   (14,026,546)   41,057 
Gain on extinguishment of debt   362,894    22,162 
Other expense   (225,268)   - 
Interest expense, net   (1,321,575)   (941,566)
Total other expense   (15,210,495)   (878,347)
           
Loss before income taxes   (18,474,835)   (3,104,894)
           
Provision for income taxes   -    - 
           
Net loss  $(18,474,835)  $(3,104,894)
           
Basic and diluted loss per share  $(0.13)  $(0.05)
Weighted average common share outstanding:          
Basic and diluted   139,206,511    59,836,620 

 

See accompanying summary of accounting policies and notes to consolidated financial statements.

 

21
 

 

Endonovo Therapeutics, Inc. and Subsidiaries

Consolidated Statement of Shareholders’ Deficit

For the Years Ended December 31, 2022 and 2021

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Receivable   Deficit   Deficit 
   Series AA   Series B
Convertible		   Series D
Convertible		   Series C
Convertible		           Additional           Total 
   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Common Stock   Paid-in   Subscription   Accumulated   Shareholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Receivable   Deficit   Deficit 
Balance December 31, 2020   25,000   $25    600   $1    305   $-    763    -    24,536,689   $2,453   $38,963,827   $(1,570)  $(53,338,522)  $(14,373,786)
Issuance of commitment shares in connection with promissory notes   -       -    -       -    -       -       -       -    7,868,668    787    221,905    -    -    222,692 
Common stock issued for cash   -    -    -    -    -    -    -    -    7,000,000    700    125,300    -    -    126,000 
Shares issued for conversion of notes payable and accrued interest   -    -    -    -    -    -    -    -    27,461,307    2,746    1,115,244    -    -    1,117,900 
Shares issued for conversion of Preferred Series C to common share   -    -    -    -    -    -    (25)   -    1,111,111    111    (111)   -    -    - 
Common shares issued for debt settlement   -    -    -    -    -    -    -    -    1,515,152    151    57,576    -    -    57,727 
Common shares issued as settlement of debt with former related party   -    -    -    -    -    -    -    -    2,505,834    251    84,446    -    -    84,697 
Common shares issued pursuant to consulting agreements   -    -    -    -    -    -    -    -    2,500,000    250    95,000    -    -    95,250 
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    (3,104,894)   (3,104,894)
Balance December 31, 2021   25,000    25    600    1    305    -    738    -    74,498,761    7,449    40,663,187    (1,570)   (56,443,416)   (15,774,324)

 

22
 

 

Endonovo Therapeutics, Inc. and Subsidiaries

Consolidated Statement of Shareholders’ Deficit

For the Years Ended December 31, 2022 and 2021

 

   Series AA   Series B
Convertible		   Series D
Convertible		   Series C
Convertible		           Additional           Total 
   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Common Stock   Paid-in   Subscription   Accumulated   Shareholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Receivable   Deficit   Deficit 
Balance December 31, 2021   25,000   $25    600   $   1    305   $  -    738      -    74,498,761   $    7,449   $40,663,187   $(1,570)  $(56,443,416)  $(15,774,324)
Issuance of Commitment shares in connection with promissory notes   -    -    -    -    -    -    -    -    3,450,000    345    46,448    -    -    46,793 
Common Stock issued for cash   -    -    -    -    -    -    -    -    15,000,000    1,500    140,500    -    -    142,000 
Shares issued for conversion of notes payable and accrued interest   -    -    -    -    -    -    -    -    25,850,000    2,585    514,415    -    -    517,000 
Shares issued for conversion of Preferred Series D to common share   -    -    -    -    (255)   -    -    -    25,500,000    2,550    (2,550)   -    -    - 
Inducement loss related to conversion of preferred stock   -    -    -    -    -    -    -    -    -    -    200,932         (200,932)   - 
Common Shares issued from debt settlement   -    -    -    -    -    -    -    -    2,428,777    243    45,904    -    -    46,147 
Common Shares issued for services   -    -    -    -    -    -    -    -    66,500,000    6,650    1,310,250    -    -    1,316,900 
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    (18,474,835)   (18,474,835)
Balance December 31, 2022   25,000   $25    600   $1    50    -    738    -    213,227,538    21,322    42,919,086    (1,570)   (75,119,183)   (32,180,319)

 

See accompanying summary of accounting policies and notes to consolidated financial statements.

 

23
 

 

Endonovo Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

For the Years Ended December 31,

 

   2022   2021 
Operating activities:          
Net loss  $(18,474,835)  $(3,104,894)
Adjustments to reconcile net loss to cash used in operating activities:          
Depreciation and amortization expense   646,912    648,492 
Bad debt expense   944    - 
Stock-based compensation   45,000    - 
Fair value of commitment shares issued with debt   7,698    70,970 
Fair value of equity issued for services   1,311,900    95,250 
Amortization of note discount and original issue discount   110,611    144,196 
Change in fair value of derivative liability   14,026,546    (41,057)
Gain on extinguishment of debt   (362,894)   (22,162)
Changes in assets and liabilities:          
Accounts receivable   -    (2)
Prepaid expenses and other current assets   (7,750)   23,850 
Accounts payable and accrued liabilities   269,391    (42,470)
Accrued interest   1,196,394    733,999 
Deferred compensation   551,245    507,244 
Net cash used in operating activities   (678,838)   (986,584)
           
Financing activities:          
Proceeds from the issuance of notes payable   465,000    950,000 
Repayments on former related party advances   (14,000)   (16,900)
Proceeds from issuance of common stock and units   142,000    126,000 
           
Net cash provided by financing activities   593,000    1,059,100 
           
Net increase (decrease) in cash   (85,838)   72,516 
Cash, beginning of year   85,936    13,420 
Cash, end of year  $98   $85,936 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 
Non-Cash Investing and Financing Activities:          
Conversion of notes payable and accrued interest to common stock  $517,000   $493,748 
Conversion of Preferred stock to common stock  $255,000   $33,333 
Original debt discount on convertible notes  $45,398   $- 
Issuance of common stock to settle debt  $-   $202,697 

 

See accompanying summary of accounting policies and notes to consolidated financial statements.

 

24
 

 

Endonovo Therapeutics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

For the Years Ended December 31, 2022 and 2021

 

Note 1 - Nature of Business and Summary of Significant Accounting Policies

 

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

 

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of inflammation on and in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

 

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

 

On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.

 

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, WeHealAnimals, Inc. and SofPulse, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.

 

Going Concern

 

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has accumulated losses of $75.1 million, negative cash flows from operations of approximately $0.7 million and $33.4 million of working capital deficit. The Company has raised approximately $0.6 million in debt and equity financing for the year ended December 31, 2022. The Company is raising additional capital through debt and/or equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential future license and distribution agreements, has raised capital through the issuance of promissory notes and has engaged a broker/dealer to raise additional capital.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

 

25
 

 

Cash and cash equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2022 and 2021, the Company does not hold any cash in excess of FDIC limits and does not have any cash equivalents.

 

Accounts Receivable

 

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at December 31, 2022 and 2021. Account receivables are written off when all collection attempts have failed.

 

Impairment of Long-lived Assets

 

The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. The Company did not recognize any impairment loss during the years ended December 31, 2022 and 2021.

 

Equity-Based Compensation

 

The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method.

 

Income Taxes

 

The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.

 

Net Loss per Share

 

Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

 

The Company has 3,012,410 stock options, of which 262,410 are exercisable and 2,000 warrants convertible into an equivalent number of common stock as of December 31, 2022. The Company has 513,730 stock options, of which 513,730 are exercisable and 22,200 warrants convertible into an equivalent number of common stock as of December 31, 2021.

 

As of December 31, 2022 and 2021, the Company has variable rate convertible notes in an aggregate amount of $7,039,832 and $6,442,035, respectively, including principal and accrued interest, which are convertible into 1,355,310,243 and 632,789,106, respectively, shares of common stock. Such shares are not included in the calculation of the diluted net loss per share as they would have an antidilutive effect.

 

26
 

 

Fair Value of Financial Instruments

 

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

 

The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

 

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

 

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: uses unobservable inputs that are not corroborated by market data.

 

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operation.

 

The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:

 

   Fair Value Measurements at December 31, 2022 Using 
   Quoted Prices in
Active
Markets for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $-   $-   $17,359,064   $17,359,064 
Total  $      -   $          -   $17,359,064   $17,359,064 

 

   Fair Value Measurements at December 31, 2021 Using 
   Quoted Prices in
Active
Markets
for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $        -   $            -   $3,442,297   $3,442,297 
Total  $-   $-   $3,442,297   $3,442,297 

 

27
 

 

The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:

 

   Derivative 
   Liability 
Balance December 31, 2020  $4,202,597 
      
Settlement by debt extinguishment   (133,386)
Settlement by debt conversion   (585,857)
Change in estimated fair value   (41,057)
      
Balance December 31, 2021  $3,442,297 
      
Settlement by debt Extinguishment   (109,779)
Change in estimated fair value   14,026,546 
      
Balance December 31, 2022  $17,359,064 

 

Derivative Liability

 

As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:

 

      For Years Ending December 31,  
      2022       2021  
                 
Expected term     0-1 month       1 -4 months  
Exercise price     $0.004-$0.015       $0.01-$0.03  
Expected volatility     153%-169%       177%-206%  
Expected dividends     None       None  
Risk-free interest rate     1.63%-4.73%       0.06%-0.39%  
Forfeitures     None       None  

 

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

 

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

 

28
 

 

Recent Accounting Standard Updates

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company’s financial statements.

 

Note 2 - Revenue Recognition

 

Contracts with Customers

 

We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

 

We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, we have an unconditional right to receive payment. Our sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.

 

Revenues for sales of our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.

 

In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

 

During the years ended December 31, 2022 and 2021, we recognized revenue of $135,355 and $73,105, respectively, from SofPulse® devices.

 

Sources of Revenue

 

We have identified the following revenues disaggregated by revenue source:

 

1.Sales to plastic surgeons
2.Sales to wound care facilities
3.Sales to hospitals
4.Sales to other physicians
5.Royalty fee from licensing, net

 

29
 

 

For the years ended December 31, 2022 and 2021, the sources of revenue were as follows:

 

   2022   2021 
   Years Ended 
   December 31, 
   2022   2021 
         
Direct sales- Plastic surgeons, gross   21,732    73,105 
Royalty/licensing, net   113,623    - 
Total sources of revenue  $135,355   $73,105 

 

The royalty/licensing revenue recognized in 2022 resulted from specific transactions. No general patent rights were assigned to the distributor. The revenue recognized was based on the number of items included in the transactions.

 

Warranty

 

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

 

Significant Judgments in the Application of the Guidance in ASC 606

 

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

 

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

 

Practical Expedients

 

Our payment terms for sales direct to distributors, end users, hospitals and doctors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

 

Effective Date and Transition Disclosures

 

Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

 

Note 3 – Patents

 

In December 2017, we acquired from RGN a patent portfolio for $4,500,000. The earliest patent expires in 2024.

 

The following is a summary of patents less accumulated amortization at December 31, 2022 and 2021:

 

 

   2022   2021 
   December 31, 
   2022   2021 
         
Patents  $4,500,000   $4,500,000 
           
Less accumulated amortization   3,234,556    2,587,644 
           
Patents net  $1,265,444   $1,912,356 

 

Amortization expense for the years ended December 31, 2022 and 2021, was $646,912.

 

30
 

 

The estimated future amortization expense related to patents as of December 31, 2022, is as follows:

 

Years Ended December 31,  Amount 
     
2023  $646,910 
2024   618,534 
Total  $1,265,444 

 

The Company determined that the patents were not impaired as of December 31, 2022 and 2021.

 

Note 4 - Notes payable

 

As of December 31, 2022 and December 31, 2021, the notes payable activity was as follows:

 

 

   2022   2021 
   As of December 31, 
   2022   2021 
         
Notes payable at beginning of period  $7,256,930   $6,835,196 
Notes payable issued   465,000    950,000 
Settlements on note payable   (163,826)   (117,770)
Repayments of notes payable in cash   (14,000)   (16,900)
Less amounts converted to stock   (380,272)   (393,596)
Notes payable at end of period   7,163,832    7,256,930 
Less debt discount   (10,587)   (75,800)
Note payable, net  $7,153,245   $7,181,130 
           
Notes payable issued to former related party  $112,100   $126,100 
Notes payable issued to non-related party  $7,041,145   $7,055,030 

 

The maturity dates on the notes are as follows:

 

 

Twelve months ending,  Non-related parties   Former
Related
party		   Total 
Past due  $6,626,145   $112,100   $6,738,245 
December 31, 2023   415,000    -    415,000 
Total  $7,041,145   $112,100   $7,153,245 

 

Activity during the year ended December 31, 2022

 

Fixed rates convertible notes

 

During the year ended December 31, 2022, the Company issued seven (7) fixed rate promissory notes totaling $465,000 in principal, for funding of $465,000 with original terms of nine to twelve months and interest rates of 15% and 18%. The holder of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, immediately to six-month after issuance date. These fixed rate promissory notes include a prepayment feature at a premium of 15% and a make good provision, which guarantees the holder additional shares if the holder does not realize a 15% or 18% return on the resale of the common shares.

 

31
 

 

As of December 31, 2022, the Company has twenty (20) fixed-rate promissory notes with an outstanding balance of $1,819,728, of which $1,404,728 are past maturity. As of December 31, 2022, the Company has a total of sixteen (16) fixed rate notes for total principal amount of $1,465,000 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. The Company accrued approximately $225,000 related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the consolidated statements of operations and accounts payable and accrued expenses in the consolidated balance sheet as of December 31, 2022.

 

During year ended December 31, 2022, the Company converted $136,728 in accrued interest and $380,272 in principal balance into 25,850,000 shares of common stock.

 

Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company. The prepayment penalty approximates $62,800 as of December 31, 2022, but the Company determined that such liability was not probable as of December 31, 2022, pursuant to ASC 450 Contingencies.

 

Variable-rate notes

 

The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2022, is $4,607,100, which are all past maturity. There was no conversion of notes into the Company’s common stock during the year ended December 31, 2022.

 

During the year ended December 31, 2022, the Company settled one variable note with a principal of $163,826 and $45,475 in accrued interest for no consideration.

 

Activity during the year ended December 31, 2021

 

During the year ended December 31, 2021, the Company issued eight (8) fixed rate promissory notes totaling $950,000 for funding of $950,000 with original terms of twelve months and interest rates of 15%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features. As of December 31, 2021, the fixed-rate notes had an outstanding balance of $1,735,000, of which $785,000 are past maturity. As of December 31, 2021, the Company has 13 fixed rate promissory notes with unrelated parties for total amount of $1,735,000. Nine of these fixed rates promissory notes for total balance of $1,000,000 carry a make whole provision requiring the Company to issue additional shares of its common stock if the underlying investor is not able to realize a profit of 15% against the conversion price of such shares after customary and reasonable expenses.

 

During the year ended December 31, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments and recorded $58,407 as loss from debt extinguishment in the consolidated statements of operations.

 

During the year ended December 31, 2021, the Company settled one of its promissory notes by issuing 1,515,152 restricted shares of the Company’s common stock with a fifteen percent (15%) make-whole provision. The Company recorded a gain on debt extinguishment of approximately $128,000.

 

During the year ended December 31, 2021, the Company converted $393,597 in principal and $100,152 in accrued but unpaid interest into 27,461,307 shares of common stock.

 

The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2021, is $4,770,926, of which $4,770,926 are past maturity.

 

Former related-party notes

 

Notes payable to a former related party in the aggregate amount of $112,100 was outstanding at December 31, 2022, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the year ended December 31, 2022, the Company paid total principal of $14,000 to this former related party. As of December 31, 2022, the Company had notes payable to related parties amounting to $112,100. Refer to Note 7– Related Party Transactions.

 

32
 

 

Notes payable to a former related party in the aggregate amount of $126,100 was outstanding at December 31, 2021, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the year ended December 31, 2021, the Company paid total principal of $16,900 to this former related party.

 

Other notes

 

In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $500,000, each, of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. During the years ended December 31, 2022, and 2021, the Company did not issue notes in connection with these private placements and did not repay any of these notes. As of December 31, 2022, and 2021, notes payable outstanding under these private placements are $624,903, all of which are past maturity.

 

Notes payable totaling $2,110,450 are secured by the intellectual property acquired from RGN including patents obtained in the acquisition.

 

Acquisition Payable

 

In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $155,000 long-term acquisition payable for costs that were not paid at closing. This payable is non-interest bearing and IPR agreed to make payments up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company.

 

There was no activity during the year ended December 31, 2022. During the year ended December 31, 2021, the Company issued 2,505,834 as extinguishment for $75,175 in principal and interest. The balance of the acquisition payable is $79,825, as of December 31, 2022 and 2021.

 

Effective Interest Rate

 

During the years ended December 31, 2022, and 2021, the Company’s effective interest rate was 18% and 12% respectively.

 

Note 5 - Shareholders’ Deficit

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

 

 

   Number of Shares
Authorized		   Number of Shares
Outstanding at
December 31,
2022		   Par Value   Liquidation Value
per Share		 
Series AA   1,000,000    25,000   $0.0010    - 
Preferred Series B   50,000    600   $0.0001    100 
Preferred Series C   8,000    738   $0.0001    1,000 
Preferred Series D   20,000    50   $0.0001    1,000 
Undesignated   3,922,000    -    -    - 

 

33
 

 

Series AA Preferred Shares

 

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

 

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of December 31, 2022 and 2021, there were 25,000 shares of Series AA Preferred stock outstanding.

 

Series B Convertible Preferred Stock

 

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value ($100 per share) divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. There has been no activity during the years ended December 31, 2022 and 2021. As of December 31, 2022 and 2021, there were 600 shares of Series B outstanding.

 

Series C Secured Redeemable Preferred Stock

 

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation for its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

 

Management determined the fair value of the new instrument based on the guidance in ASC 820 Fair Value Measurement. Management concluded that the preferred stock should not be classified as a liability per the guidance in ASC 480 Distinguishing Liabilities from Equity even though the conversion would require the issuance of variable number of shares since such obligation is not unconditional. Management classified the Series C in permanent equity as of December 31, 2022 and 2021.

 

During the years ended December 31, 2022 and 2021, the Company converted 0 and 25 shares of Series C into 0 and 1,111,111 shares of common stock, respectively. As of December 31, 2022 and 2021, there were 738 shares of Series C outstanding, respectively.

 

34
 

 

Series D Convertible Preferred Stock

 

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock.

 

The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.

 

In September 2022, the Company offered to each holder of Series D the opportunity to convert each share of Series D into 100,000 shares of the Company’s common stock at an effective conversion price of $0.01. In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale.

 

During the year ended December 31, 2022, the Company issued 25,500,000 shares of common stock upon conversion of 255 shares of Series D preferred stock, for a total value of $255,000. At December 31, 2022, based on the stock price, the value of these shares was in excess of the 15% guaranteed return.

 

As of December 31, 2022 and 2021, there were 50 and 305 shares of Series D outstanding, respectively.

 

Common Stock

 

Activity during the year ended December 31, 2022:

 

During the year ended December 31, 2022, the Company issued 25,850,000 shares of common stock for the conversion of $380,272 of principal notes and accrued interest in the amount of $136,728.

 

During the year ended December 31, 2022, the Company issued 2,428,777 shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.

 

During the year ended December 31, 2022, the Company issued 3,450,000 shares of common stock as commitment shares in connection with promissory notes.

 

During the year ended December 31, 2022, the Company issued 66,500,000 shares of common stock for services for total fair value of $1,316,900.

 

During the year ended December 31, 2022, the Company issued 25,500,000 shares of common stock in exchange for 255 shares of Series D Preferred, which resulted in an inducement loss of $200,932 recorded as a deemed dividend in the shareholders’ deficit as of December 31, 2022.

 

During the year ended December 31, 2022, the Company issued 3 units or 15,000,000 shares of common stock pursuant to a private placement for total net cash receipt of $142,000.

 

Activity during the year ended December 31, 2021:

 

During the year ended December 31, 2021, the Company issued 27,461,307 shares of common stock for the conversion of principal notes and accrued interest for aggregate fair value of issued common stock of $1,117,990.

 

During the year ended December 31, 2021, the Company issued 7,868,668 shares of common stock labeled as commitment shares in connection with the issuance of promissory notes for a total fair value of approximately $223,000.

 

During the year ended December 31, 2021, the Company issued 7,000,000 shares of common stock pursuant to securities purchase agreement for total consideration of $126,000.

 

35
 

 

During the year ended December 31, 2021, the Company issued 1,111,111 shares of common stock with a value of $33,333, related to the conversion of Series C.

 

During the year ended December 31, 2021, the Company issued 4,020,986 shares of common stock with a value of $142,424, related to the settlement of debts, of which 2,505,834 shares of common stock were issued with a fair value of $84,697 to a former related party.

 

During the year ended December 31, 2021, the Company issued 2,500,000 shares of common stock in connection with the consulting agreement, with a fair value of approximately $95,000.

 

Stock Options

 

During the year ended December 31, 2022, the Company executed an independent contractor agreement with the Company’s new President and Chief Commercial Officer of its medical division. Pursuant to this agreement, the Company granted 3,000,000 stock options to purchase an equivalent number of common stocks, with 250,000 options vesting each quarter with a term of 2 years from vesting and a strike price of $0.0076. The Company did not issue any stock options during the year ended December 31, 2021.

 

The Company cancelled 501,320 and 2,500,350 stock options during the years ended December 31, 2022 and 2021, respectively.

 

The Company did not recognize any share-based compensation expense for the years ended December 31, 2022 and 2021.

 

Stock option activity for the years ended December 31, 2022 and 2021, is as follows:

 

   Options   Weighted
Average
Exercise Price
Per Share		   Weighted
Average
Remaining
Contractual
Term (years)		   Aggregate
Intrinsic
Value		 
Outstanding at December 31, 2020   3,014,080   $0.37    1.67   $- 
Granted   -   $-    -    - 
Cancelled   (2,500,350)  $0.16    0.65    - 
Exercised   -   $-    -    - 
Outstanding at December 31, 2021   513,730   $1.43    0.76   $- 
                     
Granted   3,000,000   $0.0076    3.40    31,200 
Cancelled   (501,320)  $0.18    -    - 
Exercised   -   $-           
Outstanding at December 31, 2022   3,012,410   $0.22    3.40   $31,200 
                     
Exercisable at December 31, 2022   262,410   $2.45    2.02   $2,600 

 

36
 

 

The balance of all stock options outstanding as of December 31, 2022, is as follows:

 

    Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
Range of       Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life   Price   Exercisable   Price 
                      
 Options                          
$54.00    11,750    4.30   $54.00    11,750   $54.00 
$11.60    660    -   $11.60    660   $11.60 
$0.0076    3,000,000    3.40   $0.0076    250,000   $0.0076 
      3,012,410    3.40   $0.22    262,410   $0.22 

 

Warrants

 

During the years ended December 31, 2022, and 2021, the Company did not issue any warrants.

 

A summary of the changes of the warrants during the years ended December 31, 2022 and 2021, are presented below:

 

 

   Outstanding Warrants 
       Weighted
Average		 
       Exercise Price 
   Shares   Per Share 
Outstanding at December 31, 2020   39,295   $200.72 
Granted   -   $- 
Cancelled   (17,095)  $384.39 
Exercised   -   $- 
Outstanding at December 31, 2021   22,200   $59.25 
           
Granted   -   $- 
Cancelled   (20,200)  $60.17 
Exercised   -   $- 
Outstanding at December 31, 2022   2,000   $50.00 
           
Exercisable at December 31, 2022   2,000   $50.00 

 

The balance of all warrants outstanding as of December 31, 2022, is as follows:

 

 

    Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
Range of       Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life   Price   Exercisable   Price 
                      
 Warrants                          
                            
$50.00    2,000    0.22   $50.00    2,000   $50.00 
      2,000    0.22   $50.00    2,000   $50.00 

 

37
 

 

Note 6 – Related Party and former Related Parties Transactions

 

One executive officer, one former executive and one former operational manager of the Company have agreed to defer a portion of their compensation until cash flow improves. As of December 31, 2022, and 2021, the balances of their deferred compensation were $1,350,265 and $1,289,625, which reflects $300,000 accrual of deferred compensation in accordance with contractual arrangement, approximately $170,000 cash repayments of deferred compensation and $69,217 non-cash reduction pursuant to royalties charged to the former operational manager on SofPulse units during the year ended December 31, 2022, and $300,000 accrual of deferred compensation, $250,950 cash repayments during the year ended December 31, 2021. The royalty/licensing revenue recognized in 2022 was generated from the former operational manager who is developing business in Costa Rica and Mexico. In lieu of payment for the royalty/licensing, the former operational manager paid $44,406 directly to the Company’s vendor, and the deferred compensation due to him was reduced by $69,217.

 

During the year ended December 31, 2022, the Company issued 25,000,000 shares of common stock to a company controlled by the Company’s Chief Executive Officer with an estimated fair value of $550,000 for services.

 

During the year ended December 31, 2022, the Chief Executive Officer of the Company advanced $28,021 of funds to the Company of which $25,521 was repaid during the year 2022. During the year ended December 31, 2021, the Chief Executive Officer of the Company advanced $13,530 of funds to the Company of which $13,405 was repaid during the year 2021.

 

The balance of short-term advances due to one officer and executive of the Company at December 31, 2022 and 2021 was $2, 625 and $125, respectively and is included in the Company’s accounts payable and accrued interest balance as of December 31, 2022 and 2021.

 

At December 31, 2022 and 2021, notes payable remain outstanding to the former President of the Company, in the amounts of $112,100 and $126,100, respectively. At December 31, 2022 and 2021, accrued interest on these notes payable totaled $80,034 and $67,787, respectively, and are included in accrued interest on the consolidated balance sheets.

 

Note 7 - Income taxes

 

The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years.

 

The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2022 and 2021, the Company had approximately $33,000,000 and $28,000,000 of federal net operating loss carryforwards, respectively, that it can use to offset a certain amount of taxable income in the future. Some of these federal net operating loss carryforwards begin to expire in 2030. The resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization. Utilization of these net operating losses could be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state laws based on ownership changes and the value of the Company’s stock.

 

A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2022 and 2021:

 

   2022   2021 
Income tax computed at federal statutory rate   -21.0%   -21.0%
State taxes, net of federal benefit   -1.7%   -7.0%
Non-Deductible expenses   15.6%   1.0%
Change in valuation allowance   7.1%   27.0%
Total   0.0%   0.0%

 

The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance.

 

The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2022 and 2021.

 

38
 

 

Note 8 - Commitments and Contingencies

 

Legal matters

 

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of December 31, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

 

Note 9 – Concentrations.

 

Sales

 

During the year ended December 31, 2022, we had two significant customers which accounted for 84% and 10% of direct sales. In addition, the Company generated all of its royalty/licensing revenue from one former related party.

 

During the year ended December 31, 2021, we had two significant customers which accounted for 28% and 25% of sales.

 

Supplier

 

We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

 

Accounts Receivable

 

At December 31, 2021, we had two customers which accounted for 67% of our accounts receivable balances. There are no accounts receivable balance as of December 31, 2022.

 

Note 10 - Subsequent Events.

 

Subsequent to December 31, 2022, the Company issued 5,000,000 shares of common stock following the conversion of 50 shares of Series D preferred stock.

 

Subsequent to December 31, 2022, the Company issued 6,500,000 shares of common stock pursuant to consulting agreements with an estimated fair value of $63,700.

 

Subsequent to December 31, 2022, the Company issued 22,500,000 shares of common stock pursuant to a private placement for $225,000 in cash.

 

Subsequent to December 31, 2022, the Company issued 10,900,000 shares of common stock for the conversion of $100,000 promissory note and $9,000 in accrued interest with one investor.

 

Subsequent to December 31, 2022, the Company issued 4,300,590 shares of common stock with a fair value of approximately $67,090 as settlement of a convertible note with an approximate carrying value of $209,300.

 

Subsequent to December 31, 2022, the Company issued 1,507,277 shares of common stock with a fair value of approximately $25,000 pursuant to a make good provision from a previously executed settlement agreement.

 

Subsequent to December 31, 2022, the Company issued 6,350,000 shares of common stock as additional consideration pursuant to a securities purchase agreement with estimated fair value of $50,000.

 

39
 

 

On March 29, 2023, the Company entered into a binding Letter of Intent (“LOI”) to spin off its current medical device division to an entity managed by Ira Weisberg, the Company’s President and Chief Commercial Officer of its medical division. Mr. Weisberg will be the future President and Chief Executive Officer of this newly formed entity.

 

Subsequent to December 31, 2022, the Company executed a Service-Disabled Veteran-Owned Small Business Government Reseller Agreement with Academy Medical, Inc. to distribute SofPulse® medical devices to ensure its availability to the Veteran Health Administration (“VHA”) and Department of Defense (DoD) contracts.

 

Subsequent to December 31,2022, the Board of director approved the issuance of 39,150,000 shares of common stock for past services with estimated fair value of approximately $552,000.

 

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A. Controls and Procedures.

 

Disclosure of controls and procedures.

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2022. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2022, at the reasonable assurance level due to the material weaknesses described below.

 

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Management has identified the following two material weaknesses which have caused management to conclude that as of December 31, 2022, our disclosure controls and procedures were not effective at the reasonable assurance level:

 

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the year ended December 31, 2022. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

 

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the authorization of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. The recording of transactions function is maintained by a third-party consultant whereas authorization and custody remains under the Company’s Chief Executive Officer’s responsibility. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

 

40
 

 

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the issuer’s principal executive and principal financial officers and effected by the issuer’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

 

● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer.

 

● Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the issuer; and

 

● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

As of the end of our most recent fiscal year, management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that as of December 31, 2022, such internal control over financial reporting was not effective. This was due to deficiencies that existed in the design or operation of our internal control over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

 

The matters involving internal control over financial reporting that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives of having segregation of the initiation of transactions, the recording of transactions and the custody of assets; and (3) lack of communication between management and external accounting personnel. The aforementioned material weaknesses were identified by our Chief Executive Officer in connection with the review of our consolidated financial statements as of December 31, 2022.

 

41
 

 

Management believes that the material weaknesses set forth in items (1) and (2) above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, result in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

 

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only the management’s report in this annual report.

 

Management’s Remediation Initiatives

 

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures: we will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. First, we will create a position to segregate duties consistent with control objectives of having separate individuals perform (i) the authorization of transactions, (ii) the recording of transactions and (iii) the custody of assets. Second, we will create a senior position to focus on financial reporting and standardizing and documenting our accounting procedures with the goal of increasing the effectiveness of the internal controls in preventing and detecting misstatements of accounting information. Third, we plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us. Lastly, we will improve channels of communication between management and accounting through regularly scheduled monthly meetings. We anticipate the costs of implementing these remediation initiatives will be approximately $50,000 to $100,000 a year in increased salaries, legal and accounting expenses.

 

Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on our Board.

 

Changes in internal controls over financial reporting.

 

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

42
 

 

Item 9B. Other Information.

 

On April 3, 2013, the Company filed an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

 

The Company’s board of directors authorized the Series AA Super Voting Preferred Stock pursuant to the authority given to the board under the Articles of Incorporation, which authorizes the issuance of up to 5,000,000 shares of preferred stock, par value $0.001 per share, and authorized the board, by resolution, to establish any or all of the unissued shares of preferred stock, not then allocated to any series into one or more series and to fix and determine the designation of each such shares, the number of shares which shall constitute such series and certain preferences, limitations and relative rights of the shares of each series so established.

 

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

 

The summary of the rights, privileges and preferences of the Series AA Super Voting Preferred Stock described above is qualified in its entirety by reference to the Certificate of Designation as filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

 

Past maturity Notes

 

Due to its limited resources, the Company has not been able to pay certain promissory notes when due. As of December 31, 2022, there are $7,163,832 in existing notes with an aggregate principal of $6,748,831 which are beyond their maturity date. Management believes that the Company may have valid defenses as to some of the promissory notes and will be able to modify some of these notes if requested by the holders to do so and otherwise avoid any default.

 

PART III

 

Item 10. Directors, Executive Officers, and Corporate Governance.

 

The following table sets forth the name and age of officers and director. Our Executive Officer is elected annually by our Board of Directors. Our executive officers hold their offices until they resign, are removed by the Board, or his successor is elected and qualified.

 

Name   Age   Position
Alan Collier   57   Director, Chief Executive Officer, Interim Chief Financial Officer, and Secretary
Ira Weisberg   73   President, Chief Commercial Officer Medical division

 

Biographies

 

Alan Collier has been the Chief Executive Officer, Secretary, and a director of the Company Since March 2012. Mr. Collier has more than twenty (20) years of experience in finance, telecommunications, and consumer products. Over the progression of his career, he has specialized in the development and financing of early stage, high growth, and acquisitive companies (public and private). He has structured, participated in, and completed numerous transactions including mergers and acquisitions, equity and debt placements, capital restructuring, joint venture development, and channel partner procurement. Additionally, Mr. Collier was a Senior Managing Director at Mid-Market Securities, a FINRA-registered Broker-Dealer. He is also the co-founder and a Managing Member of C2 Capital, LLC, which provides management consulting services to companies preparing to go public. Prior to joining Mid-Market Securities, Mr. Collier was a Managing Director of Mosaic Capital and co-managed its Capital Markets Group at Mosaic Capital. He was previously a Vice President at Corporate Capital Group and Managing Director and CEO of Greenbridge Capital Group. He has held numerous board and executive positions throughout his career.

 

43
 

 

Mr. Weisberg has more than thirty years of experience in healthcare and pharmaceutical management, business development, corporate finance and marketing with a concentration in pharmaceutical and biotechnology corporate fund-raising strategy over the past five years. His expertise is in developing strategies to guide emerging medical companies to advance revenue and enhance company diversity, developmental pipelines and geographic reach particularly in fast-growing emerging medical device and pharmaceutical markets. Mr. Weisberg has been instrumental in developing licensing and acquisition strategy for an emerging specialty pharmaceutical and medical device biotechnology companies. Prior to his appointment as Endonovo’s President and Chief Commerical Officer of its Medical Division, Mr. Weisberg served as CEO and President of Amherst Pharmaceuticals, CEO of AlphaVax and Senior Vice President of Neurotrope Biosciences where he was responsible for commercial development, corporate funding, strategic planning and overseeing expansion of global operations through acquisition of licensing and partnering agreements for emerging pharmaceuticals, medical devices and other products. Over his career, Mr. Weisberg has extensive executive experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Mr. Weisberg led negotiations and signed licensing agreements for strategic acquisitions, distribution and development deals for multiple companies in the medical device and pharmaceutical industry. His past medical administrative experience includes executive positions at Alphavax, Inc., Lifecycle Pharma, Chugai Pharma USA, Haemacure Corp and Aventis Behring. As Senior business development director with Aventis Behring, a global leader in recombinant albumin, he negotiated out-licensing, supply, distribution and development agreements with major pharmaceutical companies in excess of $100 million and contributed to revenues for the company’s specialty product valued at $500 million while assisting the company to be valued in excess of $750 million. As Vice President of Operations for Haemacure Corp., the U.S. market leader in plasma-derived surgical hemostats and adhesives, Mr. Weisberg established and positioned the company globally through negotiations and signing of multinational licensing and joint venture agreements. He guided growth and generated revenue more than $30 million in an IPO, providing capital for growth and product development.

 

He joins the Endonovo executive team to structure and oversee the global expansion of licensing and distribution for SofPulse® and Roma® PEMF medical device technology.

 

Except as set forth in our discussion below in “Certain Relationships and Related Transactions,” none of our directors or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates or associates which are required to be disclosed pursuant to the rules and regulations of the Commission.

 

Key Staff Member

 

In February 2022, we retained Garry Michael Kann, age 66, as Head of Corporate Development. Mr. Kann’s primary responsibilities will be to oversee the development of Endonovo’s “build up strategy” of acquiring complementary specialty service providers in the construction industry. Key responsibilities will be in identifying, performing due diligence on, evaluating, and otherwise assisting in company mergers and acquisitions, principally in the specialty construction industry.

 

For more than the past five years, Mr. Kann has been the CEO of Firebird Partners, a private investment firm, and chairs the Capital Markets Group at Mosaic Capital LLC, a financial advisory firm both located in Los Angeles, California. Mr. Kann has been a prominent corporate finance professional in the United States on both the East and West Coasts for over 30 years. Over that time, he has been an innovator in asset backed financial instruments and has worked with clientele around the globe including Europe, Asia, Central and South America. As an investment banker he has completed more than 60 mergers and acquisition transactions exceeding $2 billion in value. Previously, while in senior management positions for a wide variety of financial institutions serving the middle market, he structured and completed more than 200 transactions exceeding several billion dollars in value.

 

On December 1, 2022, the Company executed an independent contractual agreement with Ira Weisberg as the Company’s medical device division President and Chief Commercial Officer. Ira Weisberg will be responsible for expanding global sales and marketing operations of SofPulse® and Roma® Pulsed Electro magnetic Frequency (PEMF) medical devices distribution globally.

 

Code of Ethics

 

We do not have a code of ethics that applies to our officers, employees, and directors. The Company does not have any employees for the year ended December 31, 2022.

 

Corporate Governance

 

The business and affairs of the company are managed under the direction of our board. We have a board consisting of one member. In addition to the contact information in this annual report, each stockholder will be given specific information on how he/she can direct communications to the officers and our director of the corporation. All material communications from stockholders are relayed to our board.

 

44
 

 

Role in Risk Oversight

 

Our board is primarily responsible for overseeing our risk management processes. The board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company’s assessment of risks. The board focuses on the most significant risks facing our company and our company’s general risk management strategy and ensures that risks undertaken by our company are consistent with the board’s appetite for risk. While the board oversees our company’s risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers, directors and persons who beneficially own more than ten percent of our common stock to file reports of ownership and changes in ownership with the SEC. These reporting persons are also required to furnish us with copies of all Section 16(a) forms they file. Based solely upon a review of such Forms, we believe that during the year ended December 31, 2022. there were no delinquent filers.

 

Item 11. Executive Compensation.

 

The following executive of the Company earned compensation in the amounts set forth in the chart below for the fiscal years ended December 31, 2022, and 2021. No other item of compensation was paid to any officer or director of the Company other than reimbursement of expenses.

 

Summary Compensation Table

 

Name and Principal Position  Fiscal
Year		   Salary
($)		   Bonus
($)		   Stock
Awards
($)		   All Other
Compensation
($)		   Total ($) 
                         
Alan Collier, CEO, Interim   2022   $300,000   $-   $550,000   $-   $850,000 
CFO, Secretary and Director (*)   2021   $300,000   $-   $-   $-   $300,000 

 

(*) Salary information as reflected above represents compensation earned but not paid based on the terms of the consulting agreement. The Company’s Chief Executive was paid $170,000 as compensation. The Company’s Chief Executive Officer advanced $28,021 for corporate expenses, of which $25,521 was reimbursed by the Company leaving a balance of $2,625 in accounts payable as of December 31, 2022. For the year ended December 31, 2021, the Company’s Chief Executive was paid $243,650 as compensation and receive $13,405 of expenses reimbursement and $6,529 of accounts payable.

 

On April 12, 2022, a Company controlled by our Chief Executive Officer, received 25,000,000 shares of common stock with an estimated fair value of $550,000.

 

Outstanding Equity Awards at Fiscal Year-End Table

 

Name  Number of Securities
Underlying
Unexercised Options
(#) Exercisable		   Number of Securities
Underlying
Unexercised Options
(#) Unexercisable		   Option
Exercise Price
($)		   Option
Expiration Date
Alan Collier, CEO, Interim   5,000    -   $54.00   4/17/2027
CFO, Secretary and Director                  

 

45
 

 

Compensation of Directors

 

The directors receive no compensation for serving as directors. However, the Company may reimburse its directors for any out-of-pocket cost reasonably incurred to attend a Board meeting.

 

Compensation Agreements

 

All of the new officers pursuant to the terms of the Share Exchange Agreement dated March 14, 2012, have agreed to accrue and defer payment of their compensation until the Company has generated sufficient financing proceeds or revenue to pay such compensation. Mr. Collier received compensation of $25,000 per month. No compensation was provided for Michael Mann (former President of the Company) during the year ended December 31, 2022, and 2021. Mr. Mann has been acting as an advisor since he retired on February 28, 2019.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth certain information regarding our shares of common stock beneficially owned as of April 13, 2023, for (i) each stockholder known to be the beneficial owner of 5% or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial ownership at any time within 60 days through an exercise of stock options or warrants. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.

 

For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within 60 days of April 13, 2023. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days of April 13, 2023, is deemed to be outstanding but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership. Unless otherwise specified, the address of each of the persons set forth below is care of the company at the address of 6320 Canoga Avenue, 15th Floor Woodland Hills, CA 91367.

 

Name of Beneficial Owner 

Amount of
Beneficial
Ownership

(1)

  

Percent of
Ownership

(2)

 
         
Alan Collier   45,031,219    16.7%
James Greenland   20,175,000    7.5%
Michael Mann   13,525,437    5.0%
All officers and directors as a group (1 person)   45,031,219    16.7%

 

  (1) This includes common shares controlled by Mr. Collier, Chairman, Chief Executive Officer, and Chief Financial Officer.
  (2) Based on shares of common stock outstanding as of April 14, 2023.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

On February 10, 2015, the Company issued a promissory note to Michael Mann (former President) for a principal amount of $50,000. The Note carries an interest rate of 12% per annum and a maturity date of June 4, 2015, with interest due monthly. On September 29, 2019, the maturity date of the promissory note was extended to December 31, 2019. As of December 31, 2022 and 2021, the Company has a remaining principal balance of $12,100 and $26,100, respectively. During the years ended December 31, 2022 and 2021, the Company has repaid 14,000 and $16,900 in cash, respectively.

 

46
 

 

On December 21, 2017, the Company issued a promissory note to Michael Mann (former President) for a principal amount of $100,000. The Note carries an interest rate of 10% per annum and a maturity date of March 22, 2018, with interest due monthly. On September 29, 2019, the maturity date of the promissory note was extended to December 31, 2019. As of December 31, 2022 and 2021, the Company has a remaining principal balance of $100,000.

 

The outstanding notes to Mr. Mann equal to $112,100 and $126,100 at December 31, 2022 and December 31, 2021, respectively. In the opinion of management, these notes were on terms no less favorable to the lender than the Company might have obtained from an unaffiliated party.

 

Director Independence

 

We do not have any independent directors. Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the Company’s Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that a director cannot be considered independent if:

 

● the director is, or at any time during the past three years was, an employee of the company;
   
● the director or a family member of the director accepted any compensation from the company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);

 

  a family member of the director is, or at any time during the past three years was, an executive officer of the company;
   
● the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the company made, or from which the company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
   
● the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the company served on the compensation committee of such other entity; or
   
● the director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during the past three years was a partner or employee of the Company’s outside auditor, and who worked on the company’s audit.

 

Mr. Alan Collier is not considered independent because he is the Company’s Chief Executive Officer and acting Chief Financial Officer.

 

We do not currently have a separately designated audit, nominating or compensation committee.

 

Item 14. Principal Accounting Fees and Services.

 

Audit Fees

 

For the Company’s fiscal years ended December 31, 2022 and 2021, we were billed approximately $101,915 and $98,250, respectively, for professional services rendered for the audit and review of our financial statements.

 

Audit Related Fees

 

There were no fees for audit related services for the years ended December 31, 2022 and 2021.

 

47
 

 

Tax Fees

 

For the Company’s fiscal years ended December 31, 2022 and 2021, we were billed approximately $7,195 and $8,400 for professional services rendered for tax compliance, tax advice, and tax planning.

 

All Other Fees

 

For the Company’s fiscal years ended December 31, 2022, and 2021, we were billed approximately $500 and $0, respectively.

 

The Company did not incur any other fees related to services rendered by our principal accountant for the fiscal years ended December 31, 2022 and 2021.

 

Effective May 6, 2003, the Securities and Exchange Commission adopted rules that require that before our auditor is engaged by us to render any auditing or permitted non-audit related service, the engagement be:

 

● approved by our audit committee; or
   
● entered into pursuant to pre-approval policies and procedures established by the audit committee, provided the policies and procedures are detailed as to the particular service, the audit committee is informed of each service, and such policies and procedures do not include delegation of the audit committee’s responsibilities to management.

 

We do not have an audit committee. Our board of directors pre-approves all services provided by our independent auditors. The pre-approval process has just been implemented in response to the new rules. Therefore, our board of directors does not have records of what percentage of the above fees was pre-approved. However, all of the above services and fees were reviewed and approved by the board of directors either before or after the respective services were rendered.

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(a) The following documents are filed as part of this report:

 

(1) Financial Statements and Report of Independent Registered Public Accounting Firm, which are set forth in the index to Consolidated Financial Statements of this report.

 

Report of Independent Registered Public Accounting Firm 18
Consolidated Balance Sheets 20
Consolidated Statements of Operations 21
Consolidated Statements of Shareholders’ Deficit 22
Consolidated Statements of Cash Flows 24
Notes to Consolidated Financial Statements 25

 

(2) Financial Statements Schedules: None.

 

48
 

 

(3) Exhibits

 

EXHIBIT NUMBER   DESCRIPTION
2.1   Share Exchange Agreement. Incorporated by reference to the current report on Form 8-K filed with the Securities and Exchange Commission on March 21, 2012 (Incorporated by reference from exhibit 2.1 to our annual financial statements on Form 10-K filed with the SEC on May 4, 2020).
3.1   Articles of Incorporation (Incorporated by reference to the registration statement filed with the Securities and Exchange Commission on September 22, 2011).
3.2   By-Laws (Incorporated by reference to the registration statement filed with the Securities and Exchange Commission on September 22, 2011).
3.3   Agreement and Plan of Merger (Delaware reincorporation). Incorporated by reference to the registration statement filed with the Securities and Exchange Commission on September 22, 2011.
3.4   Certificate of Designation (Super AA Voting Preferred). Incorporated by reference to the Annual Report on Form 10-K for the year ended December 31, 2012
3.5   Articles of Amendment -Name Change (Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on January 24, 2014).
3.6   Articles of Amendment – Increase Authorized Shares (Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on January 24, 2014).
3.7   Articles of Amendment – Reverse Stock Split (Incorporated by reference to Exhibit 3.7 to Form S-1 amendment filed with the Securities and Exchange Commission on October 6, 2016).
3.8   Certificate of Designation Series B Preferred Stock (Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission February 10, 2017).
3.9   Certificate of Designation Series C Preferred Stock (Incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed with the Securities and Exchange Commission December 26, 2017).
3.10   Articles of Amendment Authorizing additional Shares (Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on September 18, 2018).
4.1   Specimen Common Stock Certificate (Incorporated by reference to like numbered Exhibit to Registration on Form S-1 amendment filed on June 10, 2016).
10.1   Investment Agreement by and between the Company and Azure Capital, dated as of December 31, 2018 (Incorporated by reference to like numbered exhibit to Current Report on Form 8-k filed with the Securities Exchange Commission on January 3, 2018).
10.2   Registration Rights Agreement by and between the Company and Azure Capital, dated as of December 31, 2018 (Incorporated by reference to like numbered exhibit to Current Report on Form 8-k filed with the Securities Exchange Commission on January 3, 2018).
10.3   Acquisition Agreement between the Company and We Heal Animals, Inc (Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed November 19, 2013).
10.4   Settlement and Mutual Release, effective November 22, 2018, between the Company and Rio Grande Neurosciences, LLC (Incorporation by reference to Exhibit 10.1 to current report on Form 8-K filed with the Securities and Exchange Commission on December 26, 2017).
10.5   Exchange Agreement dated as of November 30, 2018, between the Company and Eagle Equities, LLC (Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities Exchange Commission on December 7, 2018).
10.6   Secured $1,500,000 Convertible Promissory Note, dated as of November 30, 2018, issued by the Company and Eagle Equities, LLC (Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the Securities Exchange Commission on December 7, 2018).
31.1   Certification of Chief Executive and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of Chief Executive and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.PRE*   Inline XBRL Taxonomy Presentation Linkbase
    In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.
     
*   XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of this annual report or purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

49
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 17th day of April 2023.

 

  ENDONOVO THERAPEUTICS, INC.
     
  By: /s/ Alan Collier
    Alan Collier
    Chief Executive Officer
    (Duly Authorized, Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Alan Collier   Chairman, Chief Executive Officer, Chief Financial Officer, Secretary and Director   April 17, 2023
Alan Collier   (Principal Executive, Financial and Accounting Officer)    

 

50

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Alan Collier, certify that:

 

1. I have reviewed this annual report on Form 10-K of Endonovo Therapeutics, Inc.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; and

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; and

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

 

(b) Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: April 17, 2023

 

Signature: /s/ Alan Collier  
Name: Alan Collier  
Title: Chairman, Chief Executive and Chief Financial Officer  

 

 

 EX-32.1 3 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Endonovo Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002 that based on his knowledge:

 

1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

 

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in the Report.

 

/s/ Alan Collier  
Alan Collier  
Chairman, Chief Executive and Chief Financial Officer  

 

Dated: April 17, 2023

 

 
 GRAPHIC 4 form10-k_001.jpg begin 644 form10-k_001.jpg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form10-k_002.jpg begin 644 form10-k_002.jpg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endv-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Shareholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Patents link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Shareholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party and former Related Parties Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Patents (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Notes payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Shareholders’ Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Income taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Balances of Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Sources of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Revenue Recognition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Patents (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Estimated Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Patents (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Maturity Dates of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Notes payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Warrants Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Shareholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Related Party and former Related Parties Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Income taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Concentrations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 endv-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 endv-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 endv-20221231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Super AA Super Voting Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series AA Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Subscription Receivable [Member] Retained Earnings [Member] Business Acquisition [Axis] Hanover Portfolio Acquisitions Inc [Member] Award Type [Axis] Stock Options [Member] Warrant [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Input, Exercise Price [Member] Measurement Input, Option Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Product and Service [Axis] Direct Sales Medical Care Providers Gross [Member] Royalty [Member] Legal Entity [Axis] Rio Grande Neurosciences Inc [Member] Related Party [Axis] Non Related Parties [Member] Former Related Party [Member] Debt Instrument [Axis] One Promissory Notes [Member] Seven Fixed Rate [Member] Fixed Rated Notes [Member] Scenario [Axis] Past Maturity [Member] Eighteen Fixed Rate [Member] Sixteen Fixed Rate [Member] Convertible Notes [Member] One Variable Note [Member] Eight Fixed Promissory Notes [Member] Thirteen Fixed Rate Promissory Notes [Member] Unrelated Parties [Member] Nine Fixed Rate Promissory Notes [Member] Income Statement Location [Axis] Gain (Loss) on Derivative Instruments [Member] Two Promissory Notes [Member] Notes Payable [Member] Title of Individual [Axis] Related Party [Member] Sale of Stock [Axis] Private Placement [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual Property [Member] Intellectual Property Rights [Member] Preferred Stock Designated [Member] Series AA [Member] Preferred Series B [Member] Preferred Series C [Member] Preferred Series D [Member] Undesignated [Member] Series B Preferred Stock [Member] Series C Convertible Redeemable Preferred Stock [Member] Series D Preferred Stock [Member] One Investor [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Purchase Agreement [Member] Promissory Notes [Member] Securities Purchase Agreement [Member] Conversion of Series C Preferred Stock [Member] Settlement of Debt [Member] Consulting Agreement [Member] Independent Contractor [Member] Independent Contractor Agreement [Member] Exercise Price Range [Axis] Price Range One [Member] Price Range Two [Member] Price Range Three [Member] Executive Officer Former Executive and Former Operational Manager [Member] Blue Ridge Consulting LLC [Membe] Chief Executive Officer [Member] One Officer and Executive [Member] Former President [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] One Significant Customers [Member] Two Significant Customers [Member] Supplier Concentration Risk [Member] Supplier [Member] Accounts Receivable [Member] Two Customers [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Settlement Agreement [Member] Board of Directors Chairman [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current Assets: Cash Accounts receivable, net Prepaid expenses and other current assets Total current assets Patents, net Total assets LIABILITIES AND SHAREHOLDERS’ DEFICIT Current Liabilities Accounts payable and accrued liabilities Accrued interest Deferred compensation Notes payable, net of discounts of $10,587 and $75,800 as of December 31, 2022 and 2021, respectively Notes payable – former related party Derivative liability Total current liabilities Other long term liabilities Total liabilities COMMITMENTS AND CONTINGENCIES, note 8 Shareholders’ deficit Preferred stock value Common stock, $0.0001 par value; 2,500,000,000 shares authorized; and 213,227,538 and 74,498,761 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively Additional paid-in capital Stock subscriptions Accumulated deficit Total shareholders’ deficit Total liabilities and shareholders’ deficit Discounts on notes payable current Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Loss from operations Other income (expense) Change in fair value of derivative liability Gain on extinguishment of debt Other expense Interest expense, net Total other expense Loss before income taxes Provision for income taxes Net loss Basic and diluted loss per share Weighted average common share outstanding: Basic and diluted Balance Balance, shares Issuance of Commitment shares in connection with promissory notes Issuance of Commitment shares in connection with promissory notes, shares Common Stock issued for cash Common stock issued for cash, shares Shares issued for conversion of notes payable and accrued interest Shares issued for conversion of notes payable and accrued interest, shares Shares issued for conversion of Preferred Series D to common share Shares issued for conversion of Preferred Series D to common share, shares Common Shares issued from debt settlement Common Shares issued from debt settlement, shares Common shares issued as settlement of debt with former related party Common shares issued as settlement of debt with former related party, shares Common shares issued pursuant to consulting agreements Common shares issued pursuant to consulting agreements, shares Net loss Inducement loss related to conversion of preferred stock Common Shares issued for services Common Shares issued for services, shares Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to cash used in operating activities: Depreciation and amortization expense Bad debt expense Stock-based compensation Fair value of commitment shares issued with debt Fair value of equity issued for services Amortization of note discount and original issue discount Change in fair value of derivative liability Gain on extinguishment of debt Changes in assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable and accrued liabilities Accrued interest Deferred compensation Net cash used in operating activities Financing activities: Proceeds from the issuance of notes payable Repayments on former related party advances Proceeds from issuance of common stock and units Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of year Cash, end of year Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Non-Cash Investing and Financing Activities: Conversion of notes payable and accrued interest to common stock Conversion of Preferred stock to common stock Original debt discount on convertible notes Issuance of common stock to settle debt Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business and Summary of Significant Accounting Policies Revenue from Contract with Customer [Abstract] Revenue Recognition Goodwill and Intangible Assets Disclosure [Abstract] Patents Debt Disclosure [Abstract] Notes payable Equity [Abstract] Shareholders’ Deficit Related Party Transactions [Abstract] Related Party and former Related Parties Transactions Income Tax Disclosure [Abstract] Income taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Risks and Uncertainties [Abstract] Concentrations Subsequent Events [Abstract] Subsequent Events Basis of Presentation and Principles of Consolidation Going Concern Use of Estimates Cash and cash equivalents Accounts Receivable Impairment of Long-lived Assets Equity-Based Compensation Income Taxes Net Loss per Share Fair Value of Financial Instruments Derivative Liability Recent Accounting Standard Updates Schedule of Balances of Liabilities Measured at Fair Value Schedule of Changes in the Liabilities with Significant Unobservable Inputs Schedule of Variable Debentures Black-Scholes Valuation Assumptions Schedule of Sources of Revenue Schedule of Patents Schedule of Estimated Future Amortization Expense Schedule of Notes Payable Schedule of Maturity Dates of Notes Payable Schedule of Preferred Stock Schedule of Stock Options Outstanding Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range Schedule of Warrants Outstanding Schedule of Warrants Exercise Price Range Schedule of Effective Income Tax Rate Reconciliation Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Derivative liability Total Derivative liability, beginning balance Settlements by debt extinguishment Settlements by debt extinguishment Change in estimated fair value Derivative liability,ending balance Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Expected term Derivative liability measurement Forfeitures Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Acquisitions description Common stock, voting rights Accumulated losses Cash flow from operations Working capital Debt and equity financing Provision for doubtful accounts Stock options, outstanding Stock options, exercisable Number of warrants outstanding Convertible note Principal interest convertible Principal interest convertible Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Total sources of revenue Recognized net revenues Patents Less accumulated amortization Patents net 2023 2024 Acquisition of patents Patents expiration period Amortization expense Notes payable at beginning of period Notes payable issued Settlements on note payable Repayments of notes payable in cash Less amounts converted to stock Notes payable at end of period Less debt discount Note payable, net Notes payable issued to former related party Notes payable issued to non-related party Past due December 31, 2023 Total Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Notes Payable Proceeds from issuance of note payable Debt instrument, interest rate Debt instrument description Debt instrument face amount Accrued interest Debt conversion, stock issued Debt conversion, stock issued Percentage of cash premium Prepayment penalty Convertible Debt Realized profit, percentage Gain on debt extinguishment Number of shares issued for debt Percentage of debt provision Note payable related parties Principal payment of debt Note payable outstanding Long-term acquisition payable for costs not paid at closing Percentage of proceeds from any private placement or gross profits Shares as extingusihment Debt instrument periodic payment Acquisition payable Debt effective interest rate Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of shares authorized Number of shares outstanding Par value Liquidation value Stock option outstanding, ending balance Weighted average exercise price, beginning balance Weighted Average Remaining Contractual Term (years), Outstanding Beginning Aggregated intrinsic value, outstanding beginning balance Stock option outstanding, granted Weighted average exercise price, granted Weighted average remaining contractual term (years), granted Aggregated intrinsic value, outstanding, granted Stock option outstanding, cancelled Weighted average exercise price, cancelled Weighted average remaining contractual term (years), cancelled Aggregated intrinsic value, outstanding, cancelled Stock option outstanding, exercised Weighted average exercise price, exercised Weighted average remaining contractual term (years), exercised Aggregated intrinsic value, outstanding beginning balance Weighted average remaining contractual term (years), outstanding beginning Stock option outstanding, ending balance Weighted average exercise price, beginning balance Aggregated intrinsic value, exercisable ending Stock option outstanding, exercisable ending balance Weighted average exercise price, ending balance Weighted average remaining contractual term (years), outstanding beginning Aggregated intrinsic value, exercisable ending Range of exercise prices Number of outstanding Weighted average remaining contractual life Weighted average exercise price Number of exercisable Weighted average exercise price exercisable Shares outstanding, ending balance Weighted-average exercise price, exercisable ending balance Shares, granted Weighted-average exercise price, granted Shares, cancelled Weighted average exercise price, cancelled Shares, exercised Weighted-average exercise price, exercised Shares outstanding, ending balance Weighted-average exercise price, exercisable ending balance Range of exercise prices. upper limit Weighted average remaining contractual life Weighted average exercise price Number of warrants exercisable Weighted average exerice price Schedule of Stock by Class [Table] Class of Stock [Line Items] Number of shares outstanding Preferred stock voting rights Stated value dividend Warrants term Share exercise price Liquidation value of preferred stock, per share Preferred stock, dividend per share Change in rights due to amendment and restated certificate, description Share conversion Convertible preferred stock, shares outstanding Conversion price Share price Conversion of stock description Number of shares issued Shares issued for conversion of notes payable, shares Number of stock issued, value Convertible preferred stock shares issued Shares issued for conversion of notes payable Issuance of common stock, shares Shares issued for common stock for services, shares Shares issued for common stock for services, value Inducement loss Issuance of common stock, value Stock option to officers Stock option vested Vesting period Vesting strike price Stock option cancelled Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Deferred compensation Accrual of deferred compensation Cash repayments of deferred compensation Royalty expense Payment to licensing cost Due to related parties current and noncurrent Stock Issued During Period, Value, New Issues Stock issued during period value new issues Repayments of related party Due to officer Notes payable - related parties Income tax computed at federal statutory rate State taxes, net of federal benefit Non-Deductible expenses Change in valuation allowance Total Effective income tax rate reconciliation at federal statutory income tax rate, amount Income tax examination, description Effective income tax rate reconciliation, other adjustments, percent Interest and penalties Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk, percentage Subsequent Event [Table] Subsequent Event [Line Items] Conversion of stock shares issued Conversion of stock amount issued Interest payable current Issuance of conversion of convertible securities, shares Issuance of conversion of convertible securities value Issuance of common stock services Issuance of common stock value services Notes payable issued to non-related parties. Settlements on note payable. Notes payable issued to non-related parties. Long term debt past maturity. Non Related Parties [Member] Former Related Party [Member] One Promissory Notes [Member] Fixed Rated Notes [Member] Amount of subscription receivable from investors who have been allocated common stock. Past Maturity [Member] Eighteen Fixed Rate [Member] Certain fixed percentage of cash premium Prepayment Penalty Convertible Notes [Member] One Variable Note [Member] Super AA Super Voting Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Thirteen Fixed Rate Promissory Notes [Member] Unrelated Parties [Member] Nine Fixed Rate Promissory Notes [Member] Realized profit, percentage Two Promissory Notes [Member] Percentage of debt provision. Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Notes Payable [Member] Fair value of commitment shares issued with debt Rio Grande Neurosciences Inc [Member] Long-term acquisition payable for costs not paid at closing. Intellectual Property Rights [Member] Conversion Of Preferred C Stock To Common Stock Issuance of common stock to settle debt Original debt discount on convertible notes. Percentage of proceeds from any private placement or gross profits. Schedule of preferred stock [Table text block]. Series AA [Member] Preferred Series B [Member] Preferred Series C [Member] Preferred Series D [Member] Undesignated [Member] Series AA Preferred Stock [Member] Subscription Receivable [Member] Warrant term. Share exercise percentage. Stock issued during period value connection with promissory notes. Related Party [Member] Shares issued as settlement of debt with former related party. Common Shares Issued Pursuant To Consulting Agreement. Series C Convertible Redeemable Preferred Stock [Member] Change in rights due to amendmend and restated certificate, description. Convertible preferred stock shares outstanding. Inducement loss related to conversion of preferred stock. Conversion price percentage. Stock issued during period shares connection with promissory notes. Stock issued during period shares settlement of debt with former related party. Common shares issued pursuant to consulting agreement shares. Convertible preferred stock shares issued. One Investor [Member] Purchase Agreement [Member] Stock issued during period fair values shares issued for services. Stock issued during period fair values issued for services. Hanover Portfolio Acquisitions Inc [Member] Stock Options [Member] Seven Fixed Rate [Member] Sixteen Fixed Rate [Member] Eight Fixed Promissory Notes [Member] Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation settlements by debt conversion. Promissory Notes [Member] Securities Purchase Agreement [Member] Conversion of Series C Preferred Stock [Member] Settlement of Debt [Member] Consulting Agreement [Member] Independent Contractor [Member] Schedule Of Source Of Revenue [Table TextBlock] Patents expiration period. Weighted average remaining contractual term (years), beginning outstanding. Weighted Average Remaining Contractual Term (years), Granted. Working capital deficiency. Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term cancelled. Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term exercised. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding aggregate intrinsic value granted. Acquisition Payable. Independent Contractor Agreement [Member] Price Range One [Member] Price Range Two [Member] Price Range Three [Member] Share based compensation arrangement by share based paymet award non option outstanding weighted average number of share. Share based compensation arrangement by share based paymet award non option grand in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option forfeited or expired in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option exercised in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term beginning. Share based compensation arrangement by share based payment award non option equity instruments exercises in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments exercisable number. Weighted average exercise price per share exercise price warrant exercisable. Schedule Of Share Based Compensation Shares Authorized Under Warrant Plans By Exercise Price Range Table [TextBlock] Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Exercisable Term 2. Executive Officer Former Executive and Former Operational Manager [Member] Accrual of deferred compensation. Repayments of deferred compensation. One Officer and Executive [Member] Blue Ridge Consulting LLC [Membe] Former President [Member] Two Significant Customers [Member] One Significant Customers [Member] Supplier [Member] Two Customers [Member] Settlement Agreement [Member] Payment to licensing cost. Preferred Stock Designated [Member] Accrued interest. Assets, Current Assets Liabilities, Current Liabilities CommonStockShareSubscribedButUnissuedSubscriptionReceivable Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Interest Payable, Net Increase (Decrease) in Deferred Compensation Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Derivative Assets (Liabilities), at Fair Value, Net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Finite-Lived Patents, Gross Repayments of Notes Payable Conversion of Stock, Amount Converted Debt Instrument, Unamortized Discount Notes and Loans Payable Notes Payable, Related Parties Notes payable issued to non-related parties Long-Term Debt Interest Payable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures 10. Stock Options and Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice Deferred Compensation Equity Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Effective Income Tax Rate Reconciliation, Percent EX-101.PRE 10 endv-20221231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Apr. 17, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 000-55453    
Entity Registrant Name ENDONOVO THERAPEUTICS, INC.    
Entity Central Index Key 0001528172    
Entity Tax Identification Number 45-2552528    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 6320 Canoga Avenue    
Entity Address, Address Line Two 15th Floor    
Entity Address, City or Town Woodland Hills    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91367    
City Area Code (800)    
Local Phone Number 489-4774    
Trading Symbol ENDV    
Title of 12(g) Security Common stock, par value $0.0001    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 1,128,567
Entity Common Stock, Shares Outstanding   270,285,405  
ICFR Auditor Attestation Flag false    
Auditor Firm ID 468    
Auditor Name Rose, Snyder & Jacobs LLP    
Auditor Location Encino, CA    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 98 $ 85,936
Accounts receivable, net 944
Prepaid expenses and other current assets 15,724 7,975
Total current assets 15,822 94,855
Patents, net 1,265,444 1,912,356
Total assets 1,281,266 2,007,211
Current Liabilities    
Accounts payable and accrued liabilities 884,195 658,463
Accrued interest 3,542,650 2,528,459
Deferred compensation 4,442,606 3,891,361
Notes payable, net of discounts of $10,587 and $75,800 as of December 31, 2022 and 2021, respectively 7,041,145 7,055,030
Notes payable – former related party 112,100 126,100
Derivative liability 17,359,064 3,442,297
Total current liabilities 33,381,760 17,701,710
Other long term liabilities 79,825 79,825
Total liabilities 33,461,585 17,781,535
COMMITMENTS AND CONTINGENCIES, note 8
Shareholders’ deficit    
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; and 213,227,538 and 74,498,761 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively 21,322 7,449
Additional paid-in capital 42,919,086 40,663,187
Stock subscriptions (1,570) (1,570)
Accumulated deficit (75,119,183) (56,443,416)
Total shareholders’ deficit (32,180,319) (15,774,324)
Total liabilities and shareholders’ deficit 1,281,266 2,007,211
Super AA Super Voting Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value 25 25
Series B Convertible Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value 1 1
Series C Convertible Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value
Series D Convertible Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Discounts on notes payable current $ 10,587 $ 75,800
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 2,500,000,000 2,500,000,000
Common stock, shares issued 213,227,538 74,498,761
Common stock, shares outstanding 213,227,538 74,498,761
Super AA Super Voting Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 25,000 25,000
Preferred stock, shares outstanding 25,000 25,000
Series B Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000 50,000
Preferred stock, shares issued 600 600
Preferred stock, shares outstanding 600 600
Series C Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 8,000 8,000
Preferred stock, shares issued 738 738
Preferred stock, shares outstanding 738 738
Series D Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 20,000 20,000
Preferred stock, shares issued 50 305
Preferred stock, shares outstanding 50 305
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenue $ 135,355 $ 73,105
Cost of revenue 9,990 14,985
Gross profit 125,365 58,120
Operating expenses 3,389,705 2,284,667
Loss from operations (3,264,340) (2,226,547)
Other income (expense)    
Change in fair value of derivative liability (14,026,546) 41,057
Gain on extinguishment of debt 362,894 22,162
Other expense (225,268)
Interest expense, net (1,321,575) (941,566)
Total other expense (15,210,495) (878,347)
Loss before income taxes (18,474,835) (3,104,894)
Provision for income taxes
Net loss $ (18,474,835) $ (3,104,894)
Basic and diluted loss per share $ (0.13) $ (0.05)
Weighted average common share outstanding:    
Basic and diluted 139,206,511 59,836,620
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statement of Shareholders' Deficit - USD ($)
Preferred Stock [Member]
Series AA Preferred Stock [Member]
Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 25 $ 1 $ 2,453 $ 38,963,827 $ (1,570) $ (53,338,522) $ (14,373,786)
Balance, shares at Dec. 31, 2020 25,000 600 305 763 24,536,689        
Issuance of Commitment shares in connection with promissory notes $ 787 221,905 222,692
Issuance of Commitment shares in connection with promissory notes, shares         7,868,668        
Common Stock issued for cash $ 700 125,300 $ 126,000
Common stock issued for cash, shares         7,000,000       2,505,834
Shares issued for conversion of notes payable and accrued interest $ 2,746 1,115,244 $ 1,117,900
Shares issued for conversion of notes payable and accrued interest, shares         27,461,307       27,461,307
Shares issued for conversion of Preferred Series D to common share $ 111 (111)
Shares issued for conversion of Preferred Series D to common share, shares       (25) 1,111,111        
Common Shares issued from debt settlement $ 151 57,576 57,727
Common Shares issued from debt settlement, shares         1,515,152        
Common shares issued as settlement of debt with former related party $ 251 84,446 84,697
Common shares issued as settlement of debt with former related party, shares         2,505,834        
Common shares issued pursuant to consulting agreements $ 250 95,000 95,250
Common shares issued pursuant to consulting agreements, shares         2,500,000        
Net loss (3,104,894) (3,104,894)
Balance at Dec. 31, 2021 $ 25 $ 1 $ 7,449 40,663,187 (1,570) (56,443,416) (15,774,324)
Balance, shares at Dec. 31, 2021 25,000 600 305 738 74,498,761        
Issuance of Commitment shares in connection with promissory notes $ 345 46,448 46,793
Issuance of Commitment shares in connection with promissory notes, shares         3,450,000        
Common Stock issued for cash $ 1,500 140,500 142,000
Common stock issued for cash, shares         15,000,000        
Shares issued for conversion of notes payable and accrued interest $ 2,585 514,415 $ 517,000
Shares issued for conversion of notes payable and accrued interest, shares         25,850,000       1,355,310,243
Shares issued for conversion of Preferred Series D to common share $ 2,550 (2,550)
Shares issued for conversion of Preferred Series D to common share, shares     (255)   25,500,000        
Common Shares issued from debt settlement $ 243 45,904 46,147
Common Shares issued from debt settlement, shares         2,428,777        
Net loss (18,474,835) (18,474,835)
Inducement loss related to conversion of preferred stock 200,932   (200,932)
Common Shares issued for services $ 6,650 1,310,250 1,316,900
Common Shares issued for services, shares         66,500,000        
Balance at Dec. 31, 2022 $ 25 $ 1 $ 21,322 $ 42,919,086 $ (1,570) $ (75,119,183) $ (32,180,319)
Balance, shares at Dec. 31, 2022 25,000 600 50 738 213,227,538        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating activities:    
Net loss $ (18,474,835) $ (3,104,894)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization expense 646,912 648,492
Bad debt expense 944
Stock-based compensation 45,000
Fair value of commitment shares issued with debt 7,698 70,970
Fair value of equity issued for services 1,311,900 95,250
Amortization of note discount and original issue discount 110,611 144,196
Change in fair value of derivative liability 14,026,546 (41,057)
Gain on extinguishment of debt (362,894) (22,162)
Changes in assets and liabilities:    
Accounts receivable (2)
Prepaid expenses and other current assets (7,750) 23,850
Accounts payable and accrued liabilities 269,391 (42,470)
Accrued interest 1,196,394 733,999
Deferred compensation 551,245 507,244
Net cash used in operating activities (678,838) (986,584)
Financing activities:    
Proceeds from the issuance of notes payable 465,000 950,000
Repayments on former related party advances (14,000) (16,900)
Proceeds from issuance of common stock and units 142,000 126,000
Net cash provided by financing activities 593,000 1,059,100
Net increase (decrease) in cash (85,838) 72,516
Cash, beginning of year 85,936 13,420
Cash, end of year 98 85,936
Supplemental disclosure of cash flow information:    
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities:    
Conversion of notes payable and accrued interest to common stock 517,000 493,748
Conversion of Preferred stock to common stock 255,000 33,333
Original debt discount on convertible notes 45,398
Issuance of common stock to settle debt $ 202,697
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of Business and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Summary of Significant Accounting Policies

Note 1 - Nature of Business and Summary of Significant Accounting Policies

 

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

 

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of inflammation on and in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

 

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

 

On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.

 

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, WeHealAnimals, Inc. and SofPulse, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.

 

Going Concern

 

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has accumulated losses of $75.1 million, negative cash flows from operations of approximately $0.7 million and $33.4 million of working capital deficit. The Company has raised approximately $0.6 million in debt and equity financing for the year ended December 31, 2022. The Company is raising additional capital through debt and/or equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential future license and distribution agreements, has raised capital through the issuance of promissory notes and has engaged a broker/dealer to raise additional capital.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

 

 

Cash and cash equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2022 and 2021, the Company does not hold any cash in excess of FDIC limits and does not have any cash equivalents.

 

Accounts Receivable

 

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at December 31, 2022 and 2021. Account receivables are written off when all collection attempts have failed.

 

Impairment of Long-lived Assets

 

The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. The Company did not recognize any impairment loss during the years ended December 31, 2022 and 2021.

 

Equity-Based Compensation

 

The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method.

 

Income Taxes

 

The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.

 

Net Loss per Share

 

Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

 

The Company has 3,012,410 stock options, of which 262,410 are exercisable and 2,000 warrants convertible into an equivalent number of common stock as of December 31, 2022. The Company has 513,730 stock options, of which 513,730 are exercisable and 22,200 warrants convertible into an equivalent number of common stock as of December 31, 2021.

 

As of December 31, 2022 and 2021, the Company has variable rate convertible notes in an aggregate amount of $7,039,832 and $6,442,035, respectively, including principal and accrued interest, which are convertible into 1,355,310,243 and 632,789,106, respectively, shares of common stock. Such shares are not included in the calculation of the diluted net loss per share as they would have an antidilutive effect.

 

 

Fair Value of Financial Instruments

 

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

 

The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

 

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

 

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: uses unobservable inputs that are not corroborated by market data.

 

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operation.

 

The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:

 

   Fair Value Measurements at December 31, 2022 Using 
   Quoted Prices in
Active
Markets for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $-   $-   $17,359,064   $17,359,064 
Total  $      -   $          -   $17,359,064   $17,359,064 

 

   Fair Value Measurements at December 31, 2021 Using 
   Quoted Prices in
Active
Markets
for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $        -   $            -   $3,442,297   $3,442,297 
Total  $-   $-   $3,442,297   $3,442,297 

 

 

The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:

 

   Derivative 
   Liability 
Balance December 31, 2020  $4,202,597 
      
Settlement by debt extinguishment   (133,386)
Settlement by debt conversion   (585,857)
Change in estimated fair value   (41,057)
      
Balance December 31, 2021  $3,442,297 
      
Settlement by debt Extinguishment   (109,779)
Change in estimated fair value   14,026,546 
      
Balance December 31, 2022  $17,359,064 

 

Derivative Liability

 

As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:

 

      For Years Ending December 31,  
      2022       2021  
                 
Expected term     0-1 month       1 -4 months  
Exercise price     $0.004-$0.015       $0.01-$0.03  
Expected volatility     153%-169%       177%-206%  
Expected dividends     None       None  
Risk-free interest rate     1.63%-4.73%       0.06%-0.39%  
Forfeitures     None       None  

 

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

 

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

 

 

Recent Accounting Standard Updates

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company’s financial statements.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition

Note 2 - Revenue Recognition

 

Contracts with Customers

 

We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

 

We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, we have an unconditional right to receive payment. Our sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.

 

Revenues for sales of our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.

 

In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

 

During the years ended December 31, 2022 and 2021, we recognized revenue of $135,355 and $73,105, respectively, from SofPulse® devices.

 

Sources of Revenue

 

We have identified the following revenues disaggregated by revenue source:

 

1.Sales to plastic surgeons
2.Sales to wound care facilities
3.Sales to hospitals
4.Sales to other physicians
5.Royalty fee from licensing, net

 

 

For the years ended December 31, 2022 and 2021, the sources of revenue were as follows:

 

   2022   2021 
   Years Ended 
   December 31, 
   2022   2021 
         
Direct sales- Plastic surgeons, gross   21,732    73,105 
Royalty/licensing, net   113,623    - 
Total sources of revenue  $135,355   $73,105 

 

The royalty/licensing revenue recognized in 2022 resulted from specific transactions. No general patent rights were assigned to the distributor. The revenue recognized was based on the number of items included in the transactions.

 

Warranty

 

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

 

Significant Judgments in the Application of the Guidance in ASC 606

 

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

 

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

 

Practical Expedients

 

Our payment terms for sales direct to distributors, end users, hospitals and doctors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

 

Effective Date and Transition Disclosures

 

Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Patents
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Patents

Note 3 – Patents

 

In December 2017, we acquired from RGN a patent portfolio for $4,500,000. The earliest patent expires in 2024.

 

The following is a summary of patents less accumulated amortization at December 31, 2022 and 2021:

 

 

   2022   2021 
   December 31, 
   2022   2021 
         
Patents  $4,500,000   $4,500,000 
           
Less accumulated amortization   3,234,556    2,587,644 
           
Patents net  $1,265,444   $1,912,356 

 

Amortization expense for the years ended December 31, 2022 and 2021, was $646,912.

 

 

The estimated future amortization expense related to patents as of December 31, 2022, is as follows:

 

Years Ended December 31,  Amount 
     
2023  $646,910 
2024   618,534 
Total  $1,265,444 

 

The Company determined that the patents were not impaired as of December 31, 2022 and 2021.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Notes payable
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Notes payable

Note 4 - Notes payable

 

As of December 31, 2022 and December 31, 2021, the notes payable activity was as follows:

 

 

   2022   2021 
   As of December 31, 
   2022   2021 
         
Notes payable at beginning of period  $7,256,930   $6,835,196 
Notes payable issued   465,000    950,000 
Settlements on note payable   (163,826)   (117,770)
Repayments of notes payable in cash   (14,000)   (16,900)
Less amounts converted to stock   (380,272)   (393,596)
Notes payable at end of period   7,163,832    7,256,930 
Less debt discount   (10,587)   (75,800)
Note payable, net  $7,153,245   $7,181,130 
           
Notes payable issued to former related party  $112,100   $126,100 
Notes payable issued to non-related party  $7,041,145   $7,055,030 

 

The maturity dates on the notes are as follows:

 

 

Twelve months ending,  Non-related parties   Former
Related
party		   Total 
Past due  $6,626,145   $112,100   $6,738,245 
December 31, 2023   415,000    -    415,000 
Total  $7,041,145   $112,100   $7,153,245 

 

Activity during the year ended December 31, 2022

 

Fixed rates convertible notes

 

During the year ended December 31, 2022, the Company issued seven (7) fixed rate promissory notes totaling $465,000 in principal, for funding of $465,000 with original terms of nine to twelve months and interest rates of 15% and 18%. The holder of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, immediately to six-month after issuance date. These fixed rate promissory notes include a prepayment feature at a premium of 15% and a make good provision, which guarantees the holder additional shares if the holder does not realize a 15% or 18% return on the resale of the common shares.

 

 

As of December 31, 2022, the Company has twenty (20) fixed-rate promissory notes with an outstanding balance of $1,819,728, of which $1,404,728 are past maturity. As of December 31, 2022, the Company has a total of sixteen (16) fixed rate notes for total principal amount of $1,465,000 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. The Company accrued approximately $225,000 related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the consolidated statements of operations and accounts payable and accrued expenses in the consolidated balance sheet as of December 31, 2022.

 

During year ended December 31, 2022, the Company converted $136,728 in accrued interest and $380,272 in principal balance into 25,850,000 shares of common stock.

 

Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company. The prepayment penalty approximates $62,800 as of December 31, 2022, but the Company determined that such liability was not probable as of December 31, 2022, pursuant to ASC 450 Contingencies.

 

Variable-rate notes

 

The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2022, is $4,607,100, which are all past maturity. There was no conversion of notes into the Company’s common stock during the year ended December 31, 2022.

 

During the year ended December 31, 2022, the Company settled one variable note with a principal of $163,826 and $45,475 in accrued interest for no consideration.

 

Activity during the year ended December 31, 2021

 

During the year ended December 31, 2021, the Company issued eight (8) fixed rate promissory notes totaling $950,000 for funding of $950,000 with original terms of twelve months and interest rates of 15%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features. As of December 31, 2021, the fixed-rate notes had an outstanding balance of $1,735,000, of which $785,000 are past maturity. As of December 31, 2021, the Company has 13 fixed rate promissory notes with unrelated parties for total amount of $1,735,000. Nine of these fixed rates promissory notes for total balance of $1,000,000 carry a make whole provision requiring the Company to issue additional shares of its common stock if the underlying investor is not able to realize a profit of 15% against the conversion price of such shares after customary and reasonable expenses.

 

During the year ended December 31, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments and recorded $58,407 as loss from debt extinguishment in the consolidated statements of operations.

 

During the year ended December 31, 2021, the Company settled one of its promissory notes by issuing 1,515,152 restricted shares of the Company’s common stock with a fifteen percent (15%) make-whole provision. The Company recorded a gain on debt extinguishment of approximately $128,000.

 

During the year ended December 31, 2021, the Company converted $393,597 in principal and $100,152 in accrued but unpaid interest into 27,461,307 shares of common stock.

 

The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2021, is $4,770,926, of which $4,770,926 are past maturity.

 

Former related-party notes

 

Notes payable to a former related party in the aggregate amount of $112,100 was outstanding at December 31, 2022, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the year ended December 31, 2022, the Company paid total principal of $14,000 to this former related party. As of December 31, 2022, the Company had notes payable to related parties amounting to $112,100. Refer to Note 7– Related Party Transactions.

 

 

Notes payable to a former related party in the aggregate amount of $126,100 was outstanding at December 31, 2021, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the year ended December 31, 2021, the Company paid total principal of $16,900 to this former related party.

 

Other notes

 

In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $500,000, each, of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. During the years ended December 31, 2022, and 2021, the Company did not issue notes in connection with these private placements and did not repay any of these notes. As of December 31, 2022, and 2021, notes payable outstanding under these private placements are $624,903, all of which are past maturity.

 

Notes payable totaling $2,110,450 are secured by the intellectual property acquired from RGN including patents obtained in the acquisition.

 

Acquisition Payable

 

In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $155,000 long-term acquisition payable for costs that were not paid at closing. This payable is non-interest bearing and IPR agreed to make payments up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company.

 

There was no activity during the year ended December 31, 2022. During the year ended December 31, 2021, the Company issued 2,505,834 as extinguishment for $75,175 in principal and interest. The balance of the acquisition payable is $79,825, as of December 31, 2022 and 2021.

 

Effective Interest Rate

 

During the years ended December 31, 2022, and 2021, the Company’s effective interest rate was 18% and 12% respectively.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Deficit
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Shareholders’ Deficit

Note 5 - Shareholders’ Deficit

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

 

 

   Number of Shares
Authorized		   Number of Shares
Outstanding at
December 31,
2022		   Par Value   Liquidation Value
per Share		 
Series AA   1,000,000    25,000   $0.0010    - 
Preferred Series B   50,000    600   $0.0001    100 
Preferred Series C   8,000    738   $0.0001    1,000 
Preferred Series D   20,000    50   $0.0001    1,000 
Undesignated   3,922,000    -    -    - 

 

 

Series AA Preferred Shares

 

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

 

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of December 31, 2022 and 2021, there were 25,000 shares of Series AA Preferred stock outstanding.

 

Series B Convertible Preferred Stock

 

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value ($100 per share) divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. There has been no activity during the years ended December 31, 2022 and 2021. As of December 31, 2022 and 2021, there were 600 shares of Series B outstanding.

 

Series C Secured Redeemable Preferred Stock

 

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation for its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

 

Management determined the fair value of the new instrument based on the guidance in ASC 820 Fair Value Measurement. Management concluded that the preferred stock should not be classified as a liability per the guidance in ASC 480 Distinguishing Liabilities from Equity even though the conversion would require the issuance of variable number of shares since such obligation is not unconditional. Management classified the Series C in permanent equity as of December 31, 2022 and 2021.

 

During the years ended December 31, 2022 and 2021, the Company converted 0 and 25 shares of Series C into 0 and 1,111,111 shares of common stock, respectively. As of December 31, 2022 and 2021, there were 738 shares of Series C outstanding, respectively.

 

 

Series D Convertible Preferred Stock

 

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock.

 

The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.

 

In September 2022, the Company offered to each holder of Series D the opportunity to convert each share of Series D into 100,000 shares of the Company’s common stock at an effective conversion price of $0.01. In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale.

 

During the year ended December 31, 2022, the Company issued 25,500,000 shares of common stock upon conversion of 255 shares of Series D preferred stock, for a total value of $255,000. At December 31, 2022, based on the stock price, the value of these shares was in excess of the 15% guaranteed return.

 

As of December 31, 2022 and 2021, there were 50 and 305 shares of Series D outstanding, respectively.

 

Common Stock

 

Activity during the year ended December 31, 2022:

 

During the year ended December 31, 2022, the Company issued 25,850,000 shares of common stock for the conversion of $380,272 of principal notes and accrued interest in the amount of $136,728.

 

During the year ended December 31, 2022, the Company issued 2,428,777 shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.

 

During the year ended December 31, 2022, the Company issued 3,450,000 shares of common stock as commitment shares in connection with promissory notes.

 

During the year ended December 31, 2022, the Company issued 66,500,000 shares of common stock for services for total fair value of $1,316,900.

 

During the year ended December 31, 2022, the Company issued 25,500,000 shares of common stock in exchange for 255 shares of Series D Preferred, which resulted in an inducement loss of $200,932 recorded as a deemed dividend in the shareholders’ deficit as of December 31, 2022.

 

During the year ended December 31, 2022, the Company issued 3 units or 15,000,000 shares of common stock pursuant to a private placement for total net cash receipt of $142,000.

 

Activity during the year ended December 31, 2021:

 

During the year ended December 31, 2021, the Company issued 27,461,307 shares of common stock for the conversion of principal notes and accrued interest for aggregate fair value of issued common stock of $1,117,990.

 

During the year ended December 31, 2021, the Company issued 7,868,668 shares of common stock labeled as commitment shares in connection with the issuance of promissory notes for a total fair value of approximately $223,000.

 

During the year ended December 31, 2021, the Company issued 7,000,000 shares of common stock pursuant to securities purchase agreement for total consideration of $126,000.

 

 

During the year ended December 31, 2021, the Company issued 1,111,111 shares of common stock with a value of $33,333, related to the conversion of Series C.

 

During the year ended December 31, 2021, the Company issued 4,020,986 shares of common stock with a value of $142,424, related to the settlement of debts, of which 2,505,834 shares of common stock were issued with a fair value of $84,697 to a former related party.

 

During the year ended December 31, 2021, the Company issued 2,500,000 shares of common stock in connection with the consulting agreement, with a fair value of approximately $95,000.

 

Stock Options

 

During the year ended December 31, 2022, the Company executed an independent contractor agreement with the Company’s new President and Chief Commercial Officer of its medical division. Pursuant to this agreement, the Company granted 3,000,000 stock options to purchase an equivalent number of common stocks, with 250,000 options vesting each quarter with a term of 2 years from vesting and a strike price of $0.0076. The Company did not issue any stock options during the year ended December 31, 2021.

 

The Company cancelled 501,320 and 2,500,350 stock options during the years ended December 31, 2022 and 2021, respectively.

 

The Company did not recognize any share-based compensation expense for the years ended December 31, 2022 and 2021.

 

Stock option activity for the years ended December 31, 2022 and 2021, is as follows:

 

   Options   Weighted
Average
Exercise Price
Per Share		   Weighted
Average
Remaining
Contractual
Term (years)		   Aggregate
Intrinsic
Value		 
Outstanding at December 31, 2020   3,014,080   $0.37    1.67   $- 
Granted   -   $-    -    - 
Cancelled   (2,500,350)  $0.16    0.65    - 
Exercised   -   $-    -    - 
Outstanding at December 31, 2021   513,730   $1.43    0.76   $- 
                     
Granted   3,000,000   $0.0076    3.40    31,200 
Cancelled   (501,320)  $0.18    -    - 
Exercised   -   $-           
Outstanding at December 31, 2022   3,012,410   $0.22    3.40   $31,200 
                     
Exercisable at December 31, 2022   262,410   $2.45    2.02   $2,600 

 

 

The balance of all stock options outstanding as of December 31, 2022, is as follows:

 

    Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
Range of       Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life   Price   Exercisable   Price 
                      
 Options                          
$54.00    11,750    4.30   $54.00    11,750   $54.00 
$11.60    660    -   $11.60    660   $11.60 
$0.0076    3,000,000    3.40   $0.0076    250,000   $0.0076 
      3,012,410    3.40   $0.22    262,410   $0.22 

 

Warrants

 

During the years ended December 31, 2022, and 2021, the Company did not issue any warrants.

 

A summary of the changes of the warrants during the years ended December 31, 2022 and 2021, are presented below:

 

 

   Outstanding Warrants 
       Weighted
Average		 
       Exercise Price 
   Shares   Per Share 
Outstanding at December 31, 2020   39,295   $200.72 
Granted   -   $- 
Cancelled   (17,095)  $384.39 
Exercised   -   $- 
Outstanding at December 31, 2021   22,200   $59.25 
           
Granted   -   $- 
Cancelled   (20,200)  $60.17 
Exercised   -   $- 
Outstanding at December 31, 2022   2,000   $50.00 
           
Exercisable at December 31, 2022   2,000   $50.00 

 

The balance of all warrants outstanding as of December 31, 2022, is as follows:

 

 

    Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
Range of       Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life   Price   Exercisable   Price 
                      
 Warrants                          
                            
$50.00    2,000    0.22   $50.00    2,000   $50.00 
      2,000    0.22   $50.00    2,000   $50.00 

 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party and former Related Parties Transactions
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party and former Related Parties Transactions

Note 6 – Related Party and former Related Parties Transactions

 

One executive officer, one former executive and one former operational manager of the Company have agreed to defer a portion of their compensation until cash flow improves. As of December 31, 2022, and 2021, the balances of their deferred compensation were $1,350,265 and $1,289,625, which reflects $300,000 accrual of deferred compensation in accordance with contractual arrangement, approximately $170,000 cash repayments of deferred compensation and $69,217 non-cash reduction pursuant to royalties charged to the former operational manager on SofPulse units during the year ended December 31, 2022, and $300,000 accrual of deferred compensation, $250,950 cash repayments during the year ended December 31, 2021. The royalty/licensing revenue recognized in 2022 was generated from the former operational manager who is developing business in Costa Rica and Mexico. In lieu of payment for the royalty/licensing, the former operational manager paid $44,406 directly to the Company’s vendor, and the deferred compensation due to him was reduced by $69,217.

 

During the year ended December 31, 2022, the Company issued 25,000,000 shares of common stock to a company controlled by the Company’s Chief Executive Officer with an estimated fair value of $550,000 for services.

 

During the year ended December 31, 2022, the Chief Executive Officer of the Company advanced $28,021 of funds to the Company of which $25,521 was repaid during the year 2022. During the year ended December 31, 2021, the Chief Executive Officer of the Company advanced $13,530 of funds to the Company of which $13,405 was repaid during the year 2021.

 

The balance of short-term advances due to one officer and executive of the Company at December 31, 2022 and 2021 was $2, 625 and $125, respectively and is included in the Company’s accounts payable and accrued interest balance as of December 31, 2022 and 2021.

 

At December 31, 2022 and 2021, notes payable remain outstanding to the former President of the Company, in the amounts of $112,100 and $126,100, respectively. At December 31, 2022 and 2021, accrued interest on these notes payable totaled $80,034 and $67,787, respectively, and are included in accrued interest on the consolidated balance sheets.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income taxes

Note 7 - Income taxes

 

The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years.

 

The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2022 and 2021, the Company had approximately $33,000,000 and $28,000,000 of federal net operating loss carryforwards, respectively, that it can use to offset a certain amount of taxable income in the future. Some of these federal net operating loss carryforwards begin to expire in 2030. The resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization. Utilization of these net operating losses could be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state laws based on ownership changes and the value of the Company’s stock.

 

A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2022 and 2021:

 

   2022   2021 
Income tax computed at federal statutory rate   -21.0%   -21.0%
State taxes, net of federal benefit   -1.7%   -7.0%
Non-Deductible expenses   15.6%   1.0%
Change in valuation allowance   7.1%   27.0%
Total   0.0%   0.0%

 

The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance.

 

The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2022 and 2021.

 

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 8 - Commitments and Contingencies

 

Legal matters

 

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of December 31, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Concentrations
 12 Months Ended
Dec. 31, 2022
Risks and Uncertainties [Abstract]  
Concentrations

Note 9 – Concentrations.

 

Sales

 

During the year ended December 31, 2022, we had two significant customers which accounted for 84% and 10% of direct sales. In addition, the Company generated all of its royalty/licensing revenue from one former related party.

 

During the year ended December 31, 2021, we had two significant customers which accounted for 28% and 25% of sales.

 

Supplier

 

We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

 

Accounts Receivable

 

At December 31, 2021, we had two customers which accounted for 67% of our accounts receivable balances. There are no accounts receivable balance as of December 31, 2022.

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 10 - Subsequent Events.

 

Subsequent to December 31, 2022, the Company issued 5,000,000 shares of common stock following the conversion of 50 shares of Series D preferred stock.

 

Subsequent to December 31, 2022, the Company issued 6,500,000 shares of common stock pursuant to consulting agreements with an estimated fair value of $63,700.

 

Subsequent to December 31, 2022, the Company issued 22,500,000 shares of common stock pursuant to a private placement for $225,000 in cash.

 

Subsequent to December 31, 2022, the Company issued 10,900,000 shares of common stock for the conversion of $100,000 promissory note and $9,000 in accrued interest with one investor.

 

Subsequent to December 31, 2022, the Company issued 4,300,590 shares of common stock with a fair value of approximately $67,090 as settlement of a convertible note with an approximate carrying value of $209,300.

 

Subsequent to December 31, 2022, the Company issued 1,507,277 shares of common stock with a fair value of approximately $25,000 pursuant to a make good provision from a previously executed settlement agreement.

 

Subsequent to December 31, 2022, the Company issued 6,350,000 shares of common stock as additional consideration pursuant to a securities purchase agreement with estimated fair value of $50,000.

 

 

On March 29, 2023, the Company entered into a binding Letter of Intent (“LOI”) to spin off its current medical device division to an entity managed by Ira Weisberg, the Company’s President and Chief Commercial Officer of its medical division. Mr. Weisberg will be the future President and Chief Executive Officer of this newly formed entity.

 

Subsequent to December 31, 2022, the Company executed a Service-Disabled Veteran-Owned Small Business Government Reseller Agreement with Academy Medical, Inc. to distribute SofPulse® medical devices to ensure its availability to the Veteran Health Administration (“VHA”) and Department of Defense (DoD) contracts.

 

Subsequent to December 31,2022, the Board of director approved the issuance of 39,150,000 shares of common stock for past services with estimated fair value of approximately $552,000.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of Business and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, WeHealAnimals, Inc. and SofPulse, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.

 
Going Concern

Going Concern

 

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has accumulated losses of $75.1 million, negative cash flows from operations of approximately $0.7 million and $33.4 million of working capital deficit. The Company has raised approximately $0.6 million in debt and equity financing for the year ended December 31, 2022. The Company is raising additional capital through debt and/or equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential future license and distribution agreements, has raised capital through the issuance of promissory notes and has engaged a broker/dealer to raise additional capital.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

 

 
Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2022 and 2021, the Company does not hold any cash in excess of FDIC limits and does not have any cash equivalents.

 
Accounts Receivable

Accounts Receivable

 

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at December 31, 2022 and 2021. Account receivables are written off when all collection attempts have failed.

 
Impairment of Long-lived Assets

Impairment of Long-lived Assets

 

The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. The Company did not recognize any impairment loss during the years ended December 31, 2022 and 2021.

 
Equity-Based Compensation

Equity-Based Compensation

 

The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method.

 
Income Taxes

Income Taxes

 

The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.

 
Net Loss per Share

Net Loss per Share

 

Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

 

The Company has 3,012,410 stock options, of which 262,410 are exercisable and 2,000 warrants convertible into an equivalent number of common stock as of December 31, 2022. The Company has 513,730 stock options, of which 513,730 are exercisable and 22,200 warrants convertible into an equivalent number of common stock as of December 31, 2021.

 

As of December 31, 2022 and 2021, the Company has variable rate convertible notes in an aggregate amount of $7,039,832 and $6,442,035, respectively, including principal and accrued interest, which are convertible into 1,355,310,243 and 632,789,106, respectively, shares of common stock. Such shares are not included in the calculation of the diluted net loss per share as they would have an antidilutive effect.

 

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

 

The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

 

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

 

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: uses unobservable inputs that are not corroborated by market data.

 

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operation.

 

The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:

 

   Fair Value Measurements at December 31, 2022 Using 
   Quoted Prices in
Active
Markets for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $-   $-   $17,359,064   $17,359,064 
Total  $      -   $          -   $17,359,064   $17,359,064 

 

   Fair Value Measurements at December 31, 2021 Using 
   Quoted Prices in
Active
Markets
for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $        -   $            -   $3,442,297   $3,442,297 
Total  $-   $-   $3,442,297   $3,442,297 

 

 

The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:

 

   Derivative 
   Liability 
Balance December 31, 2020  $4,202,597 
      
Settlement by debt extinguishment   (133,386)
Settlement by debt conversion   (585,857)
Change in estimated fair value   (41,057)
      
Balance December 31, 2021  $3,442,297 
      
Settlement by debt Extinguishment   (109,779)
Change in estimated fair value   14,026,546 
      
Balance December 31, 2022  $17,359,064 

 
Derivative Liability

Derivative Liability

 

As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:

 

      For Years Ending December 31,  
      2022       2021  
                 
Expected term     0-1 month       1 -4 months  
Exercise price     $0.004-$0.015       $0.01-$0.03  
Expected volatility     153%-169%       177%-206%  
Expected dividends     None       None  
Risk-free interest rate     1.63%-4.73%       0.06%-0.39%  
Forfeitures     None       None  

 

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

 

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

 

 
Recent Accounting Standard Updates

Recent Accounting Standard Updates

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company’s financial statements.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of Business and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Balances of Liabilities Measured at Fair Value

The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:

 

   Fair Value Measurements at December 31, 2022 Using 
   Quoted Prices in
Active
Markets for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $-   $-   $17,359,064   $17,359,064 
Total  $      -   $          -   $17,359,064   $17,359,064 

 

   Fair Value Measurements at December 31, 2021 Using 
   Quoted Prices in
Active
Markets
for		   Significant
Other		   Significant     
   Identical
Assets		   Observable
Inputs		   Unobservable
Inputs		     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
Derivative liability  $        -   $            -   $3,442,297   $3,442,297 
Total  $-   $-   $3,442,297   $3,442,297 
Schedule of Changes in the Liabilities with Significant Unobservable Inputs

The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:

 

   Derivative 
   Liability 
Balance December 31, 2020  $4,202,597 
      
Settlement by debt extinguishment   (133,386)
Settlement by debt conversion   (585,857)
Change in estimated fair value   (41,057)
      
Balance December 31, 2021  $3,442,297 
      
Settlement by debt Extinguishment   (109,779)
Change in estimated fair value   14,026,546 
      
Balance December 31, 2022  $17,359,064 
Schedule of Variable Debentures Black-Scholes Valuation Assumptions

As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:

 

      For Years Ending December 31,  
      2022       2021  
                 
Expected term     0-1 month       1 -4 months  
Exercise price     $0.004-$0.015       $0.01-$0.03  
Expected volatility     153%-169%       177%-206%  
Expected dividends     None       None  
Risk-free interest rate     1.63%-4.73%       0.06%-0.39%  
Forfeitures     None       None  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Sources of Revenue

For the years ended December 31, 2022 and 2021, the sources of revenue were as follows:

 

   2022   2021 
   Years Ended 
   December 31, 
   2022   2021 
         
Direct sales- Plastic surgeons, gross   21,732    73,105 
Royalty/licensing, net   113,623    - 
Total sources of revenue  $135,355   $73,105 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Patents (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Patents

The following is a summary of patents less accumulated amortization at December 31, 2022 and 2021:

 

 

   2022   2021 
   December 31, 
   2022   2021 
         
Patents  $4,500,000   $4,500,000 
           
Less accumulated amortization   3,234,556    2,587,644 
           
Patents net  $1,265,444   $1,912,356 
Schedule of Estimated Future Amortization Expense

The estimated future amortization expense related to patents as of December 31, 2022, is as follows:

 

Years Ended December 31,  Amount 
     
2023  $646,910 
2024   618,534 
Total  $1,265,444 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Notes payable (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Notes Payable

As of December 31, 2022 and December 31, 2021, the notes payable activity was as follows:

 

 

   2022   2021 
   As of December 31, 
   2022   2021 
         
Notes payable at beginning of period  $7,256,930   $6,835,196 
Notes payable issued   465,000    950,000 
Settlements on note payable   (163,826)   (117,770)
Repayments of notes payable in cash   (14,000)   (16,900)
Less amounts converted to stock   (380,272)   (393,596)
Notes payable at end of period   7,163,832    7,256,930 
Less debt discount   (10,587)   (75,800)
Note payable, net  $7,153,245   $7,181,130 
           
Notes payable issued to former related party  $112,100   $126,100 
Notes payable issued to non-related party  $7,041,145   $7,055,030 
Schedule of Maturity Dates of Notes Payable

The maturity dates on the notes are as follows:

 

 

Twelve months ending,  Non-related parties   Former
Related
party		   Total 
Past due  $6,626,145   $112,100   $6,738,245 
December 31, 2023   415,000    -    415,000 
Total  $7,041,145   $112,100   $7,153,245 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Deficit (Tables)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Schedule of Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

 

 

   Number of Shares
Authorized		   Number of Shares
Outstanding at
December 31,
2022		   Par Value   Liquidation Value
per Share		 
Series AA   1,000,000    25,000   $0.0010    - 
Preferred Series B   50,000    600   $0.0001    100 
Preferred Series C   8,000    738   $0.0001    1,000 
Preferred Series D   20,000    50   $0.0001    1,000 
Undesignated   3,922,000    -    -    - 
Schedule of Stock Options Outstanding

Stock option activity for the years ended December 31, 2022 and 2021, is as follows:

 

   Options   Weighted
Average
Exercise Price
Per Share		   Weighted
Average
Remaining
Contractual
Term (years)		   Aggregate
Intrinsic
Value		 
Outstanding at December 31, 2020   3,014,080   $0.37    1.67   $- 
Granted   -   $-    -    - 
Cancelled   (2,500,350)  $0.16    0.65    - 
Exercised   -   $-    -    - 
Outstanding at December 31, 2021   513,730   $1.43    0.76   $- 
                     
Granted   3,000,000   $0.0076    3.40    31,200 
Cancelled   (501,320)  $0.18    -    - 
Exercised   -   $-           
Outstanding at December 31, 2022   3,012,410   $0.22    3.40   $31,200 
                     
Exercisable at December 31, 2022   262,410   $2.45    2.02   $2,600 
Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range

The balance of all stock options outstanding as of December 31, 2022, is as follows:

 

    Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
Range of       Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life   Price   Exercisable   Price 
                      
 Options                          
$54.00    11,750    4.30   $54.00    11,750   $54.00 
$11.60    660    -   $11.60    660   $11.60 
$0.0076    3,000,000    3.40   $0.0076    250,000   $0.0076 
      3,012,410    3.40   $0.22    262,410   $0.22 
Schedule of Warrants Outstanding

A summary of the changes of the warrants during the years ended December 31, 2022 and 2021, are presented below:

 

 

   Outstanding Warrants 
       Weighted
Average		 
       Exercise Price 
   Shares   Per Share 
Outstanding at December 31, 2020   39,295   $200.72 
Granted   -   $- 
Cancelled   (17,095)  $384.39 
Exercised   -   $- 
Outstanding at December 31, 2021   22,200   $59.25 
           
Granted   -   $- 
Cancelled   (20,200)  $60.17 
Exercised   -   $- 
Outstanding at December 31, 2022   2,000   $50.00 
           
Exercisable at December 31, 2022   2,000   $50.00 
Schedule of Warrants Exercise Price Range

The balance of all warrants outstanding as of December 31, 2022, is as follows:

 

 

    Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
Range of       Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life   Price   Exercisable   Price 
                      
 Warrants                          
                            
$50.00    2,000    0.22   $50.00    2,000   $50.00 
      2,000    0.22   $50.00    2,000   $50.00 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2022 and 2021:

 

   2022   2021 
Income tax computed at federal statutory rate   -21.0%   -21.0%
State taxes, net of federal benefit   -1.7%   -7.0%
Non-Deductible expenses   15.6%   1.0%
Change in valuation allowance   7.1%   27.0%
Total   0.0%   0.0%
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Balances of Liabilities Measured at Fair Value (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]      
Derivative liability $ 17,359,064 $ 3,442,297  
Total 17,359,064 3,442,297 $ 4,202,597
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Derivative liability  
Total  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Derivative liability  
Total  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Derivative liability 17,359,064 3,442,297  
Total $ 17,359,064 $ 3,442,297  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Derivative liability, beginning balance $ 3,442,297 $ 4,202,597
Settlements by debt extinguishment (109,779) (133,386)
Settlements by debt extinguishment   (585,857)
Change in estimated fair value 14,026,546 (41,057)
Derivative liability,ending balance $ 17,359,064 $ 3,442,297
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Forfeitures
Measurement Input, Expected Term [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term 0 months 1 month
Measurement Input, Expected Term [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term 1 month 4 months
Measurement Input, Exercise Price [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 0.004 0.01
Measurement Input, Exercise Price [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 0.015 0.03
Measurement Input, Option Volatility [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 153 177
Measurement Input, Option Volatility [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 169 206
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 0 0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 1.63 0.06
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement 4.73 0.39
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]      
Accumulated losses $ 75,119,183 $ 56,443,416  
Cash flow from operations 678,838 986,584  
Working capital 33,400,000    
Debt and equity financing 600,000    
Provision for doubtful accounts 0 0  
Convertible note $ 7,039,832 $ 6,442,035  
Principal interest convertible 1,355,310,243 27,461,307  
Principal interest convertible 632,789,106    
Warrant [Member]      
Restructuring Cost and Reserve [Line Items]      
Number of warrants outstanding 2,000 22,200 39,295
Stock Options [Member]      
Restructuring Cost and Reserve [Line Items]      
Stock options, outstanding 3,012,410 513,730 3,014,080
Stock options, exercisable 262,410 513,730  
Hanover Portfolio Acquisitions Inc [Member]      
Restructuring Cost and Reserve [Line Items]      
Acquisitions description On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.    
Common stock, voting rights Common Stock representing in excess of 50% of the total issued and outstanding voting power    
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Sources of Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Total sources of revenue $ 135,355 $ 73,105
Direct Sales Medical Care Providers Gross [Member]    
Disaggregation of Revenue [Line Items]    
Total sources of revenue 21,732 73,105
Royalty [Member]    
Disaggregation of Revenue [Line Items]    
Total sources of revenue $ 113,623
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Recognized net revenues $ 135,355 $ 73,105
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Patents (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Patents $ 4,500,000 $ 4,500,000
Less accumulated amortization 3,234,556 2,587,644
Patents net $ 1,265,444 $ 1,912,356
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Estimated Future Amortization Expense (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
2023 $ 646,910  
2024 618,534  
Patents net $ 1,265,444 $ 1,912,356
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Patents (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 31, 2017
Dec. 31, 2022
Dec. 31, 2021
Amortization expense   $ 646,912 $ 646,912
Rio Grande Neurosciences Inc [Member]      
Acquisition of patents $ 4,500,000    
Patents expiration period 2024    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Notes Payable (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Notes payable at beginning of period $ 7,256,930 $ 6,835,196
Notes payable issued 465,000 950,000
Settlements on note payable (163,826) (117,770)
Repayments of notes payable in cash (14,000) (16,900)
Less amounts converted to stock (380,272) (393,596)
Notes payable at end of period 7,163,832 7,256,930
Less debt discount (10,587) (75,800)
Note payable, net 7,153,245 7,181,130
Notes payable issued to former related party 112,100 126,100
Notes payable issued to non-related party $ 7,041,145 $ 7,055,030
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Maturity Dates of Notes Payable (Details)
Dec. 31, 2022
USD ($)
Defined Benefit Plan Disclosure [Line Items]  
Past due $ 6,738,245
December 31, 2023 415,000
Total 7,153,245
Non Related Parties [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Past due 6,626,145
December 31, 2023 415,000
Total 7,041,145
Former Related Party [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Past due 112,100
December 31, 2023
Total $ 112,100
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Notes payable (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 31, 2015
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2022
Dec. 31, 2020
Short-Term Debt [Line Items]          
Notes Payable   $ 7,163,832 $ 7,256,930   $ 6,835,196
Proceeds from issuance of note payable   $ 465,000 950,000    
Accrued interest     100,152    
Debt conversion, stock issued     $ 393,597    
Debt conversion, stock issued   1,355,310,243 27,461,307    
Percentage of cash premium   Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company      
Prepayment penalty   $ 62,800      
Convertible Debt   7,039,832 $ 6,442,035    
Gain on debt extinguishment   362,894 22,162    
Note payable related parties   112,100 126,100    
Note payable outstanding   7,041,145 $ 7,055,030    
Shares as extingusihment     2,505,834    
Debt instrument periodic payment     $ 75,175    
Acquisition payable   $ 79,825 $ 79,825    
Debt effective interest rate   18.00% 12.00%    
Intellectual Property Rights [Member]          
Short-Term Debt [Line Items]          
Long-term acquisition payable for costs not paid at closing     $ 155,000    
Percentage of proceeds from any private placement or gross profits     25.00%    
Rio Grande Neurosciences Inc [Member] | Intellectual Property [Member]          
Short-Term Debt [Line Items]          
Notes Payable     $ 2,110,450    
Private Placement [Member]          
Short-Term Debt [Line Items]          
Proceeds from issuance of note payable $ 25,000        
Debt instrument, interest rate 10.00%        
Debt instrument face amount $ 500,000        
Note payable outstanding   $ 624,903 624,903    
Shares as extingusihment   15,000,000      
One Promissory Notes [Member]          
Short-Term Debt [Line Items]          
Notes Payable   $ 465,000      
Proceeds from issuance of note payable   $ 465,000      
Gain on debt extinguishment     $ 128,000    
Number of shares issued for debt     1,515,152    
Percentage of debt provision     15.00%    
One Promissory Notes [Member] | Minimum [Member]          
Short-Term Debt [Line Items]          
Debt instrument, interest rate   15.00%      
One Promissory Notes [Member] | Maximum [Member]          
Short-Term Debt [Line Items]          
Debt instrument, interest rate   18.00%      
Seven Fixed Rate [Member]          
Short-Term Debt [Line Items]          
Debt instrument description   These fixed rate promissory notes include a prepayment feature at a premium of 15% and a make good provision, which guarantees the holder additional shares if the holder does not realize a 15% or 18% return on the resale of the common shares      
Fixed Rated Notes [Member]          
Short-Term Debt [Line Items]          
Notes Payable   $ 1,819,728 $ 1,735,000    
Accrued interest   380,272      
Debt conversion, stock issued   $ 136,728      
Debt conversion, stock issued   25,850,000      
Fixed Rated Notes [Member] | Past Maturity [Member]          
Short-Term Debt [Line Items]          
Notes Payable   $ 1,404,728 785,000    
Eighteen Fixed Rate [Member]          
Short-Term Debt [Line Items]          
Debt instrument face amount   $ 1,465,000      
Accrued interest       $ 225,000  
Sixteen Fixed Rate [Member]          
Short-Term Debt [Line Items]          
Debt instrument description   Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares      
Convertible Notes [Member]          
Short-Term Debt [Line Items]          
Convertible Debt   $ 4,607,100 4,770,926    
Convertible Notes [Member] | Past Maturity [Member]          
Short-Term Debt [Line Items]          
Convertible Debt     4,770,926    
One Variable Note [Member]          
Short-Term Debt [Line Items]          
Debt instrument face amount   163,826      
Accrued interest   45,475      
Eight Fixed Promissory Notes [Member]          
Short-Term Debt [Line Items]          
Notes Payable     950,000    
Proceeds from issuance of note payable     $ 950,000    
Debt instrument, interest rate     15.00%    
Thirteen Fixed Rate Promissory Notes [Member] | Unrelated Parties [Member]          
Short-Term Debt [Line Items]          
Notes Payable     $ 1,735,000    
Nine Fixed Rate Promissory Notes [Member] | Unrelated Parties [Member]          
Short-Term Debt [Line Items]          
Notes Payable     $ 1,000,000    
Realized profit, percentage     1500.00%    
Two Promissory Notes [Member] | Gain (Loss) on Derivative Instruments [Member]          
Short-Term Debt [Line Items]          
Gain on debt extinguishment     $ 58,407    
Notes Payable [Member] | Former Related Party [Member]          
Short-Term Debt [Line Items]          
Note payable related parties   112,100 126,100    
Principal payment of debt   14,000 $ 16,900    
Notes Payable [Member] | Related Party [Member]          
Short-Term Debt [Line Items]          
Note payable related parties   $ 112,100      
Notes Payable [Member] | Minimum [Member] | Former Related Party [Member]          
Short-Term Debt [Line Items]          
Debt instrument, interest rate   10.00% 10.00%    
Notes Payable [Member] | Maximum [Member] | Former Related Party [Member]          
Short-Term Debt [Line Items]          
Debt instrument, interest rate   12.00% 12.00%    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Preferred Stock (Details)
Dec. 31, 2022
USD ($)
$ / shares
shares
Preferred Stock Designated [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares authorized 5,000,000
Series AA [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares authorized 1,000,000
Number of shares outstanding 25,000
Par value | $ / shares $ 0.0010
Liquidation value | $
Preferred Series B [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares authorized 50,000
Number of shares outstanding 600
Par value | $ / shares $ 0.0001
Liquidation value | $ $ 100
Preferred Series C [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares authorized 8,000
Number of shares outstanding 738
Par value | $ / shares $ 0.0001
Liquidation value | $ $ 1,000
Preferred Series D [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares authorized 20,000
Number of shares outstanding 50
Par value | $ / shares $ 0.0001
Liquidation value | $ $ 1,000
Undesignated [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares authorized 3,922,000
Number of shares outstanding
Par value | $ / shares
Liquidation value | $
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Stock Options Outstanding (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Weighted average exercise price, beginning balance   $ 0.37  
Stock option outstanding, cancelled (501,320) (2,500,350)  
Stock option outstanding, exercised  
Weighted average exercise price, exercised  
Weighted average exercise price, beginning balance     $ 0.37
Warrant [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Weighted Average Remaining Contractual Term (years), Outstanding Beginning     1 year 8 months 1 day
Stock Options [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stock option outstanding, ending balance 513,730 3,014,080  
Weighted average exercise price, beginning balance $ 1.43    
Aggregated intrinsic value, outstanding beginning balance    
Stock option outstanding, granted 3,000,000  
Weighted average exercise price, granted $ 0.0076  
Weighted average remaining contractual term (years), granted 3 years 4 months 24 days  
Aggregated intrinsic value, outstanding, granted $ 31,200  
Weighted average exercise price, cancelled $ 0.18 $ 0.16  
Weighted average remaining contractual term (years), cancelled 7 months 24 days  
Aggregated intrinsic value, outstanding, cancelled  
Weighted average remaining contractual term (years), exercised    
Aggregated intrinsic value, outstanding beginning balance  
Weighted average remaining contractual term (years), outstanding beginning 3 years 4 months 24 days 9 months 3 days  
Stock option outstanding, ending balance 3,012,410 513,730 3,014,080
Weighted average exercise price, beginning balance $ 0.22 $ 1.43  
Aggregated intrinsic value, exercisable ending $ 31,200  
Stock option outstanding, exercisable ending balance 262,410 513,730  
Weighted average exercise price, ending balance $ 2.45    
Weighted average remaining contractual term (years), outstanding beginning 2 years 7 days    
Aggregated intrinsic value, exercisable ending $ 2,600    
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) - Stock Options [Member]
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of outstanding | shares 3,012,410
Weighted average remaining contractual life 3 years 4 months 24 days
Weighted average exercise price $ 0.22
Number of exercisable | shares 262,410
Weighted average exercise price exercisable $ 0.22
Price Range One [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Range of exercise prices $ 54.00
Number of outstanding | shares 11,750
Weighted average remaining contractual life 4 years 3 months 18 days
Weighted average exercise price $ 54.00
Number of exercisable | shares 11,750
Weighted average exercise price exercisable $ 54.00
Price Range Two [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Range of exercise prices $ 11.60
Number of outstanding | shares 660
Weighted average remaining contractual life
Weighted average exercise price $ 11.60
Number of exercisable | shares 660
Weighted average exercise price exercisable $ 11.60
Price Range Three [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Range of exercise prices $ 0.0076
Number of outstanding | shares 3,000,000
Weighted average remaining contractual life 3 years 4 months 24 days
Weighted average exercise price $ 0.0076
Number of exercisable | shares 250,000
Weighted average exercise price exercisable $ 0.0076
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Warrants Outstanding (Details) - Warrant [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Shares outstanding, ending balance 22,200 39,295
Weighted-average exercise price, exercisable ending balance $ 59.25 $ 200.72
Shares, granted
Weighted-average exercise price, granted
Shares, cancelled (20,200) (17,095)
Weighted average exercise price, cancelled $ 60.17 $ 384.39
Shares, exercised
Weighted-average exercise price, exercised
Shares outstanding, ending balance 2,000 22,200
Weighted-average exercise price, exercisable ending balance $ 50.00 $ 59.25
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Warrants Exercise Price Range (Details) - Warrant [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of warrants outstanding 2,000 22,200 39,295
Weighted average remaining contractual life 2 months 19 days    
Weighted average exercise price $ 50.00    
Number of warrants exercisable 2,000    
Weighted average exerice price 50.00    
Price Range One [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Range of exercise prices. upper limit $ 50.00    
Number of warrants outstanding 2,000    
Weighted average remaining contractual life 2 months 19 days    
Weighted average exercise price $ 50.00    
Number of warrants exercisable 2,000    
Weighted average exerice price 50.00    
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Deficit (Details Narrative) - USD ($)
 12 Months Ended
Sep. 27, 2022
Jan. 29, 2020
Dec. 22, 2017
Feb. 07, 2017
Feb. 22, 2013
Dec. 31, 2022
Dec. 31, 2021
Nov. 11, 2019
Class of Stock [Line Items]                
Share price $ 0.01              
Conversion of stock description In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale         At December 31, 2022, based on the stock price, the value of these shares was in excess of the 15% guaranteed return.    
Accrued interest             $ 100,152  
Issuance of common stock, shares             2,505,834  
Shares issued for common stock for services, shares           66,500,000    
Shares issued for common stock for services, value           $ 1,316,900    
Inducement loss              
Issuance of common stock, value           $ 142,000 $ 126,000  
Stock option cancelled           501,320 2,500,350  
Former Related Party [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares             2,505,834  
Issuance of common stock, value             $ 84,697  
Promissory Notes [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares             7,868,668  
Issuance of common stock, value             $ 223,000  
Settlement of Debt [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares             4,020,986  
Issuance of common stock, value             $ 142,424  
Private Placement [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares           15,000,000    
Issuance of common stock, value           $ 142,000    
Purchase Agreement [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares           3,450,000    
Securities Purchase Agreement [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares             7,000,000  
Issuance of common stock, value             $ 126,000  
Conversion of Series C Preferred Stock [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares             1,111,111  
Issuance of common stock, value             $ 33,333  
Consulting Agreement [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares             2,500,000  
Issuance of common stock, value             $ 95,000  
Independent Contractor Agreement [Member]                
Class of Stock [Line Items]                
Vesting period           2 years    
Vesting strike price           $ 0.0076    
One Investor [Member]                
Class of Stock [Line Items]                
Issuance of common stock, shares           2,428,777    
Independent Contractor [Member]                
Class of Stock [Line Items]                
Stock option vested           250,000    
Independent Contractor [Member] | Minimum [Member]                
Class of Stock [Line Items]                
Stock option to officers           3,000,000    
Common Stock [Member]                
Class of Stock [Line Items]                
Share conversion 100,000         0 1,111,111  
Number of shares issued           25,500,000    
Shares issued for conversion of notes payable, shares           25,850,000 27,461,307  
Shares issued for conversion of notes payable           $ 380,272 $ 1,117,990  
Accrued interest           $ 136,728    
Issuance of common stock, shares           15,000,000 7,000,000  
Inducement loss              
Issuance of common stock, value           $ 1,500 $ 700  
Series AA Preferred Stock [Member]                
Class of Stock [Line Items]                
Number of shares outstanding         1,000,000      
Preferred stock, par value         $ 0.001      
Preferred stock voting rights         Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company      
Preferred stock, shares outstanding           25,000 25,000  
Series B Preferred Stock [Member]                
Class of Stock [Line Items]                
Number of shares outstanding       50,000        
Preferred stock, shares outstanding           600 600  
Stated value dividend       75.00%        
Warrants term       three-year        
Share exercise price       150.00%        
Liquidation value of preferred stock, per share       $ 100        
Series C Convertible Redeemable Preferred Stock [Member]                
Class of Stock [Line Items]                
Number of shares outstanding     8,000          
Liquidation value of preferred stock, per share     $ 1,000     $ 1,000    
Preferred stock, dividend per share     $ 20.00          
Change in rights due to amendment and restated certificate, description   the Company filed the amended and restated certificate of designation for its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock            
Share conversion           0 25  
Convertible preferred stock, shares outstanding           738 738  
Series D Convertible Preferred Stock [Member]                
Class of Stock [Line Items]                
Number of shares outstanding           20,000 20,000 20,000
Preferred stock, par value           $ 0.0001 $ 0.0001  
Preferred stock, shares outstanding           50 305  
Liquidation value of preferred stock, per share             $ 1,000  
Conversion price               0.01%
Convertible preferred stock shares issued           50 305  
Series D Preferred Stock [Member]                
Class of Stock [Line Items]                
Inducement loss           $ 200,932    
Series D Preferred Stock [Member] | Common Stock [Member]                
Class of Stock [Line Items]                
Shares issued for conversion of notes payable, shares           255    
Number of stock issued, value           $ 255,000    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party and former Related Parties Transactions (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]    
Common stock issued for cash, shares   2,505,834
Stock Issued During Period, Value, New Issues $ 142,000 $ 126,000
Repayments of related party 14,000 16,900
Notes payable - related parties 112,100 126,100
Accrued interest $ 3,542,650 $ 2,528,459
Common Stock [Member]    
Related Party Transaction [Line Items]    
Common stock issued for cash, shares 15,000,000 7,000,000
Stock Issued During Period, Value, New Issues $ 1,500 $ 700
Executive Officer Former Executive and Former Operational Manager [Member]    
Related Party Transaction [Line Items]    
Deferred compensation 1,350,265 1,289,625
Accrual of deferred compensation 300,000 300,000
Cash repayments of deferred compensation 170,000 250,950
Royalty expense 69,217  
Payment to licensing cost 44,406  
Due to related parties current and noncurrent $ 69,217  
Blue Ridge Consulting LLC [Membe] | Common Stock [Member]    
Related Party Transaction [Line Items]    
Common stock issued for cash, shares 25,000,000  
Stock Issued During Period, Value, New Issues $ 550,000  
Repayments of related party 25,521 13,405
Chief Executive Officer [Member]    
Related Party Transaction [Line Items]    
Stock issued during period value new issues 28,021 13,530
One Officer and Executive [Member]    
Related Party Transaction [Line Items]    
Due to officer 2 125
Former President [Member]    
Related Party Transaction [Line Items]    
Notes payable - related parties 112,100 126,100
Accrued interest $ 80,034 $ 67,787
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Income tax computed at federal statutory rate (21.00%) (21.00%)
State taxes, net of federal benefit (1.70%) (7.00%)
Non-Deductible expenses 15.60% 1.00%
Change in valuation allowance 7.10% 27.00%
Total 0.00% 0.00%
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Effective income tax rate reconciliation at federal statutory income tax rate, amount $ 33,000,000 $ 28,000,000
Income tax examination, description begin to expire in 2030  
Effective income tax rate reconciliation, other adjustments, percent 100.00%  
Interest and penalties $ 0 $ 0
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Concentrations (Details Narrative)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Significant Customers [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 84.00% 28.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Significant Customers [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 10.00% 25.00%
Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 100.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   67.00%
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details Narrative) - USD ($)
 4 Months Ended 12 Months Ended
Apr. 17, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 31, 2015
Subsequent Event [Line Items]        
Common stock issued for cash, shares     2,505,834  
Common Stock issued for cash   $ 142,000 $ 126,000  
Cash   98 85,936  
Interest payable current   3,542,650 2,528,459  
Issuance of conversion of convertible securities value    
Issuance of common stock value services   $ 1,316,900    
Private Placement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares   15,000,000    
Common Stock issued for cash   $ 142,000    
Debt instrument face amount       $ 500,000
Consulting Agreement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares     2,500,000  
Common Stock issued for cash     $ 95,000  
Purchase Agreement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares   3,450,000    
Common Stock [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares   15,000,000 7,000,000  
Common Stock issued for cash   $ 1,500 $ 700  
Conversion of stock shares issued   25,850,000 27,461,307  
Conversion of stock amount issued   $ 380,272 $ 1,117,990  
Issuance of conversion of convertible securities, shares   25,500,000 1,111,111  
Issuance of conversion of convertible securities value   $ 2,550 $ 111  
Issuance of common stock services   66,500,000    
Issuance of common stock value services   $ 6,650    
Common Stock [Member] | Series D Preferred Stock [Member]        
Subsequent Event [Line Items]        
Conversion of stock shares issued   255    
Subsequent Event [Member] | Series D Preferred Stock [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares 50      
Subsequent Event [Member] | Common Stock [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares 5,000,000      
Conversion of stock amount issued $ 100,000      
Issuance of conversion of convertible securities, shares 4,300,590      
Issuance of conversion of convertible securities value $ 67,090      
Debt instrument face amount $ 209,300      
Subsequent Event [Member] | Common Stock [Member] | Board of Directors Chairman [Member]        
Subsequent Event [Line Items]        
Issuance of common stock services 39,150,000      
Issuance of common stock value services $ 552,000      
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares 22,500,000      
Cash $ 225,000      
Conversion of stock shares issued 10,900,000      
Interest payable current $ 9,000      
Subsequent Event [Member] | Common Stock [Member] | Consulting Agreement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares 6,500,000      
Common Stock issued for cash $ 63,700      
Subsequent Event [Member] | Common Stock [Member] | Settlement Agreement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares 1,507,277      
Common Stock issued for cash $ 25,000      
Subsequent Event [Member] | Common Stock [Member] | Purchase Agreement [Member]        
Subsequent Event [Line Items]        
Common stock issued for cash, shares 6,350,000      
Common Stock issued for cash $ 50,000      
XML 57 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001528172 2022-01-01 2022-12-31 0001528172 2022-06-30 0001528172 2023-04-17 0001528172 2022-12-31 0001528172 2021-12-31 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2022-12-31 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2021-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2021-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2021-12-31 0001528172 2021-01-01 2021-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001528172 us-gaap:CommonStockMember 2020-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001528172 ENDV:SubscriptionReceivableMember 2020-12-31 0001528172 us-gaap:RetainedEarningsMember 2020-12-31 0001528172 2020-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 us-gaap:CommonStockMember 2021-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001528172 ENDV:SubscriptionReceivableMember 2021-12-31 0001528172 us-gaap:RetainedEarningsMember 2021-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001528172 ENDV:SubscriptionReceivableMember 2021-01-01 2021-12-31 0001528172 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001528172 ENDV:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001528172 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 us-gaap:CommonStockMember 2022-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001528172 ENDV:SubscriptionReceivableMember 2022-12-31 0001528172 us-gaap:RetainedEarningsMember 2022-12-31 0001528172 ENDV:HanoverPortfolioAcquisitionsIncMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember 2022-12-31 0001528172 us-gaap:WarrantMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2021-12-31 0001528172 us-gaap:WarrantMember 2021-12-31 0001528172 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001528172 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2022-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2022-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2021-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2021-12-31 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001528172 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001528172 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2022-01-01 2022-12-31 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2021-01-01 2021-12-31 0001528172 us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0001528172 us-gaap:RoyaltyMember 2021-01-01 2021-12-31 0001528172 ENDV:RioGrandeNeurosciencesIncMember 2017-12-01 2017-12-31 0001528172 ENDV:NonRelatedPartiesMember 2022-12-31 0001528172 ENDV:FormerRelatedPartyMember 2022-12-31 0001528172 ENDV:OnePromissoryNotesMember 2022-12-31 0001528172 ENDV:OnePromissoryNotesMember 2022-01-01 2022-12-31 0001528172 srt:MinimumMember ENDV:OnePromissoryNotesMember 2022-12-31 0001528172 srt:MaximumMember ENDV:OnePromissoryNotesMember 2022-12-31 0001528172 ENDV:SevenFixedRateMember 2022-01-01 2022-12-31 0001528172 ENDV:FixedRatedNotesMember 2022-12-31 0001528172 ENDV:PastMaturityMember ENDV:FixedRatedNotesMember 2022-12-31 0001528172 ENDV:EighteenFixedRateMember 2022-12-31 0001528172 ENDV:SixteenFixedRateMember 2022-01-01 2022-12-31 0001528172 ENDV:EighteenFixedRateMember 2022-09-30 0001528172 ENDV:FixedRatedNotesMember 2022-01-01 2022-12-31 0001528172 ENDV:ConvertibleNotesMember 2022-12-31 0001528172 ENDV:OneVariableNoteMember 2022-12-31 0001528172 ENDV:EightFixedPromissoryNotesMember 2021-12-31 0001528172 ENDV:EightFixedPromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:FixedRatedNotesMember 2021-12-31 0001528172 ENDV:PastMaturityMember ENDV:FixedRatedNotesMember 2021-12-31 0001528172 ENDV:ThirteenFixedRatePromissoryNotesMember ENDV:UnrelatedPartiesMember 2021-12-31 0001528172 ENDV:NineFixedRatePromissoryNotesMember ENDV:UnrelatedPartiesMember 2021-12-31 0001528172 ENDV:TwoPromissoryNotesMember us-gaap:GainLossOnDerivativeInstrumentsMember 2021-01-01 2021-12-31 0001528172 ENDV:OnePromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:ConvertibleNotesMember 2021-12-31 0001528172 ENDV:PastMaturityMember ENDV:ConvertibleNotesMember 2021-12-31 0001528172 ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2022-12-31 0001528172 srt:MinimumMember ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2022-12-31 0001528172 srt:MaximumMember ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2022-12-31 0001528172 ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2022-01-01 2022-12-31 0001528172 ENDV:RelatedPartyMember ENDV:NotesPayableMember 2022-12-31 0001528172 ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2021-12-31 0001528172 srt:MinimumMember ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2021-12-31 0001528172 srt:MaximumMember ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2021-12-31 0001528172 ENDV:FormerRelatedPartyMember ENDV:NotesPayableMember 2021-01-01 2021-12-31 0001528172 us-gaap:PrivatePlacementMember 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2015-08-01 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2022-12-31 0001528172 us-gaap:PrivatePlacementMember 2021-12-31 0001528172 us-gaap:IntellectualPropertyMember ENDV:RioGrandeNeurosciencesIncMember 2021-12-31 0001528172 ENDV:IntellectualPropertyRightsMember 2021-12-31 0001528172 ENDV:PreferredStockDesignatedMember 2022-12-31 0001528172 ENDV:SeriesAAMember 2022-12-31 0001528172 ENDV:PreferredSeriesBMember 2022-12-31 0001528172 ENDV:PreferredSeriesCMember 2022-12-31 0001528172 ENDV:PreferredSeriesDMember 2022-12-31 0001528172 ENDV:UndesignatedMember 2022-12-31 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-21 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2022-12-31 0001528172 ENDV:SeriesAAPreferredStockMember 2021-12-31 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-06 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001528172 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-21 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2020-01-28 2020-01-29 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2022-01-01 2022-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2019-11-11 0001528172 us-gaap:CommonStockMember 2022-09-26 2022-09-27 0001528172 2022-09-27 0001528172 2022-09-26 2022-09-27 0001528172 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001528172 ENDV:OneInvestorMember 2022-01-01 2022-12-31 0001528172 ENDV:PurchaseAgreementMember 2022-01-01 2022-12-31 0001528172 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001528172 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001528172 ENDV:PromissoryNotesMember 2021-01-01 2021-12-31 0001528172 ENDV:SecuritiesPurchaseAgreementMember 2021-01-01 2021-12-31 0001528172 ENDV:ConversionOfSeriesCPreferredStockMember 2021-01-01 2021-12-31 0001528172 ENDV:SettlementOfDebtMember 2021-01-01 2021-12-31 0001528172 ENDV:FormerRelatedPartyMember 2021-01-01 2021-12-31 0001528172 ENDV:ConsultingAgreementMember 2021-01-01 2021-12-31 0001528172 srt:MinimumMember ENDV:IndependentContractorMember 2022-01-01 2022-12-31 0001528172 ENDV:IndependentContractorMember 2022-12-31 0001528172 ENDV:IndependentContractorAgreementMember 2022-01-01 2022-12-31 0001528172 ENDV:StockOptionsMember 2020-12-31 0001528172 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001528172 ENDV:StockOptionsMember 2021-01-01 2021-12-31 0001528172 ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 ENDV:PriceRangeOneMember ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 ENDV:PriceRangeOneMember ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:PriceRangeTwoMember ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 ENDV:PriceRangeTwoMember ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:PriceRangeThreeMember ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 ENDV:PriceRangeThreeMember ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2022-01-01 2022-12-31 0001528172 us-gaap:WarrantMember 2020-12-31 0001528172 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001528172 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001528172 ENDV:PriceRangeOneMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001528172 ENDV:PriceRangeOneMember us-gaap:WarrantMember 2022-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2022-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2021-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2022-01-01 2022-12-31 0001528172 ENDV:ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember 2021-01-01 2021-12-31 0001528172 ENDV:BlueRidgeConsultingLLCMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001528172 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001528172 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001528172 ENDV:BlueRidgeConsultingLLCMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001528172 ENDV:OneOfficerAndExecutiveMember 2022-12-31 0001528172 ENDV:OneOfficerAndExecutiveMember 2021-12-31 0001528172 ENDV:FormerPresidentMember 2022-12-31 0001528172 ENDV:FormerPresidentMember 2021-12-31 0001528172 ENDV:OneSignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001528172 ENDV:TwoSignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001528172 ENDV:OneSignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001528172 ENDV:TwoSignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001528172 ENDV:SupplierMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001528172 ENDV:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-17 0001528172 us-gaap:SeriesDPreferredStockMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-17 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember ENDV:ConsultingAgreementMember 2023-01-01 2023-04-17 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2023-01-01 2023-04-17 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2023-04-17 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-04-17 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember ENDV:SettlementAgreementMember 2023-01-01 2023-04-17 0001528172 us-gaap:CommonStockMember us-gaap:SubsequentEventMember ENDV:PurchaseAgreementMember 2023-01-01 2023-04-17 0001528172 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-17 iso4217:USD shares iso4217:USD shares pure 0001528172 false FY 2 10-K true 2022-12-31 --12-31 2022 false 000-55453 ENDONOVO THERAPEUTICS, INC. DE 45-2552528 6320 Canoga Avenue 15th Floor Woodland Hills CA 91367 (800) 489-4774 Common stock, par value $0.0001 ENDV No No Yes Yes Non-accelerated Filer true false false false 1128567 270285405 468 Rose, Snyder & Jacobs LLP Encino, CA 98 85936 944 15724 7975 15822 94855 1265444 1912356 1281266 2007211 884195 658463 3542650 2528459 4442606 3891361 10587 75800 7041145 7055030 112100 126100 17359064 3442297 33381760 17701710 79825 79825 33461585 17781535 0.001 0.001 1000000 1000000 25000 25000 25000 25000 25 25 0.0001 0.0001 50000 50000 600 600 600 600 1 1 0.0001 0.0001 8000 8000 738 738 738 738 0.0001 0.0001 20000 20000 50 50 305 305 0.0001 0.0001 2500000000 2500000000 213227538 213227538 74498761 74498761 21322 7449 42919086 40663187 1570 1570 -75119183 -56443416 -32180319 -15774324 1281266 2007211 135355 73105 9990 14985 125365 58120 3389705 2284667 -3264340 -2226547 -14026546 41057 362894 22162 -225268 -1321575 -941566 -15210495 -878347 -18474835 -3104894 -18474835 -3104894 -0.13 -0.05 139206511 59836620 25000 25 600 1 305 763 24536689 2453 38963827 -1570 -53338522 -14373786 7868668 787 221905 222692 7000000 700 125300 126000 27461307 2746 1115244 1117900 -25 1111111 111 -111 1515152 151 57576 57727 2505834 251 84446 84697 2500000 250 95000 95250 -3104894 -3104894 25000 25 600 1 305 738 74498761 7449 40663187 -1570 -56443416 -15774324 25000 25 600 1 305 738 74498761 7449 40663187 -1570 -56443416 -15774324 25000 25 600 1 305 738 74498761 7449 40663187 -1570 -56443416 -15774324 25000 25 600 1 305 738 74498761 7449 40663187 -1570 -56443416 -15774324 3450000 345 46448 46793 15000000 1500 140500 142000 25850000 2585 514415 517000 -255 25500000 2550 -2550 200932 -200932 2428777 243 45904 46147 66500000 6650 1310250 1316900 -18474835 -18474835 25000 25 600 1 50 738 213227538 21322 42919086 -1570 -75119183 -32180319 25000 25 600 1 50 738 213227538 21322 42919086 -1570 -75119183 -32180319 -18474835 -3104894 646912 648492 944 45000 7698 70970 1311900 95250 110611 144196 -14026546 41057 362894 22162 2 7750 -23850 269391 -42470 1196394 733999 551245 507244 -678838 -986584 465000 950000 14000 16900 142000 126000 593000 1059100 -85838 72516 85936 13420 98 85936 517000 493748 255000 33333 45398 202697 <p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zYoxc6RX64k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_824_zJgluBrsAWMb">Nature of Business and Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of inflammation on and in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical<sup>®</sup> Therapy. Endonovo’s bioelectric Electroceutical<sup>®</sup> devices harnesses <i>bioelectricity</i> to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--HanoverPortfolioAcquisitionsIncMember_zBQU6Medriq" title="Acquisitions description">On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of <span id="xdx_903_eus-gaap--CommonStockVotingRights_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--HanoverPortfolioAcquisitionsIncMember_zLPCSBFWQHgd" title="Common stock, voting rights">Common Stock representing in excess of 50% of the total issued and outstanding voting power</span> of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmu3oQxYLhK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zrN31GnyvZV9">Basis of Presentation and Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, WeHealAnimals, Inc. and SofPulse, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zoOOcNw1jdGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zhfgPuV4Wrgb">Going Concern</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has accumulated losses of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zJDF7JQGzPp2" title="Accumulated losses">75.1</span> million, negative cash flows from operations of approximately $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zwWRdJjkrnwd" title="Cash flow from operations">0.7</span> million and $<span id="xdx_902_ecustom--WorkingCapitalDeficiency_iI_pn5n6_c20221231_zkG5wT077u4f" title="Working capital">33.4</span> million of working capital deficit. The Company has raised approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20220101__20221231_z10F4BnYDmwg" title="Debt and equity financing">0.6</span> million in debt and equity financing for the year ended December 31, 2022. The Company is raising additional capital through debt and/or equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential future license and distribution agreements, has raised capital through the issuance of promissory notes and has engaged a broker/dealer to raise additional capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zlN9gfygGlNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zRY86fpiG9c4">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGvQrDaA74Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zA8bhwrnHzRh">Cash and cash equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2022 and 2021, the Company does not hold any cash in excess of FDIC limits and does not have any cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zCxeTwnMlNC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zTDyqYOykHbl">Accounts Receivable</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the specific identification method for recording the provision for doubtful accounts, which was $<span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_znPXpX2dKKDl" title="Provision for doubtful accounts"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zogSkCSrDFn5" title="Provision for doubtful accounts">0</span></span> at December 31, 2022 and 2021. Account receivables are written off when all collection attempts have failed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1rlnTdtGQ2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zeRDDMqnK1ih">Impairment of Long-lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. The Company did not recognize any impairment loss during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zV0nkDixDqL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zi4NHBnB1Ll8">Equity-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z0Fu06iJ0Tpa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zDBnpSWnv3Ma">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_841_eus-gaap--EarningsPerShareTextBlock_zS9RjbQutsE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zoHgkV8Oh1I2">Net Loss per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zS3LCGDdjwcb" title="Stock options, outstanding">3,012,410</span> stock options, of which <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zX7DXv39zBTl" title="Stock options, exercisable">262,410</span> are exercisable and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgd1ABWapMS6" title="Number of warrants outstanding">2,000</span> warrants convertible into an equivalent number of common stock as of December 31, 2022. The Company has <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQIgFp5pwbAj" title="Stock options, outstanding">513,730</span> stock options, of which <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSU1C9TrYcCk" title="Stock options, exercisable">513,730</span> are exercisable and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUBShVlR3Ihh" title="Number of warrants outstanding">22,200</span> warrants convertible into an equivalent number of common stock as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has variable rate convertible notes in an aggregate amount of $<span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20221231_zVmSScwk8Xec" title="Convertible note">7,039,832</span> and $<span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20211231_zfltG6YTWJoi" title="Convertible note">6,442,035</span>, respectively, including principal and accrued interest, which are convertible into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231_zkr3r43iL05e" title="Principal interest convertible">1,355,310,243</span> and <span id="xdx_901_ecustom--AccruedInterest_c20220101__20221231_z6Z1W4Edz6nh" title="Principal interest convertible">632,789,106</span>, respectively, shares of common stock. Such shares are not included in the calculation of the diluted net loss per share as they would have an antidilutive effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUYByP7Rqhf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zdFty9zsLRe1">Fair Value of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: uses quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: uses unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_znEltpBDykE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zRFdQASvVcD3" style="display: none">Schedule of Balances of Liabilities Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value Measurements at December 31, 2022 Using</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted Prices in <br/> Active <br/> Markets for</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant <br/> Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identical <br/> Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD6T11n4tevd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRPHWxPkg7wi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzKTQXJHh89" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231_zzeHnLoYiKz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztDCoBl87CT1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMW2c8QLVste" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          <span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsacLWtsikWe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231_zeWMGWcL03ai" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value Measurements at December 31, 2021 Using</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted Prices in <br/> Active <br/> Markets <br/> for</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant <br/> Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identical <br/> Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRDb8ShoCd0a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLG9OhB5cfL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgze7bpbTvTe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231_zb6gHEHJ0mMa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpT6FYiWkYH2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXGiiXnMhDRa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLwSqenL048l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231_zPSmYxxqZ9N" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_z9gk5YxGy5w9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zzFV8QgWzLma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zBF2y6Y8AL32" style="display: none">Schedule of Changes in the Liabilities with Significant Unobservable Inputs</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20210101__20211231_zmmA2k1Dspf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Derivative liability , beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,202,597</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_di_c20210101__20211231_znnCphyHf2Bc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt conversion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsByDebtConversion_c20210101__20211231_zwbwkLqw9nHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(585,857</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in estimated fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20210101__20211231_zXPwVJcDI5L2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(41,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231_zbdzr4gwGZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt Extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_di_c20220101__20221231_zVh22RXy8ft3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in estimated fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20220101__20221231_z1UTq0vRlz99" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,026,546</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20220101__20221231_z2TxSGGaoJOi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liability,ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zs3oVviQTFjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zWqMoQ4aCPYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjPnnspL4Ukh">Derivative Liability</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zNfsiaAaisah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zeZQePlKauG2" style="display: none">Schedule of Variable Debentures Black-Scholes Valuation Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="5" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Years Ending December 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--CreditDerivativeTerm1_dtM_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zv5fDDvYYa5h" title="Expected term">0</span>-<span id="xdx_901_eus-gaap--CreditDerivativeTerm1_dtM_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zr05r0YR7cZi" title="Expected term">1</span> month</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--CreditDerivativeTerm1_dtM_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zC9AXZbmunlb" title="Expected term">1</span> -<span id="xdx_907_eus-gaap--CreditDerivativeTerm1_dtM_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zUzeKa3navD1" title="Expected term">4</span> months</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zYxSpPRWshEl">0.004</span>-$<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zXvIUfVhVWTh">0.015</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zEKjixER6wb5">0.01</span>-$<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_z7NPx5NNMDq6">0.03</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zSv87nv6xT36" title="Derivative liability measurement">153</span>%-<span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zaE2CDo5S208" title="Derivative liability measurement">169</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_z12legePGQmk" title="Derivative liability measurement">177</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zsnQ0hoLYXe2" title="Derivative liability measurement">206</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividends</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dn_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z9Pu6SQJwUth" title="Derivative liability measurement">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dn_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z67urxljk0y3" title="Derivative liability measurement">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zSHVN3DImbHe" title="Derivative liability measurement">1.63</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3A36xMRNbKj" title="Derivative liability measurement">4.73</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgFMxGWXHAad" title="Derivative liability measurement">0.06</span>%-<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zsm0nq9AD4J8" title="Derivative liability measurement">0.39</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeitures</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationForfeited_dxL_c20220101__20221231_zjajiKwA6XD1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Forfeitures::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0854"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationForfeited_dxL_c20210101__20211231_zQ0CBPl8RqIl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Forfeitures::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0856"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_z7FhMSD6z6Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTTXUJujAnIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zuEXuKOzXNK1">Recent Accounting Standard Updates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company’s financial statements.</span></p> <p id="xdx_850_z0GPbpTqPNN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014. Common Stock representing in excess of 50% of the total issued and outstanding voting power <p id="xdx_843_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmu3oQxYLhK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zrN31GnyvZV9">Basis of Presentation and Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, WeHealAnimals, Inc. and SofPulse, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zoOOcNw1jdGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zhfgPuV4Wrgb">Going Concern</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has accumulated losses of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zJDF7JQGzPp2" title="Accumulated losses">75.1</span> million, negative cash flows from operations of approximately $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zwWRdJjkrnwd" title="Cash flow from operations">0.7</span> million and $<span id="xdx_902_ecustom--WorkingCapitalDeficiency_iI_pn5n6_c20221231_zkG5wT077u4f" title="Working capital">33.4</span> million of working capital deficit. The Company has raised approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20220101__20221231_z10F4BnYDmwg" title="Debt and equity financing">0.6</span> million in debt and equity financing for the year ended December 31, 2022. The Company is raising additional capital through debt and/or equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential future license and distribution agreements, has raised capital through the issuance of promissory notes and has engaged a broker/dealer to raise additional capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -75100000 -700000 33400000 600000 <p id="xdx_847_eus-gaap--UseOfEstimates_zlN9gfygGlNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zRY86fpiG9c4">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGvQrDaA74Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zA8bhwrnHzRh">Cash and cash equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2022 and 2021, the Company does not hold any cash in excess of FDIC limits and does not have any cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zCxeTwnMlNC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zTDyqYOykHbl">Accounts Receivable</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the specific identification method for recording the provision for doubtful accounts, which was $<span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_znPXpX2dKKDl" title="Provision for doubtful accounts"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zogSkCSrDFn5" title="Provision for doubtful accounts">0</span></span> at December 31, 2022 and 2021. Account receivables are written off when all collection attempts have failed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1rlnTdtGQ2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zeRDDMqnK1ih">Impairment of Long-lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. The Company did not recognize any impairment loss during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zV0nkDixDqL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zi4NHBnB1Ll8">Equity-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z0Fu06iJ0Tpa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zDBnpSWnv3Ma">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_841_eus-gaap--EarningsPerShareTextBlock_zS9RjbQutsE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zoHgkV8Oh1I2">Net Loss per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zS3LCGDdjwcb" title="Stock options, outstanding">3,012,410</span> stock options, of which <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zX7DXv39zBTl" title="Stock options, exercisable">262,410</span> are exercisable and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgd1ABWapMS6" title="Number of warrants outstanding">2,000</span> warrants convertible into an equivalent number of common stock as of December 31, 2022. The Company has <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQIgFp5pwbAj" title="Stock options, outstanding">513,730</span> stock options, of which <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSU1C9TrYcCk" title="Stock options, exercisable">513,730</span> are exercisable and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUBShVlR3Ihh" title="Number of warrants outstanding">22,200</span> warrants convertible into an equivalent number of common stock as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has variable rate convertible notes in an aggregate amount of $<span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20221231_zVmSScwk8Xec" title="Convertible note">7,039,832</span> and $<span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20211231_zfltG6YTWJoi" title="Convertible note">6,442,035</span>, respectively, including principal and accrued interest, which are convertible into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231_zkr3r43iL05e" title="Principal interest convertible">1,355,310,243</span> and <span id="xdx_901_ecustom--AccruedInterest_c20220101__20221231_z6Z1W4Edz6nh" title="Principal interest convertible">632,789,106</span>, respectively, shares of common stock. Such shares are not included in the calculation of the diluted net loss per share as they would have an antidilutive effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3012410 262410 2000 513730 513730 22200 7039832 6442035 1355310243 632789106 <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUYByP7Rqhf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zdFty9zsLRe1">Fair Value of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: uses quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: uses unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_znEltpBDykE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zRFdQASvVcD3" style="display: none">Schedule of Balances of Liabilities Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value Measurements at December 31, 2022 Using</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted Prices in <br/> Active <br/> Markets for</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant <br/> Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identical <br/> Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD6T11n4tevd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRPHWxPkg7wi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzKTQXJHh89" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231_zzeHnLoYiKz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztDCoBl87CT1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMW2c8QLVste" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          <span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsacLWtsikWe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231_zeWMGWcL03ai" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value Measurements at December 31, 2021 Using</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted Prices in <br/> Active <br/> Markets <br/> for</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant <br/> Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identical <br/> Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRDb8ShoCd0a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLG9OhB5cfL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgze7bpbTvTe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231_zb6gHEHJ0mMa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpT6FYiWkYH2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXGiiXnMhDRa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLwSqenL048l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231_zPSmYxxqZ9N" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_z9gk5YxGy5w9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zzFV8QgWzLma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zBF2y6Y8AL32" style="display: none">Schedule of Changes in the Liabilities with Significant Unobservable Inputs</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20210101__20211231_zmmA2k1Dspf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Derivative liability , beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,202,597</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_di_c20210101__20211231_znnCphyHf2Bc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt conversion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsByDebtConversion_c20210101__20211231_zwbwkLqw9nHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(585,857</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in estimated fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20210101__20211231_zXPwVJcDI5L2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(41,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231_zbdzr4gwGZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt Extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_di_c20220101__20221231_zVh22RXy8ft3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in estimated fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20220101__20221231_z1UTq0vRlz99" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,026,546</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20220101__20221231_z2TxSGGaoJOi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liability,ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zs3oVviQTFjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_znEltpBDykE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zRFdQASvVcD3" style="display: none">Schedule of Balances of Liabilities Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value Measurements at December 31, 2022 Using</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted Prices in <br/> Active <br/> Markets for</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant <br/> Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identical <br/> Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD6T11n4tevd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRPHWxPkg7wi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzKTQXJHh89" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20221231_zzeHnLoYiKz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztDCoBl87CT1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMW2c8QLVste" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          <span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsacLWtsikWe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20221231_zeWMGWcL03ai" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value Measurements at December 31, 2021 Using</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted Prices in <br/> Active <br/> Markets <br/> for</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant <br/> Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identical <br/> Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable <br/> Inputs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRDb8ShoCd0a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLG9OhB5cfL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgze7bpbTvTe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231_zb6gHEHJ0mMa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpT6FYiWkYH2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXGiiXnMhDRa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLwSqenL048l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pp0p0_c20211231_zPSmYxxqZ9N" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 17359064 17359064 17359064 17359064 3442297 3442297 3442297 3442297 <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zzFV8QgWzLma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zBF2y6Y8AL32" style="display: none">Schedule of Changes in the Liabilities with Significant Unobservable Inputs</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20210101__20211231_zmmA2k1Dspf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Derivative liability , beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,202,597</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_di_c20210101__20211231_znnCphyHf2Bc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt conversion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsByDebtConversion_c20210101__20211231_zwbwkLqw9nHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(585,857</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in estimated fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20210101__20211231_zXPwVJcDI5L2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(41,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231_zbdzr4gwGZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,442,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement by debt Extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_di_c20220101__20221231_zVh22RXy8ft3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements by debt extinguishment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in estimated fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20220101__20221231_z1UTq0vRlz99" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,026,546</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20220101__20221231_z2TxSGGaoJOi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liability,ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,359,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 4202597 133386 -585857 -41057 3442297 109779 14026546 17359064 <p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zWqMoQ4aCPYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjPnnspL4Ukh">Derivative Liability</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zNfsiaAaisah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zeZQePlKauG2" style="display: none">Schedule of Variable Debentures Black-Scholes Valuation Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="5" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Years Ending December 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--CreditDerivativeTerm1_dtM_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zv5fDDvYYa5h" title="Expected term">0</span>-<span id="xdx_901_eus-gaap--CreditDerivativeTerm1_dtM_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zr05r0YR7cZi" title="Expected term">1</span> month</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--CreditDerivativeTerm1_dtM_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zC9AXZbmunlb" title="Expected term">1</span> -<span id="xdx_907_eus-gaap--CreditDerivativeTerm1_dtM_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zUzeKa3navD1" title="Expected term">4</span> months</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zYxSpPRWshEl">0.004</span>-$<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zXvIUfVhVWTh">0.015</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zEKjixER6wb5">0.01</span>-$<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_z7NPx5NNMDq6">0.03</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zSv87nv6xT36" title="Derivative liability measurement">153</span>%-<span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zaE2CDo5S208" title="Derivative liability measurement">169</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_z12legePGQmk" title="Derivative liability measurement">177</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zsnQ0hoLYXe2" title="Derivative liability measurement">206</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividends</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dn_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z9Pu6SQJwUth" title="Derivative liability measurement">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dn_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z67urxljk0y3" title="Derivative liability measurement">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zSHVN3DImbHe" title="Derivative liability measurement">1.63</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3A36xMRNbKj" title="Derivative liability measurement">4.73</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgFMxGWXHAad" title="Derivative liability measurement">0.06</span>%-<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zsm0nq9AD4J8" title="Derivative liability measurement">0.39</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeitures</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationForfeited_dxL_c20220101__20221231_zjajiKwA6XD1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Forfeitures::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0854"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationForfeited_dxL_c20210101__20211231_zQ0CBPl8RqIl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Forfeitures::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0856"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_z7FhMSD6z6Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zNfsiaAaisah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zeZQePlKauG2" style="display: none">Schedule of Variable Debentures Black-Scholes Valuation Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="5" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Years Ending December 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--CreditDerivativeTerm1_dtM_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zv5fDDvYYa5h" title="Expected term">0</span>-<span id="xdx_901_eus-gaap--CreditDerivativeTerm1_dtM_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zr05r0YR7cZi" title="Expected term">1</span> month</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--CreditDerivativeTerm1_dtM_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zC9AXZbmunlb" title="Expected term">1</span> -<span id="xdx_907_eus-gaap--CreditDerivativeTerm1_dtM_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zUzeKa3navD1" title="Expected term">4</span> months</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zYxSpPRWshEl">0.004</span>-$<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zXvIUfVhVWTh">0.015</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zEKjixER6wb5">0.01</span>-$<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_z7NPx5NNMDq6">0.03</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zSv87nv6xT36" title="Derivative liability measurement">153</span>%-<span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zaE2CDo5S208" title="Derivative liability measurement">169</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_z12legePGQmk" title="Derivative liability measurement">177</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zsnQ0hoLYXe2" title="Derivative liability measurement">206</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividends</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dn_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z9Pu6SQJwUth" title="Derivative liability measurement">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dn_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z67urxljk0y3" title="Derivative liability measurement">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zSHVN3DImbHe" title="Derivative liability measurement">1.63</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3A36xMRNbKj" title="Derivative liability measurement">4.73</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgFMxGWXHAad" title="Derivative liability measurement">0.06</span>%-<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zsm0nq9AD4J8" title="Derivative liability measurement">0.39</span>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeitures</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationForfeited_dxL_c20220101__20221231_zjajiKwA6XD1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Forfeitures::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0854"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationForfeited_dxL_c20210101__20211231_zQ0CBPl8RqIl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Forfeitures::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0856"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> P0M P1M P1M P4M 0.004 0.015 0.01 0.03 153 169 177 206 0 0 1.63 4.73 0.06 0.39 <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTTXUJujAnIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zuEXuKOzXNK1">Recent Accounting Standard Updates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company’s financial statements.</span></p> <p id="xdx_80A_eus-gaap--RevenueFromContractWithCustomerTextBlock_z5uVjaMWIbNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span id="xdx_822_z9Qj4HYHGnY5">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contracts with Customers</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have adopted ASC 606, <i>Revenue from Contracts with Customers</i> effective January 1, 2018, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018<i>.</i> These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, we have an unconditional right to receive payment. Our sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues for sales of our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, we recognized revenue of $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zfq1XsS05EXi" title="Recognized net revenues">135,355</span> and $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20211231_zSAN838zlHb9" title="Recognized net revenues">73,105</span>, respectively, from SofPulse® devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources of Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified the following revenues disaggregated by revenue source:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to plastic surgeons</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to wound care facilities</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to hospitals</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to other physicians</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty fee from licensing, net</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfSourceOfRevenueTableTextBlock_zg8DhdxrM8H" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2022 and 2021, the sources of revenue were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zqc7gtEJUBBb" style="display: none">Schedule of Sources of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zxb4h2XDgI9i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zTorIEBOhi97" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DirectSalesMedicalCareProvidersGrossMember_zmySNW8XuVh6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct sales- Plastic surgeons, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_z7UymmyipZXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty/licensing, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,623</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z86jihPnm7li" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total sources of revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zVyIU0WQHhc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalty/licensing revenue recognized in 2022 resulted from specific transactions. No general patent rights were assigned to the distributor. The revenue recognized was based on the number of items included in the transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warranty</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant Judgments in the Application of the Guidance in ASC 606</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Practical Expedients</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our payment terms for sales direct to distributors, end users, hospitals and doctors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effective Date and Transition Disclosures</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 135355 73105 <p id="xdx_89E_ecustom--ScheduleOfSourceOfRevenueTableTextBlock_zg8DhdxrM8H" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2022 and 2021, the sources of revenue were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zqc7gtEJUBBb" style="display: none">Schedule of Sources of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zxb4h2XDgI9i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zTorIEBOhi97" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DirectSalesMedicalCareProvidersGrossMember_zmySNW8XuVh6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct sales- Plastic surgeons, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_z7UymmyipZXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty/licensing, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,623</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z86jihPnm7li" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total sources of revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 21732 73105 113623 135355 73105 <p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zYkjlSGIj8Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_826_zECNuT0vek05">Patents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2017, we acquired from RGN a patent portfolio for $<span id="xdx_906_eus-gaap--PaymentsToAcquireIntangibleAssets_c20171201__20171231__dei--LegalEntityAxis__custom--RioGrandeNeurosciencesIncMember_zMIRKzpHF7f" title="Acquisition of patents">4,500,000</span>. The earliest patent expires in <span id="xdx_906_ecustom--PatentsExpirationPeriod_c20171201__20171231__dei--LegalEntityAxis__custom--RioGrandeNeurosciencesIncMember_zUOmeSvh8G8a" title="Patents expiration period">2024</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zvbQX0s4IAxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of patents less accumulated amortization at December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zDvFolz96ja9" style="display: none">Schedule of Patents</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20221231_zrpk1fwfK3ba" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20211231_zyABPgSlBbEg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedPatentsGross_iI_maFLIANzX8N_zwTS0CsVQSC7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msFLIANzX8N_zju9ZSaIGhpa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,234,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,587,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzX8N_zbIoqyCBaTi1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,265,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,912,356</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_ztd7N27sRUBc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for the years ended December 31, 2022 and 2021, was $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zWKAUry3QZxc" title="Amortization expense"><span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_z7eW8dMLVWpe" title="Amortization expense">646,912</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zdK1n54oQPaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated future amortization expense related to patents as of December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_z7Q89pjPKFFb" style="display: none">Schedule of Estimated Future Amortization Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20221231_ziuwhnjlHLCc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzbYA_zfydn8mdAOL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">646,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzbYA_zXmUOY5vjCVl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,534</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzbYA_zSewSIv18bqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,265,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zDFOgKFBviAe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the patents were not impaired as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4500000 2024 <p id="xdx_89D_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zvbQX0s4IAxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of patents less accumulated amortization at December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zDvFolz96ja9" style="display: none">Schedule of Patents</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20221231_zrpk1fwfK3ba" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20211231_zyABPgSlBbEg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedPatentsGross_iI_maFLIANzX8N_zwTS0CsVQSC7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msFLIANzX8N_zju9ZSaIGhpa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,234,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,587,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzX8N_zbIoqyCBaTi1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,265,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,912,356</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 4500000 4500000 3234556 2587644 1265444 1912356 646912 646912 <p id="xdx_899_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zdK1n54oQPaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated future amortization expense related to patents as of December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_z7Q89pjPKFFb" style="display: none">Schedule of Estimated Future Amortization Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20221231_ziuwhnjlHLCc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzbYA_zfydn8mdAOL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">646,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzbYA_zXmUOY5vjCVl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,534</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzbYA_zSewSIv18bqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,265,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 646910 618534 1265444 <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zLaXBckKmZ8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - <span id="xdx_827_z120vwzYUbN2">Notes payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtTableTextBlock_zfFzlu2Arthh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, the notes payable activity was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B4_zdJk21Oqs3Dh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Notes Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_z3HNdwuuB7tk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20210101__20211231_zvvxSCb6NeTk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--NotesPayable_iS_pp0p0_z1WyrXtX3WK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable at beginning of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,256,930</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,835,196</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_ecustom--NotesPayableIssued_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">465,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">950,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--SettlementsOnNotePayable_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlements on note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(163,826</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(117,770</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40B_eus-gaap--RepaymentsOfNotesPayable_iN_pp0p0_di_z9zVbyiBDoAa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayments of notes payable in cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_zXF1M9prYHBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts converted to stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(380,272</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(393,596</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--NotesPayable_iE_pp0p0_zq9svNsipgsc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable at end of period</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,163,832</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,256,930</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNE_pp0p0_di_z87NeHLttT08" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,587</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(75,800</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--NotesAndLoansPayable_iE_pp0p0_z8JUjA2cVRXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,153,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,181,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iE_pp0p0_zDTNZPjtVf84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable issued to former related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--NotesPayableIssuedToNonrelatedParties_iE_pp0p0_zuyOfcCFlZAb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable issued to non-related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,041,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,055,030</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zKFhRoZUC9Wi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhk6oQdrR5rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturity dates on the notes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zlEv7xLay7W7" style="display: none">Schedule of Maturity Dates of Notes Payable</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve months ending,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former <br/> Related <br/> party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past due</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--LongTermDebtPastMaturity_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zROPsiRsjCgk" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Past due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,626,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--LongTermDebtPastMaturity_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_z52o71YqVN0e" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Past due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_ecustom--LongTermDebtPastMaturity_iI_c20221231_zVpTGf9AgCo2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Past due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,738,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_znbL48wFuA06" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="December 31, 2023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zPDquGKrXryi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="December 31, 2023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pdp0_c20221231_zbR0dyWnW8Xe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="December 31, 2023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zDQSLS47EHuc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,041,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zy9hKrpogRs7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--LongTermDebt_iI_c20221231_zkP5sqbmSh4l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,153,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_z8RtfWNBef8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Activity during the year ended December 31, 2022</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fixed rates convertible notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued seven (7) fixed rate promissory notes totaling $<span id="xdx_903_eus-gaap--NotesPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember_znCo2Pp55Pu5" title="Promissory notes">465,000</span> in principal, for funding of $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember_zLiHdLpjDPUf" title="Proceeds from Notes Payable">465,000</span> with original terms of nine to twelve months and interest rates of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zs50EcYRntS" title="Debt instrument, interest rate">15</span>% and <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zBp7bUnG2wlc" title="Debt instrument, interest rate">18</span>%. The holder of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, immediately to six-month after issuance date. <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SevenFixedRateMember_ze6eWC7JwY06" title="Debt instrument description">These fixed rate promissory notes include a prepayment feature at a premium of 15% and a make good provision, which guarantees the holder additional shares if the holder does not realize a 15% or 18% return on the resale of the common shares</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company has twenty (20) fixed-rate promissory notes with an outstanding balance of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_zEwapBhjt8Qe" title="Notes Payable">1,819,728</span>, of which $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20221231__srt--StatementScenarioAxis__custom--PastMaturityMember__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_znt9MMTlpa15" title="Notes Payable">1,404,728</span> are past maturity. As of December 31, 2022, the Company has a total of sixteen (16) fixed rate notes for total principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--EighteenFixedRateMember_z7bZ2Bc5djs2" title="Debt instrument, face amount">1,465,000</span> includes a make good shares provision. <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SixteenFixedRateMember_zMogE38rEYn3" title="Debt instrument description">Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares</span>. The Company accrued approximately $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--EighteenFixedRateMember_zmqcErEslXC5" title="Accrued interest">225,000</span> related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the consolidated statements of operations and accounts payable and accrued expenses in the consolidated balance sheet as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During year ended December 31, 2022, the Company converted $<span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_z72NYbN07C25" title="Debt conversion, orginal amount">136,728</span> in accrued interest and $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_zaJqZU5AqUjg" title="Accured interest">380,272</span> in principal balance into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_zFY7Kvez44Jh" title="Debt conversion, stock issued">25,850,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--CertainFixedPercentageOfCashPremium_c20220101__20221231_zUVQ69pZlKwk" title="Percentage of cash premium">Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company</span>. The prepayment penalty approximates $<span id="xdx_901_ecustom--PrepaymentPenalty_iI_c20221231_zFbRyzK36qt" title="Prepayment penalty">62,800</span> as of December 31, 2022, but the Company determined that such liability was not probable as of December 31, 2022, pursuant to ASC 450 Contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Variable-rate notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2022, is $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zIs4tFQu2Goh" title="Convertible Debt">4,607,100</span>, which are all past maturity. There was no conversion of notes into the Company’s common stock during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company settled one variable note with a principal of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OneVariableNoteMember_zgqvDFlqFph2" title="Debt principal amount">163,826</span> and $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OneVariableNoteMember_zwiiQvx2Fr4d" title="Accrued interest">45,475</span> in accrued interest for no consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Activity during the year ended December 31, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued eight (8) fixed rate promissory notes totaling $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--EightFixedPromissoryNotesMember_z3lfWjX0A62c">950,000</span> for funding of $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--EightFixedPromissoryNotesMember_zzaYIg78kWzg" title="Proceeds from Notes Payable">950,000</span> with original terms of twelve months and interest rates of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--EightFixedPromissoryNotesMember_zwSYgRV1ZeEl" title="Debt instrument, interest rate">15</span>%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features. As of December 31, 2021, the fixed-rate notes had an outstanding balance of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_zYzoqEkh2l3j">1,735,000</span>, of which $<span id="xdx_909_eus-gaap--NotesPayable_iI_c20211231__srt--StatementScenarioAxis__custom--PastMaturityMember__us-gaap--DebtInstrumentAxis__custom--FixedRatedNotesMember_zaAULDCPIt1b">785,000</span> are past maturity. As of December 31, 2021, the Company has 13 fixed rate promissory notes with unrelated parties for total amount of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--ThirteenFixedRatePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedPartiesMember_z89GjjjYdqd4">1,735,000</span>. Nine of these fixed rates promissory notes for total balance of $<span id="xdx_90A_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--NineFixedRatePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedPartiesMember_zNnSFjEgfFs9">1,000,000</span> carry a make whole provision requiring the Company to issue additional shares of its common stock if the underlying investor is not able to realize a profit of <span id="xdx_90D_ecustom--RealizedProfitPercentage_iI_pid_c20211231__us-gaap--DebtInstrumentAxis__custom--NineFixedRatePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedPartiesMember_zZSlsx86QvY5" title="Realized profit, percentage">15</span>% against the conversion price of such shares after customary and reasonable expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 <i>Debt-Modifications and Extinguishments</i> and recorded $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GainLossOnDerivativeInstrumentsMember__us-gaap--DebtInstrumentAxis__custom--TwoPromissoryNotesMember_zGPhSNpEMUv6" title="Gain on debt extinguishment">58,407</span> as loss from debt extinguishment in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company settled one of its promissory notes by issuing <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember_zlKDqWaidxGf" title="Number of shares issued for debt">1,515,152</span> restricted shares of the Company’s common stock with a fifteen percent (<span id="xdx_909_ecustom--PercentageOfDebtProvision_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember_zvWjbhfZjtcj" title="Percentage of debt provision">15</span>%) make-whole provision. The Company recorded a gain on debt extinguishment of approximately $<span id="xdx_902_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OnePromissoryNotesMember_zWAtlr9G98vf" title="Gain on debt extinguishment">128,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company converted $<span id="xdx_905_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210101__20211231_z9oiyb0oGt15" title="Debt conversion, stock issued">393,597</span> in principal and $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231_zEnRfzmEK17b" title="Accrued interest">100,152</span> in accrued but unpaid interest into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231_zBjHVJS6Njia" title="Debt conversion, stock issued">27,461,307</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2021, is $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zLLQ3NDpfT0f">4,770,926</span>, of which $<span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__srt--StatementScenarioAxis__custom--PastMaturityMember_zZC2YDuN4zgc">4,770,926</span> are past maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former related-party notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to a former related party in the aggregate amount of $<span id="xdx_90E_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember_znJnh4Y8V5J2" title="Note payable related parties">112,100</span> was outstanding at December 31, 2022, which are past maturity date. The notes bear interest between <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember__srt--RangeAxis__srt--MinimumMember_zzz2DJrJGSzj" title="Debt instrument, interest rate">10</span>% and <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember__srt--RangeAxis__srt--MaximumMember_z8DTP2lXgO1" title="Debt instrument, interest rate">12</span>% per annum. During the year ended December 31, 2022, the Company paid total principal of $<span id="xdx_900_eus-gaap--RepaymentsOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember_zW8cQQIXhsb7" title="Principal payment of debt">14,000</span> to this former related party. As of December 31, 2022, the Company had notes payable to related parties amounting to $<span id="xdx_90C_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--RelatedPartyMember_zG2GkBXDskK8" title="Note payable related parties">112,100</span>. Refer to Note 7– Related Party Transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to a former related party in the aggregate amount of $<span id="xdx_90F_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember_zPIAQgOfwow1" title="Note payable related parties">126,100</span> was outstanding at December 31, 2021, which are past maturity date. The notes bear interest between <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember__srt--RangeAxis__srt--MinimumMember_zXTnrxnUpGW2" title="Debt instrument, interest rate">10</span>% and <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember__srt--RangeAxis__srt--MaximumMember_zn8CZXUV40C9" title="Debt instrument, interest rate">12</span>% per annum. During the year ended December 31, 2021, the Company paid total principal of $<span id="xdx_902_eus-gaap--RepaymentsOfDebt_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__custom--FormerRelatedPartyMember_zae7Yi13XxX2" title="Principal payment of debt">16,900</span> to this former related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20150831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGmbtgBqThc2" title="Debt instrument face amount">500,000</span>, each, of financing by the issuance of notes payable at a minimum of $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20150801__20150831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGkMVzbdASRj" title="Proceeds from issuance of note payable">25,000</span>, one unit. The notes bear interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20150831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGeHCTduEjT5" title="Debt instrument, interest rate">10</span>% per annum and were due and payable with accrued interest one year from issuance. During the years ended December 31, 2022, and 2021, the Company did not issue notes in connection with these private placements and did not repay any of these notes. As of December 31, 2022, and 2021, notes payable outstanding under these private placements are $<span id="xdx_90D_eus-gaap--NotesPayableCurrent_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMn6vC6jzjsc" title="Note payable outstanding"><span id="xdx_903_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zyMtu3ojz3Oa" title="Note payable outstanding">624,903</span></span>, all of which are past maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable totaling $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211231__dei--LegalEntityAxis__custom--RioGrandeNeurosciencesIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zQTidcycV2W2">2,110,450</span> are secured by the intellectual property acquired from RGN including patents obtained in the acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition Payable</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $<span id="xdx_902_ecustom--LongtermAcquisitionPayableForCostsNotPaidAtClosing_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__custom--IntellectualPropertyRightsMember_zI1yZS8Q8Xw5" title="Long-term acquisition payable for costs not paid at closing">155,000</span> long-term acquisition payable for costs that were not paid at closing. This payable is non-interest bearing and IPR agreed to make payments up to <span id="xdx_90F_ecustom--PercentageOfProceedsFromAnyPrivatePlacementOrGrossProfits_iI_dp_uPure_c20211231__us-gaap--AwardTypeAxis__custom--IntellectualPropertyRightsMember_zPfiY8S8Flch" title="Percentage of proceeds from any private placement or gross profits">25</span>% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no activity during the year ended December 31, 2022. During the year ended December 31, 2021, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231_zdYv0uzv3v1j" title="Shares as extingusihment">2,505,834</span> as extinguishment for $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20210101__20211231_zOf1ZhB4f124" title="Debt instrument periodic payment">75,175</span> in principal and interest. The balance of the acquisition payable is $<span id="xdx_902_ecustom--AcquisitionPayable_c20220101__20221231_ztukDJSAl8wa" title="Acquisition payable"><span id="xdx_90E_ecustom--AcquisitionPayable_c20210101__20211231_z9tZJ2ciMCs8" title="Acquisition payable">79,825</span></span>, as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effective Interest Rate</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022, and 2021, the Company’s effective interest rate was <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20221231_zK1xSJQS6Tc3" title="Debt effective interest rate">18</span>% and <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20211231_zYbzpQKQ3Mye" title="Debt effective interest rate">12</span>% respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtTableTextBlock_zfFzlu2Arthh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, the notes payable activity was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B4_zdJk21Oqs3Dh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Notes Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_z3HNdwuuB7tk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20210101__20211231_zvvxSCb6NeTk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--NotesPayable_iS_pp0p0_z1WyrXtX3WK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable at beginning of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,256,930</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,835,196</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_ecustom--NotesPayableIssued_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">465,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">950,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--SettlementsOnNotePayable_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlements on note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(163,826</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(117,770</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40B_eus-gaap--RepaymentsOfNotesPayable_iN_pp0p0_di_z9zVbyiBDoAa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayments of notes payable in cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_zXF1M9prYHBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts converted to stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(380,272</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(393,596</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--NotesPayable_iE_pp0p0_zq9svNsipgsc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable at end of period</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,163,832</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,256,930</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNE_pp0p0_di_z87NeHLttT08" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,587</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(75,800</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--NotesAndLoansPayable_iE_pp0p0_z8JUjA2cVRXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,153,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,181,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iE_pp0p0_zDTNZPjtVf84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable issued to former related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--NotesPayableIssuedToNonrelatedParties_iE_pp0p0_zuyOfcCFlZAb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable issued to non-related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,041,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,055,030</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 7256930 6835196 465000 950000 -163826 -117770 14000 16900 380272 393596 7163832 7256930 10587 75800 7153245 7181130 112100 126100 7041145 7055030 <p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhk6oQdrR5rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturity dates on the notes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zlEv7xLay7W7" style="display: none">Schedule of Maturity Dates of Notes Payable</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve months ending,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former <br/> Related <br/> party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past due</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--LongTermDebtPastMaturity_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zROPsiRsjCgk" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Past due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,626,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--LongTermDebtPastMaturity_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_z52o71YqVN0e" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Past due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_ecustom--LongTermDebtPastMaturity_iI_c20221231_zVpTGf9AgCo2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Past due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,738,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_znbL48wFuA06" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="December 31, 2023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zPDquGKrXryi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="December 31, 2023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pdp0_c20221231_zbR0dyWnW8Xe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="December 31, 2023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zDQSLS47EHuc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,041,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zy9hKrpogRs7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--LongTermDebt_iI_c20221231_zkP5sqbmSh4l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,153,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 6626145 112100 6738245 415000 415000 7041145 112100 7153245 465000 465000 0.15 0.18 These fixed rate promissory notes include a prepayment feature at a premium of 15% and a make good provision, which guarantees the holder additional shares if the holder does not realize a 15% or 18% return on the resale of the common shares 1819728 1404728 1465000 Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares 225000 136728 380272 25850000 Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company 62800 4607100 163826 45475 950000 950000 0.15 1735000 785000 1735000 1000000 15 58407 1515152 0.15 128000 393597 100152 27461307 4770926 4770926 112100 0.10 0.12 14000 112100 126100 0.10 0.12 16900 500000 25000 0.10 624903 624903 2110450 155000 0.25 2505834 75175 79825 79825 0.18 0.12 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z07nIoom60L" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 - <span id="xdx_827_zJe2rt4Uq6Va">Shareholders’ Deficit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfPreferredStockTableTextBlock_zAEwDKyFuSB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockDesignatedMember_zirwdeQ12Ja4" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock which have been designated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zC69lbFqhtEh" style="display: none">Schedule of Preferred Stock</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares<br/> Authorized</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares<br/> Outstanding at<br/> December 31, <br/> 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidation Value<br/> per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series AA</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_z7d2NQrZT37f" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zMvIX8UnAlIb" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zBtzDHetfNhi" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0010</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zn9v0f0xppjj" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series B</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_z0fO0gcBUUAc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_z7QV2C7ui1p2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zV0L3nnlXxCk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zhMjAtOVwmw5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series C</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zXVlGsmKKaWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zaxgurD5r2Ek" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_z5258nsLR7xe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zky1BSLHxab5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zETujHXDTzLi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zBY5XxFuzJBj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zXxtPfWnfQc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zMsjPgNjtSe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesignated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zKI83gTvCNzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,922,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zFGI9DsVYOrl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zsuI9PeWcOX4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zK5ktuNc41Yj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zEXI80I3q7T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series AA Preferred Shares</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (<span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20130222__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zMGPzpF1Qns4" title="Number of shares authorized">1,000,000</span>) shares of a new series of preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20130222__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_ztYCiZxup6Ha" title="Preferred stock, par value">0.001</span> per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PreferredStockVotingRights_c20130221__20130222__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zKnJNyX7A1Ff" title="Preferred stock voting rights">Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company</span>. As of December 31, 2022 and 2021, there were <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_z65fOrdYD837" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zRSJUkxcsQqb" title="Preferred stock, shares outstanding">25,000</span></span> shares of Series AA Preferred stock outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2017, the Company filed a certificate of designation for <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHRjnV4f6vS8" title="Number of shares authorized">50,000</span> shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value ($100 per share) divided by <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20170206__20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYU0rqvxwZP" title="Stated value dividend">75</span>% of the market price on the date of purchase of Series B and a <span id="xdx_902_ecustom--WarrantTerm_c20170206__20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAQx2xMUQDzg" title="Warrants term">three-year</span> warrant exercisable into up to a like amount of common shares with an exercise price of <span id="xdx_90A_ecustom--ShareExercisePercentage_pid_dp_uPure_c20170206__20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYb06l9t1RRe" title="Share exercise price">150</span>% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_c20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgBL1RwkiwZ1" title="Liquidation value of preferred stock, per share">100</span> per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. There has been no activity during the years ended December 31, 2022 and 2021. As of December 31, 2022 and 2021, there were <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6MsiZwJrHKj" title="Preferred stock, shares outstanding"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkj2uhWNpxP9" title="Preferred stock, shares outstanding">600</span></span> shares of Series B outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C Secured Redeemable Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the Company filed a certificate of designation for <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20171222__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zRi53LYDWTfi" title="Number of shares authorized">8,000</span> shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $<span id="xdx_902_eus-gaap--PreferredStockDividendsPerShareCashPaid_c20171221__20171222__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zzIvaoxKpual" title="Preferred stock, dividend per share">20.00</span> quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_c20171222__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zEDT7SmR6upa" title="Liquidation value of preferred stock, per share">1,000</span> per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. On January 29, 2020, <span id="xdx_90F_ecustom--ChangeInRightsDueToAmendmendAndRestatedCertificateDescription_c20200128__20200129__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zCtl6crP2Cyb" title="Change in rights due to amendment and restated certificate, description">the Company filed the amended and restated certificate of designation for its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock</span>. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zq79ZAs24Up4" title="Liquidation value of preferred stock, per share">1,000</span> per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management determined the fair value of the new instrument based on the guidance in ASC 820 Fair Value Measurement. Management concluded that the preferred stock should not be classified as a liability per the guidance in ASC 480 Distinguishing Liabilities from Equity even though the conversion would require the issuance of variable number of shares since such obligation is not unconditional. Management classified the Series C in permanent equity as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, the Company converted <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zAYZ9hlugT9l" title="Conversion of stock, shares converted">0</span> and <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zs4gchnveQN" title="Conversion of stock, shares converted">25</span> shares of Series C into <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYBwakWVlzsi" title="Conversion of stock, shares converted">0</span> and <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoYEY6E4pEq5" title="Conversion of stock, shares converted">1,111,111</span> shares of common stock, respectively. As of December 31, 2022 and 2021, there were <span id="xdx_909_ecustom--ConvertiblePreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zeS5VjqtrKRj" title="Convertible preferred stock, shares outstanding"><span id="xdx_90C_ecustom--ConvertiblePreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zEvyBJoah4oc" title="Convertible preferred stock, shares outstanding">738</span></span> shares of Series C outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2019, the Company filed a certificate of designation for <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20191111__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zMauj5aqk6o1" title="Number of shares outstanding">20,000</span> shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to <span id="xdx_907_ecustom--ConversionPricePercentage_iI_pid_dp_uPure_c20191111__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zM7TfbC0vpx9" title="Conversion price">0.01</span>% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zYDVl99AnMqe" title="Liquidation value of preferred stock, per share">1,000</span> per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the Company offered to each holder of Series D the opportunity to convert each share of Series D into <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20220926__20220927__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsxbVXGLAv24" title="Share conversion">100,000</span> shares of the Company’s common stock at an effective conversion price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20220927_z8JQz1vqO2Wa" title="Share price">0.01</span>. <span id="xdx_905_eus-gaap--ConversionOfStockDescription_c20220926__20220927_zFaF6MM6JFFd" title="Conversion of stock description">In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_909_eus-gaap--SharesIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDWhZ9tRA0Yh" title="Number of shares issued">25,500,000</span> shares of common stock upon conversion of <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zlmUV5Yq2x12" title="Conversion of stock issued, shares">255</span> shares of Series D preferred stock, for a total value of $<span id="xdx_90B_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zQvsfX9cc1Ej" title="Number of stock issued, value">255,000</span>. <span id="xdx_907_eus-gaap--ConversionOfStockDescription_c20220101__20221231_zVwMX7wOdDie" title="Conversion of stock description">At December 31, 2022, based on the stock price, the value of these shares was in excess of the 15% guaranteed return.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, there were <span id="xdx_90D_ecustom--ConvertiblePreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zc4FB7pHc3Oi" title="Convertible preferred stock shares issued">50</span> and <span id="xdx_906_ecustom--ConvertiblePreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z98uUBMVecM4" title="Convertible preferred stock shares issued">305</span> shares of Series D outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Activity during the year ended December 31, 2022:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt2kA4mcrZy5" title="Shares issued for conversion of notes payable, shares">25,850,000</span> shares of common stock for the conversion of $<span id="xdx_902_eus-gaap--ConversionOfStockAmountIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK3L9dngVLU9" title="Shares issued for conversion of notes payable">380,272</span> of principal notes and accrued interest in the amount of $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEOuQkwZDXkc" title="Accrued interest">136,728</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OneInvestorMember_zHPmlRIW6bod" title="Issuance of common stock">2,428,777</span> shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zkDRbN4u0ELf" title="Issuance of common stock">3,450,000</span> shares of common stock as commitment shares in connection with promissory notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_90D_ecustom--StockIssuedDuringPeriodFairValuesSharesIssuedForServices_c20220101__20221231_zpUiqUWurgrj" title="Shares issued for common stock for services, shares">66,500,000</span> shares of common stock for services for total fair value of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodFairValuesIssuedForServices_c20220101__20221231_zFo0tYFQ1wG6" title="Shares issued for common stock for services, value">1,316,900</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_904_eus-gaap--SharesIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKcATmz9PH92" title="Number of shares issued">25,500,000</span> shares of common stock in exchange for <span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_znrUcKKBDcm" title="Conversion of stock issued, shares">255</span> shares of Series D Preferred, which resulted in an inducement loss of $<span id="xdx_903_ecustom--InducementLossRelatedToConversionOfPreferredStock_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zExj1Jq8LUVj" title="Inducement loss">200,932</span> recorded as a deemed dividend in the shareholders’ deficit as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued 3 units or <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlkDEHhZfecd" title="Common stock new issunace, shares">15,000,000</span> shares of common stock pursuant to a private placement for total net cash receipt of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zEM2nvvYpakk" title="Common stock new issuance, value">142,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Activity during the year ended December 31, 2021:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zggiQXghgNj3" title="Shares issued for conversion of notes payable, shares">27,461,307</span> shares of common stock for the conversion of principal notes and accrued interest for aggregate fair value of issued common stock of $<span id="xdx_903_eus-gaap--ConversionOfStockAmountIssued1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zspWOhubapod" title="Shares issued for conversion of notes payable">1,117,990</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNotesMember_zFSmGt8gc8of" title="Issuance of common stock, shares">7,868,668</span> shares of common stock labeled as commitment shares in connection with the issuance of promissory notes for a total fair value of approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNotesMember_zl4tojHZqhD9" title="Issuance of common stock, value">223,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zjh4x2ASHgjh" title="Issuance of common stock, shares">7,000,000</span> shares of common stock pursuant to securities purchase agreement for total consideration of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZDfQRgc9a07" title="Issuance of common stock, value">126,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConversionOfSeriesCPreferredStockMember_zQtlXxYE4Z2i" title="Issuance of common stock, shares">1,111,111</span> shares of common stock with a value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConversionOfSeriesCPreferredStockMember_zGrNizVr1lS8" title="Issuance of common stock, value">33,333</span>, related to the conversion of Series C.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--SettlementOfDebtMember_zBa7gXJggCHh" title="Issuance of common stock, shares">4,020,986</span> shares of common stock with a value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--SettlementOfDebtMember_zbiGk2v64sCb" title="Issuance of common stock, value">142,424</span>, related to the settlement of debts, of which <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zRZMQORas7l2">2,505,834</span> shares of common stock were issued with a fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zFSySfAJVpX3" title="Issuance of common stock, value">84,697</span> to a former related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zP7lb8zeoCLa" title="Issuance of common stock, shares">2,500,000</span> shares of common stock in connection with the consulting agreement, with a fair value of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zgGrP6FMnxt2" title="Issuance of common stock, value">95,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company executed an independent contractor agreement with the Company’s new President and Chief Commercial Officer of its medical division. Pursuant to this agreement, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--IndependentContractorMember__srt--RangeAxis__srt--MinimumMember_z81oYNXWwl6l" title="Stock option to officers">3,000,000</span> stock options to purchase an equivalent number of common stocks, with <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__srt--TitleOfIndividualAxis__custom--IndependentContractorMember_zQWQAQovqyph" title="Stock option vested">250,000</span> options vesting each quarter with a term of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--IndependentContractorAgreementMember_zk5jst61xKg4" title="Vesting period">2</span> years from vesting and a strike price of $<span id="xdx_901_eus-gaap--OptionIndexedToIssuersEquityStrikePrice1_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--IndependentContractorAgreementMember_zgv2bz3jFBt1" title="Vesting strike price">0.0076</span>. The Company did not issue any stock options during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company cancelled <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zgS6QypKoHUe" title="Stock option cancelled">501,320</span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zOTw0CDhbiMe" title="Stock option cancelled">2,500,350</span> stock options during the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not recognize any share-based compensation expense for the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQI5RbBrsIai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity for the years ended December 31, 2022 and 2021, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zj1zvaGI6EJd" style="display: none">Schedule of Stock Options Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Exercise Price <br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate <br/> Intrinsic <br/> Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRLgsfkHcMBk" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock option outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,014,080</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zUIfujt774Ih" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWcP0VDCOKFc" title="Weighted Average Remaining Contractual Term (years), Outstanding Beginning">1.67</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zaNiBq1ckUWe" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregated intrinsic value, outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z3NNsXqvZou9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYffOYigEhe3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrzW1bTtwZ1l" title="Weighted average remaining contractual term (years), granted"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z59JwQmNaaoa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_zFqxxvj5stw1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,500,350</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVc3aFnZ6VOi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zXd5MO1Os8E5" title="Weighted average remaining contractual term (years), cancelled">0.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueCancelled_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zbjgENTc9LKd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zIwRHKMf3R2h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpWOBo0uE0i1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z1BQudTufd9k" title="Weighted average remaining contractual term (years), exercised"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueExercised_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zvfSjezHesG4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Aggregated intrinsic value, outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBuBOyI8sLC3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">513,730</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6fmihJ9oudk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zm96cU3A0opi" title="Weighted average remaining contractual term (years), outstanding beginning">0.76</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueExercised_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z3DVU6hMC5dd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjHN7M0KaGa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z1knuHkqcvN3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJ80vV0AVTK1" title="Weighted average remaining contractual term (years), granted">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdL8ozyAVwXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zQnYkCGhvhr8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(501,320</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z7U4Rqwj1mvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zmCvMI5kLqck" title="Weighted average remaining contractual term (years), cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueCancelled_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zusKhlSNXLQ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z3e79KgAYu14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zAQquIC5lBW" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTuqBXaF83x4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,012,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zngNQwskV0W4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zxHywyogDpDi" title="Weighted average remaining contractual term (years), outstanding beginning">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJG8cdVrCxY3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregated intrinsic value, exercisable ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJc0Iuym7lj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">262,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_znOgXE3I46D" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ziZRys0TSSgg" title="Weighted average remaining contractual term (years), outstanding beginning">2.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCPZBUatXkt8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregated intrinsic value, exercisable ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zBgFTkaehq1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zNDIm7nboMOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all stock options outstanding as of December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zSvj9mhEakY8" style="display: none">Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prices</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Options</i></b></span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zleNibtnhBj6" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Range of exercise prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zsyb5FQuNhb8" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zMpnq4DrKHZ8" title="Weighted average remaining contractual life">4.30</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zk8MuP7sA0W9" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_z3zE23e0dnMl" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zErhbw6JZZt5" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_z7CkJWJcLoQa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zrZNvnE3NAjc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zneu7jzVdY85" title="Weighted average remaining contractual life"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_z0Vob1A2hhZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zAcpUACbjPjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zYbEPwtyC5yl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zMvfHKFfvT8c" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Range of exercise prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zay1ef0KJtBd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zjoA5vgD2b3b" title="Weighted average remaining contractual life">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zQWAFWnWWFi8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zl8f5ZDPnja9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_z6ZDmysX7y4e" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zFmTJ6dMjQU7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,012,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zb5BZNTQFTH5" title="Weighted average remaining contractual life">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zRU56599Gt2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zlb3qPrcW6Be" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">262,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zdWmpdsRQEsk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zEyPbnjg3Sgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022, and 2021, the Company did not issue any warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ze0DCsef8sQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the changes of the warrants during the years ended December 31, 2022 and 2021, are presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z1t31B7oQAfj" style="display: none">Schedule of Warrants Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx7fmNzq5he7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Shares outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,295</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfowtKHyRXw7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price per shares outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znnHmDlU3sj2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1379">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuxGm7x1JX0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr7vKruFGeqf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,095</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hGMhMj59Bb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">384.39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhM7ZZx3qsb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF0Kk8QrSvXb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ4H9CrWr208" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6czk5ZT2W7j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkZ0BUAyymph" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zi1i8YR1RFDa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1397">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRA3Rc0D3t12" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkT31UJNOiwg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxaRaHrFZS6d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHHzaYCRilni" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT4kMWoFXZ21" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQsbN0PHxMgb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA7bLMSKOMV2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztIYXkDaWqO1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zyfbNqC0dIy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p id="xdx_89C_ecustom--ScheduleOfShareBasedCompensationSharesAuthorizedUnderWarrantPlansByExercisePriceRangeTableTextBlock_zC8Lmz4B30X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all warrants outstanding as of December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zGhiz5snlyP5" style="display: none">Schedule of Warrants Exercise Price Range</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prices</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zo8JVCMJszNf" title="Range of exercise prices. upper limit">50.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zPZ6qWJXXARe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zOBtullP3j9b" title="Weighted average remaining contractual life">0.22</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zYruysIJZ6Jf" title="Weighted average exercise price">50.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zBMhKmJgiN6l" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_z2XMY4QoWoxa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exerice price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkh6d4fZ9dO7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHaKZx7Wxm43" title="Weighted average remaining contractual life">0.22</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUUD54SJDBb5" title="Weighted average exercise price">50.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz55oMtP1Nul" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19fE2j9Msg2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exerice price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_z9OMFC5x0mf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfPreferredStockTableTextBlock_zAEwDKyFuSB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockDesignatedMember_zirwdeQ12Ja4" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock which have been designated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zC69lbFqhtEh" style="display: none">Schedule of Preferred Stock</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares<br/> Authorized</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares<br/> Outstanding at<br/> December 31, <br/> 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidation Value<br/> per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series AA</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_z7d2NQrZT37f" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zMvIX8UnAlIb" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zBtzDHetfNhi" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0010</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zn9v0f0xppjj" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series B</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_z0fO0gcBUUAc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_z7QV2C7ui1p2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zV0L3nnlXxCk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zhMjAtOVwmw5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series C</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zXVlGsmKKaWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zaxgurD5r2Ek" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_z5258nsLR7xe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zky1BSLHxab5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zETujHXDTzLi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zBY5XxFuzJBj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zXxtPfWnfQc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zMsjPgNjtSe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesignated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zKI83gTvCNzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares authorized"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,922,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zFGI9DsVYOrl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zsuI9PeWcOX4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Par value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20221231__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zK5ktuNc41Yj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Liquidation value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5000000 1000000 25000 0.0010 50000 600 0.0001 100 8000 738 0.0001 1000 20000 50 0.0001 1000 3922000 1000000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company 25000 25000 50000 0.75 three-year 1.50 100 600 600 8000 20.00 1000 the Company filed the amended and restated certificate of designation for its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock 1000 0 25 0 1111111 738 738 20000 0.0001 1000 100000 0.01 In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale 25500000 255 255000 At December 31, 2022, based on the stock price, the value of these shares was in excess of the 15% guaranteed return. 50 305 25850000 380272 136728 2428777 3450000 66500000 1316900 25500000 255 200932 15000000 142000 27461307 1117990 7868668 223000 7000000 126000 1111111 33333 4020986 142424 2505834 84697 2500000 95000 3000000 250000 P2Y 0.0076 501320 2500350 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQI5RbBrsIai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity for the years ended December 31, 2022 and 2021, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zj1zvaGI6EJd" style="display: none">Schedule of Stock Options Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Exercise Price <br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate <br/> Intrinsic <br/> Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRLgsfkHcMBk" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock option outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,014,080</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zUIfujt774Ih" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWcP0VDCOKFc" title="Weighted Average Remaining Contractual Term (years), Outstanding Beginning">1.67</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zaNiBq1ckUWe" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregated intrinsic value, outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z3NNsXqvZou9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYffOYigEhe3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrzW1bTtwZ1l" title="Weighted average remaining contractual term (years), granted"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z59JwQmNaaoa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_zFqxxvj5stw1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,500,350</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVc3aFnZ6VOi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zXd5MO1Os8E5" title="Weighted average remaining contractual term (years), cancelled">0.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueCancelled_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zbjgENTc9LKd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zIwRHKMf3R2h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpWOBo0uE0i1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z1BQudTufd9k" title="Weighted average remaining contractual term (years), exercised"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueExercised_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zvfSjezHesG4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Aggregated intrinsic value, outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBuBOyI8sLC3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">513,730</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6fmihJ9oudk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zm96cU3A0opi" title="Weighted average remaining contractual term (years), outstanding beginning">0.76</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueExercised_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z3DVU6hMC5dd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjHN7M0KaGa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z1knuHkqcvN3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJ80vV0AVTK1" title="Weighted average remaining contractual term (years), granted">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdL8ozyAVwXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zQnYkCGhvhr8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(501,320</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z7U4Rqwj1mvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zmCvMI5kLqck" title="Weighted average remaining contractual term (years), cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueCancelled_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zusKhlSNXLQ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregated intrinsic value, outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z3e79KgAYu14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zAQquIC5lBW" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTuqBXaF83x4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,012,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zngNQwskV0W4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zxHywyogDpDi" title="Weighted average remaining contractual term (years), outstanding beginning">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJG8cdVrCxY3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregated intrinsic value, exercisable ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJc0Iuym7lj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock option outstanding, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">262,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_znOgXE3I46D" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ziZRys0TSSgg" title="Weighted average remaining contractual term (years), outstanding beginning">2.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCPZBUatXkt8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregated intrinsic value, exercisable ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 3014080 0.37 P1Y8M1D 2500350 0.16 P0Y7M24D 513730 1.43 P0Y9M3D 3000000 0.0076 P3Y4M24D 31200 501320 0.18 3012410 0.22 P3Y4M24D 31200 262410 2.45 P2Y7D 2600 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zNDIm7nboMOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all stock options outstanding as of December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zSvj9mhEakY8" style="display: none">Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prices</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Options</i></b></span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zleNibtnhBj6" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Range of exercise prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zsyb5FQuNhb8" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zMpnq4DrKHZ8" title="Weighted average remaining contractual life">4.30</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zk8MuP7sA0W9" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_z3zE23e0dnMl" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zErhbw6JZZt5" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_z7CkJWJcLoQa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zrZNvnE3NAjc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zneu7jzVdY85" title="Weighted average remaining contractual life"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_z0Vob1A2hhZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zAcpUACbjPjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeTwoMember_zYbEPwtyC5yl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zMvfHKFfvT8c" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Range of exercise prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zay1ef0KJtBd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zjoA5vgD2b3b" title="Weighted average remaining contractual life">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zQWAFWnWWFi8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_zl8f5ZDPnja9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeThreeMember_z6ZDmysX7y4e" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0076</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zFmTJ6dMjQU7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,012,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zb5BZNTQFTH5" title="Weighted average remaining contractual life">3.40</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zRU56599Gt2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zlb3qPrcW6Be" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">262,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zdWmpdsRQEsk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 54.00 11750 P4Y3M18D 54.00 11750 54.00 11.60 660 11.60 660 11.60 0.0076 3000000 P3Y4M24D 0.0076 250000 0.0076 3012410 P3Y4M24D 0.22 262410 0.22 <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ze0DCsef8sQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the changes of the warrants during the years ended December 31, 2022 and 2021, are presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z1t31B7oQAfj" style="display: none">Schedule of Warrants Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx7fmNzq5he7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Shares outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,295</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfowtKHyRXw7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price per shares outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znnHmDlU3sj2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1379">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuxGm7x1JX0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr7vKruFGeqf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,095</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hGMhMj59Bb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">384.39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhM7ZZx3qsb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF0Kk8QrSvXb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ4H9CrWr208" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6czk5ZT2W7j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkZ0BUAyymph" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zi1i8YR1RFDa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1397">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRA3Rc0D3t12" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkT31UJNOiwg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxaRaHrFZS6d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHHzaYCRilni" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT4kMWoFXZ21" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQsbN0PHxMgb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA7bLMSKOMV2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztIYXkDaWqO1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average exercise price, exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 39295 200.72 17095 384.39 22200 59.25 20200 60.17 2000 50.00 2000 50.00 <p id="xdx_89C_ecustom--ScheduleOfShareBasedCompensationSharesAuthorizedUnderWarrantPlansByExercisePriceRangeTableTextBlock_zC8Lmz4B30X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all warrants outstanding as of December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zGhiz5snlyP5" style="display: none">Schedule of Warrants Exercise Price Range</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prices</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zo8JVCMJszNf" title="Range of exercise prices. upper limit">50.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zPZ6qWJXXARe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zOBtullP3j9b" title="Weighted average remaining contractual life">0.22</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zYruysIJZ6Jf" title="Weighted average exercise price">50.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_zBMhKmJgiN6l" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--PriceRangeOneMember_z2XMY4QoWoxa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exerice price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkh6d4fZ9dO7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHaKZx7Wxm43" title="Weighted average remaining contractual life">0.22</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUUD54SJDBb5" title="Weighted average exercise price">50.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz55oMtP1Nul" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19fE2j9Msg2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exerice price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 50.00 2000 P0Y2M19D 50.00 2000 50.00 2000 P0Y2M19D 50.00 2000 50.00 <p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zBjQE7QWl3Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_824_z5drb246cDw3">Related Party and former Related Parties Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One executive officer, one former executive and one former operational manager of the Company have agreed to defer a portion of their compensation until cash flow improves. As of December 31, 2022, and 2021, the balances of their deferred compensation were $<span id="xdx_90E_eus-gaap--DeferredCompensationEquity_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zDA7Fd63JXRa" title="Deferred compensation">1,350,265</span> and $<span id="xdx_908_eus-gaap--DeferredCompensationEquity_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zoL242Iv9ucj" title="Deferred compensation">1,289,625</span>, which reflects $<span id="xdx_90E_ecustom--AccrualOfDeferredCompensation_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zQjMtkKbxYS9" title="Accrual of deferred compensation">300,000</span> accrual of deferred compensation in accordance with contractual arrangement, approximately $<span id="xdx_903_ecustom--RepaymentsOfDeferredCompensation_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_z2FwpPbOZDK3" title="Cash repayments of deferred compensation">170,000</span> cash repayments of deferred compensation and $<span id="xdx_907_eus-gaap--RoyaltyExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zyJZ38tpIHLh" title="Royalty expense">69,217</span> non-cash reduction pursuant to royalties charged to the former operational manager on SofPulse units during the year ended December 31, 2022, and $<span id="xdx_909_ecustom--AccrualOfDeferredCompensation_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zTphTFA6U5xa" title="Accrual of deferred compensation">300,000</span> accrual of deferred compensation, $<span id="xdx_905_ecustom--RepaymentsOfDeferredCompensation_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zioSHywnphU6" title="Cash repayments of deferred compensation">250,950</span> cash repayments during the year ended December 31, 2021. The royalty/licensing revenue recognized in 2022 was generated from the former operational manager who is developing business in Costa Rica and Mexico. In lieu of payment for the royalty/licensing, the former operational manager paid $<span id="xdx_904_ecustom--PaymentToLicensingCost_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_zEnyQKxqc3I8" title="Payment to licensing cost">44,406</span> directly to the Company’s vendor, and the deferred compensation due to him was reduced by $<span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember_z37xFQr2BGee" title="Due to related parties current and noncurrent">69,217</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlueRidgeConsultingLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZlzNL5w1aJg">25,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to a company controlled by the Company’s Chief Executive Officer with an estimated fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlueRidgeConsultingLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmG0QNY4zuo5">550,000 for services.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Chief Executive Officer of the Company advanced $<span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zNyXNNuBW6m7" title="Stock issued during period value new issues">28,021</span> of funds to the Company of which $<span id="xdx_90D_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlueRidgeConsultingLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPKtijkUR9Rc" title="Repayments of related party">25,521</span> was repaid during the year 2022. During the year ended December 31, 2021, the Chief Executive Officer of the Company advanced $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zCSpg7PrhG08" title="Stock issued during period value new issues">13,530</span> of funds to the Company of which $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlueRidgeConsultingLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDD2Ktzi7ar8" title="Repayments of related party">13,405</span> was repaid during the year 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of short-term advances due to one officer and executive of the Company at December 31, 2022 and 2021 was $<span id="xdx_90D_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneOfficerAndExecutiveMember_zHjVVBooNKOd" title="Due to officer"><span style="-sec-ix-hidden: xdx2ixbrl1469">2, 625</span></span> and $<span id="xdx_90B_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneOfficerAndExecutiveMember_zd0PublAbBW5" title="Due to officer">125</span>, respectively and is included in the Company’s accounts payable and accrued interest balance as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022 and 2021, notes payable remain outstanding to the former President of the Company, in the amounts of $<span id="xdx_90F_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerPresidentMember_zpgodfuDP9Ld" title="Notes payable - related parties">112,100</span> and $<span id="xdx_907_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerPresidentMember_ziPU2wakceLe" title="Notes payable - related parties">126,100</span>, respectively. At December 31, 2022 and 2021, accrued interest on these notes payable totaled $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerPresidentMember_z1XAWCl7dioj" title="Accrued interest">80,034</span> and $<span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerPresidentMember_zEaz7kNTxki" title="Accrued interest">67,787</span>, respectively, and are included in accrued interest on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1350265 1289625 300000 170000 69217 300000 250950 44406 69217 25000000 550000 28021 25521 13530 13405 125 112100 126100 80034 67787 <p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z8lffrJDDG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 - <span id="xdx_825_zeOTouQ9iOW8">Income taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2022 and 2021, the Company had approximately $<span id="xdx_902_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20220101__20221231_zCjhqvykkmze" title="Effective income tax rate reconciliation at federal statutory income tax rate, amount">33,000,000</span> and $<span id="xdx_908_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20210101__20211231_zAWANWd1eJ7k" title="Effective income tax rate reconciliation at federal statutory income tax rate, amount">28,000,000</span> of federal net operating loss carryforwards, respectively, that it can use to offset a certain amount of taxable income in the future. Some of these federal net operating loss carryforwards <span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231_zI8EVSJZLyz8" title="Income tax examination, description">begin to expire in 2030</span>. The resulting deferred tax asset is offset by a <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_c20220101__20221231_z7sXjbNgnHNl" title="Effective income tax rate reconciliation, other adjustments, percent">100</span>% valuation allowance due to the uncertainty of its realization. Utilization of these net operating losses could be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state laws based on ownership changes and the value of the Company’s stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zpFlqcvaguh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zAKD7YUNQJRh" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_z0oXjfhatyg7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zGXJlf5hzzPb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_zZOXLT0Fkypj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax computed at federal statutory rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_uPure_zjttWV9sppzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State taxes, net of federal benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-1.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-7.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_zX2duNxcCv8a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Deductible expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zLavPzPyk7hi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zlOQU01UPAfh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A2_z5uvLL93oNpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $<span id="xdx_909_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20211231_zRmwM9NTAOCc" title="Interest and penalties"><span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20221231_zFp7NYKt2PJi" title="Interest and penalties">0</span></span> for the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 33000000 28000000 begin to expire in 2030 1 <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zpFlqcvaguh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zAKD7YUNQJRh" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_z0oXjfhatyg7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zGXJlf5hzzPb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_zZOXLT0Fkypj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax computed at federal statutory rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_uPure_zjttWV9sppzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State taxes, net of federal benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-1.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-7.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_zX2duNxcCv8a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Deductible expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zLavPzPyk7hi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zlOQU01UPAfh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.210 0.210 0.017 0.070 0.156 0.010 0.071 0.270 0.000 0.000 0 0 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_ztoGUXM5b8hf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 - <span id="xdx_821_z1dU5quzF0z4">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal matters</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of December 31, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_808_eus-gaap--ConcentrationRiskDisclosureTextBlock_znPCzMWwsiik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_82C_zlzBdvBKwWy2">Concentrations</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, we had two significant customers which accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneSignificantCustomersMember_zh0NdaWYIUw2" title="Concentration risk, percentage">84</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoSignificantCustomersMember_ztZDx2kF51x" title="Concentration risk, percentage">10</span>% of direct sales. In addition, the Company generated all of its royalty/licensing revenue from one former related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, we had two significant customers which accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneSignificantCustomersMember_zu0qv6cPjFuj" title="Concentration risk, percentage">28</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoSignificantCustomersMember_znHrsRGinkFl" title="Concentration risk, percentage">25</span>% of sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Supplier</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also have a single source for our bioelectric medical devices, which account for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zdyqiOM3DiO1" title="Concentration risk, percentage">100</span>% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts Receivable</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021, we had two customers which accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_za3A4ax6hN04" title="Concentration risk, percentage">67</span>% of our accounts receivable balances. There are no accounts receivable balance as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.84 0.10 0.28 0.25 1 0.67 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zquNBSc1z7Jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 - <span id="xdx_822_zdkUJIxIbAC3">Subsequent Events</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXRbwFtIAef" title="Issuance of common stock">5,000,000</span> shares of common stock following the conversion of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z6OO9LYdgWDe" title="Issuance of common stock">50</span> shares of Series D preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znOFSukArsM3" title="Issuance of common stock">6,500,000</span> shares of common stock pursuant to consulting agreements with an estimated fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zcu0mlPQ7MG6" title="Issuance of common stock value">63,700</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOl8fEh5mqje" title="Issuance of common stock">22,500,000</span> shares of common stock pursuant to a private placement for $<span id="xdx_90D_eus-gaap--Cash_iI_c20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z0f8Zqpmbq5l" title="Cash">225,000</span> in cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2r62gbBPvt2" title="Conversion of stock shares issued">10,900,000</span> shares of common stock for the conversion of $<span id="xdx_90E_eus-gaap--ConversionOfStockAmountIssued1_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBYi6KIucUee" title="Conversion of stock amount issued">100,000</span> promissory note and $<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCbBGFkpBDV9" title="Interest payable current">9,000</span> in accrued interest with one investor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNvP06uFDqLe" title="Issuance of conversion of convertible securities, shares">4,300,590</span> shares of common stock with a fair value of approximately $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8qmuwumtco9" title="Issuance of conversion of convertible securities value">67,090</span> as settlement of a convertible note with an approximate carrying value of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmrFa4ZoEwoc" title="Debt instrument face amount">209,300</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zqTKowSl7ERc" title="Issuance of common stock">1,507,277</span> shares of common stock with a fair value of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zOcJfaaZHzAi" title="Issuance of common stock value">25,000</span> pursuant to a make good provision from a previously executed settlement agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zACWi9fpIlq3" title="Issuance of common stock">6,350,000</span> shares of common stock as additional consideration pursuant to a securities purchase agreement with estimated fair value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zHrb008jisdh" title="Issuance of common stock value">50,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 29, 2023, the Company entered into a binding Letter of Intent (“LOI”) to spin off its current medical device division to an entity managed by Ira Weisberg, the Company’s President and Chief Commercial Officer of its medical division. Mr. Weisberg will be the future President and Chief Executive Officer of this newly formed entity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, the Company executed a Service-Disabled Veteran-Owned Small Business Government Reseller Agreement with Academy Medical, Inc. to distribute SofPulse® medical devices to ensure its availability to the Veteran Health Administration (“VHA”) and Department of Defense (DoD) contracts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31,2022, the Board of director approved the issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z520MgILjqa9" title="Issuance of common stock services">39,150,000</span> shares of common stock for past services with estimated fair value of approximately $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zj5egqdzHuu6" title="Issuance of common stock value services">552,000</span>.</span></p> 5000000 50 6500000 63700 22500000 225000 10900000 100000 9000 4300590 67090 209300 1507277 25000 6350000 50000 39150000 552000 EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '6$D58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !UA)%6DR-'T>\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O32="J'+BV-/"H(#Q;>0W+9@TX3DI-VWMZU;A^@'\#%W__SN M=W"-B=*$A,\I1$SD,-\,ONVR-''-CD11 F1S1*]S.2:ZL;D/R6L:G^D 49L/ M?4 0G-^!1])6DX8)6,2%R%1CC30)-85TQENSX.-G:F>8-8 M>NPH0U56P-0T M,9Z&MH$K8((1)I^_"V@7XES]$SMW@)V30W9+JN_[LJ_GW+A#!6]/CR_SNH7K M,NG.X/@K.TFGB&MVF?Q:/VQV6Z8$%W7!5T5UOQ-&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !UA)%6!%U407@' -,0 & 'AL+W=OZ%PZX"1K@G#%) M^]^?(224RGP)DK,7+21\'_!GV#P/=J^VC/^.5I0*]!SX873=6 FQ_M1J1& ^(D+M\V8K6G!(W+0K\%C:,;BL@7MCH7Z6?37G_BL7"]T(Z MY2B*@X#PEQOJL^UUPVSL/WCPEBN1?-#J7ZW)DLZH^+&>+1H]OHU39*FK)@['>R,W:O&T9R1=2GCD@DB/RUH3;U M_41)7L=_F6CC<,ZD\/7V7GV4-EXV9D$B:C/_I^>*U77CHH%<^D1B7SRP[1>: M-:B3Z#G,C]*?:+L[MMUN(">.! NR8GD%@1?N?I/G#,2K@JY54H"S ORFP"P[ M@Y456,<6M+."=DIFUY24PY (TK_B;(MX6(XQ \Y36(%/ MY\"G S9P(.&X*:"13Y8J0'#]$_$C%5<;+*M+2)-8@5#W0*A[W!TT",.8^.B! MKAD7*E*PCN"Q$A1851>4)K$"J-X!5._(KL:)?*2G3^1R6+!6Z6T%EM6EI4FL M0.OB0.OB.%I3RCWF)@\^)!^^RC&J0FG_J"M]UH'U=:%I$BM NSQ NSP.VLB+ M'-D7,W8C^7&D @>KC7ZI8($U=6%I$BO ,HW;&WH2M M>0;1EMV5RZXZEL'Q&7VC+TJ,L)2\\\P.OC![Z@%.J]G7I5:DEMM]$_;K&;4Y M>49C5Z+SGCR'I%8-Z+>P9+O3Q)T.E@"5]+0& 5UJ17IY%#!A#Y_1&X<.X]+8 MIN#.T$S(IP-B'-DLEC>CO">9J^[-%4GC5@E0:T#0I58$F$<$$_;U&<"!ZTKU MZ&R_@>[D<>@^5%.#);L6-MZA&O]L$K(E08,-#=6)##YA;>*G2!EF'C-,.!V MQ.=;IB0.2YH=L:I%?.0SIAI9;/A$M4F?(IJ8>38QX3CQEK2=[,E183,=6A!<,IXRVV*8N$=$1_>^O2)U&%XJ5I=7M*;EI3BRZU(K<\ MM6 X<*0==, I*<<$"WRX, S5;(<-U]7&=(JT@O.T@N&0<;O4-H-"91$LK^Z:!Q%<4F' MA34G*F=HPT6UL9TBC. \C."CPL@C\V5L(WSW_HHKWXU6*)7 TIHC=*D58>4Y M A^5(_8O2'<3.^E )TV:^H5RA>(OJG2T<%5M:J?(!#C/!/BH3# .!>6[U2G) MJV2RQZBD!BN64=.: W2I%1<[Y#G .BH'I-U1QG5!EXPKGPT5.A,6-HGC4"DC M1=R=H'*Y@]8XH$NM2"^/ ]91<6 6$-]'-W$DOXZ4_;-"IVS"&BZK#>L4&<#* M,X!UU,S%;4#Y,AG-_I(*8B4#0; FH?J>@P5+9Z[ANMK83I$)K%?KD8Z:P9BM MI.4 8<$RY;#T+D Z122P\DA@'353,8T7ONQZ@G$T$()*2.D43MD2 MK@J]\EZHU>WK4BM2R]V^!7OT/;"1QP,T'BHYP0KMKG*&"ZZJ3>D4-M_*;;X% MF_(]I;()Z8KR!Q91V7W#%U'E;M^" MO?D>7O+&+.F02H!5@<'Q0G;V3OW:&BZN34NKRV^]6C^>N*ET'7Z$G&1.=+>4 M_/#I8:W_(%WAWLH/W_VAP'>2F+$(^?1)EAKG/3G>\MW:^]V.8.MT-?J""<&" M='-%B;SGD@/D]T^,B?U.GDXF(%BRCXH0O6:[>>>)%1J6Z+9XG M8EDP&I>#LG2"(?0F&4WRT?2\?.V^F)[SE4R3G-T70*RRC!8_KEC*7R]&:/3V MPN?D>2'U"Y/I^9(^LSF37Y;WA;J;U%GB)&.Y2'@."O9T,;I$IS,2Z %EQ->$ MO8J-:Z"I/'+^3=_B_!^\KF/A"$0K M(7FV'JP09$E>_:7?UQ.Q,0 Y/0/P>@#>=P!9#R ET0I92>N:2CH]+_@K*'2T MRJ8ORKDI1RLV2:Z7<2X+]6ZBQLGIC.>"ITE,)8O!%4UI'C$PU^D$. 9?YM?@ MYZ-?SB=2?90>,(G6::^JM+@G[36+3@!!8X AQH;AL_V'H_;PB2)8L\0U2USF M(WTL5T7!<@DNA5#$3DU\J@2..8'>3*=B22-V,5*[1;#BA8VF'WY"'CPSL1LH M68LKJ;D26_;IC(J%B6 URBU'ZC_-!WS;"]&K9GA?W M)4WW0.@9$ 9ZZ[80=J-")W![(/HU1-\^LZKWJ/KH+0J_"PU[KN-L3Y\A+D28 MN#WU&]3P@CUFL'_F @.\0"'TMN!UXY34^A@A,[RPAA?NU=K^2.ACDB8R84:4 MX9#M;:!D+;X(-HH%]VLH2_I#=Y-R)](H*E9*PE+[-*Q3;ZY"$#@H=+<6RQ#G MN8'C$?-BH0VY1;O ESB37#(U.<:"7Z?8_'#B.JKFX3;*;B!V<>"X80_,1B^1 M5:*4 #\Q55#WUCQJ]0W;!N^.2 MU<50=A' GT"5D/(W?2;=C00*PMQG7AM]H*K*+ZC4KE"/0,UQO7#-0@X#Z MQ VAMRT"ADBBZA&'?@_61DC1(4JZJ\]TE9(0$B#?Z\RM07E]'R(?]2\OP9J&:3[<3<%5 _#'"GF'>%M=$V,HOVT=E=&+LJ2HCC*:_2@6G0 M9=\/D$OZD#:*BZP"-YU]NKV]>;C]>/[AYNZWCW>SFX]SU8#4 MG@2!$?T[A-/H;P=(U#Y'->*+H=5NS!>T8 N>QJP09;OQS_2I.8D2HY1AJY0? M?*P:*%N;>Z/=V*[=,YYE/ ?J3!Y]&X,C> (A1+J[@A>:KM@9P&,7PC&L_@&A MITJ=$U9RP8OD7Q:?5=J"R!AC?^R2H+SWG;$3!F/?0V\C$B&T12@/&"LII+I( MU!ZV"=;VJWNH%S:8!T0ZEM\0YCM.C\' &P=RN\&XC.-$>PJUY?6QZCC)0427 MB6H!1JP&EX%#%,)@VV:8(J'G$13T" !N? :V^XRY7G<@5H\B*I*E!F]L4;@K M]L?JM+?=]W>&M5$VC@#O/&ZOLE4E_+:-V97T8]]%ZL04D&VDAE#7[$ M0[D8Y-]X?#0$6L^/N+$)V&X3YJNE:AR7EZ"Z^,JE[C;WQ=L1H*K[OV[+!O.W MD83U P[N\@-E:T]'XT-P,*C"65W-P=P'RM;FWC@;;'L-:;]W6;C/XC]\#]7)P:UTZ[ C.NUU#9VK/1.!*" MAJQ58O4W!W,?*%N;>^,@B-U![%VKI&L)T%:I6D/:^#:^AM]A%ZI*G;V_4JWY M#UZM@;*U9Z.Q)<09M%+?\23 PGV@;&WNC^"AB_SYG_ZI_A^Q75[P.J&\F7Y2/V1RXES\K+ M!:-JU76 >O^)<_EVHY_:U[_2F/X'4$L#!!0 ( '6$D59D&>K+(00 !H6 M 8 >&PO=V]R:W-H965T&ULM9A1C]HX%(7_BI5=K5JI M.XD-(S%P3;2K2P8 M>]$[?T=CQ]-$D$ HM055;SN80I)H)\7Q7VGJ5,?4A8?;K^Y_Y_T M1[D0!P7X5 $I"\BY!;VRH)3JVUC5RK0VL -R\,\%8I1G4D9DR#0AOZDBP34FG/==%.+A:>?>^KQV$VPYP^#D;L[[,16 M!?[0\RJ5 =RK@'NMP%.6I@I5G0[ARP?%RM&.)EMHHBR,@H/C>W>>Y^$CS$Z9 MP=FO./L7<(JU.H$$HENY9CS^!5$3;V$X. AOE?^'3&?)36X_8K;OYP[%F+; MS.S;(+A'2.#WAD?(MC+H]^^'P>#$0@\JX,'EP.HR+23-HCA;-5$/SJ:VE>W4 M044=M%+/MQO@Z/$1%1O?F%2H:*:NW*"F+D)SW0[Z]S.D"^#?FWIH]=>9]R V M-(2QHT)- -^!,_GC-SSP/C9==&YD9BS%L%J*8>M2U$V?,]2%U_!H6H]GNDME M@-Y7H/>7@9XUU??6&80;1[I;9T!CK\XU[RKLTT-=&EJ7ER/B3ID)?!#$^"K@ MCJ$N73NINV0F=1VDN#U)Y\!C!?F$U ^)'7 9ZPR]9*#;_2^=Z%NYF:M1IS1N MC^G+AAJ?&=7=.A.W#FON4QNTQ?>U0VP'<0-PN,HGKA,8=$5T,]/3Z@;YI1-_*S5R-.J3Q+5.Z-.L> MZ$Z=B5M'-7Z+K,9V" \;YKE#9=Z(U3E-;IW3Q [@P/H%VR$R8>N,)F^2T<0. MWP;B=I%)?'"C>U8^/U\]SNW^EX[SK=S,U:CSF=PRG\F9^=RM,W'K?"9OD<^D MX3:Y(9\[929TG<_DUOE,[.CU+5I;T_/\$ZQU/),WB6=B)Z\-;&ML8/?@P9U^ M:OJ9\E6<"93 4E5Y=X'JFA8:: 1<"]3W2\;DZXY^ M/%@]#I[\#U!+ P04 " !UA)%6G-NL=IP$ !+$0 & 'AL+W=OPHY&>U94RCER(O MU>UDJ_7NQO/4:LL*JJ[%CI7PSUK(@FIXE!M/[22CF54J3^Y3SF=CKG)?L42*U+PHJO]RS7!QO)WAR>O'$-UMM7GCSV8YNV#/3'W>/$IZ\ MQDK&"U8J+DHDV?IV&5>60GPV#^^RVXEO$+&%R8 N6Y\82X/BW-CIIUC2*Y_J*;SF11')(TT6#,W-C96&[SAI4GCLY;P+P<]/5^(4HF< M9U2S##UKN$".M$)BC3[LF*0FU@I=H8_/#^C-]S_./ V+&E5O52]P7RU !A; M!+T7I=XJ]'.9L>S2@ =H&\CD!/F>C%I\8*MK%."WB/B$. MOET=C\ )F@@& MUEXP8.]=N1(%:V.'_KY;*BVA/O]Q1:LR%KJ-F4U[HW9TQ6XGL"L5DPOI*Q"[_#QN]PS/K\B1U8N6P&24$RY$$Y[2P=! MDD[]+L2^'"%)&,=3-\BD 9F,@OS=Q&\M18%$TYU<,)/>\E MHS7E$AUHOF=F+V9,\@,U?(UR3I<\Y_J+DTG\?C9PZ)MTQ)V\.41#Z!T#6<-G M=(C'=RBU@=HLDT"8:: M$&[)$(^SH>V72P;'?79J1IJ^N%L[[E/>%4[":9@$/< .4:#N\+SJ+Q&W#(G' M*?)1B@.W0P* _CKF46/?5+*U1__?T*7#+>WB<=[] V:U'-+D=&_:.R(-IL0A M.IZ2EG/Q..G>4\57B)89RGB^-X-";H\Q4/]J2Z6[^BN3Z3D<_QH'7=1.L:$S M(&[9%X_3[R<[O@%2>H!C G 2E%$!-67Q(AAGE09_H,/?.,&_*B>_EK7+8:DE M93).RKWLN3PF?3K%04K\.,*XDS*':)0F01SW#J#>V5A:,+FQT[J"5.Q+78U[ MS=OFB\"=G8,[[^_QS:*:ZULSU6>&]U1N. RH.5N#2?]Z"O4OJ\F]>M!B9X?? MI= P2MO;+:-P(#$"\/]:"'UZ, LTWT_F_P%02P,$% @ =8215K'PN>>E M"@ J&8 !@ !X;"]W;W)K [ MMMNL_/Z9;8J7JQF9O?[B:_[P6#>_F%]?[K,'=LOJW_9?2OYJ?J2L\RW;57FQ M,TIV?S7[1#ZFEMLT:"/^G;.7ZN1GH]F4NZ+XUKQ(UE+XQ=UG%EL7F/_FZ?KR:^3-CS>ZSITW] MM7B)6;=!3L-;%9NJ_=]X.<1ZWLQ8/55UL>T:\QYL\]WA>_9'MR-.&KCF2 /: M-:!" X^,-+"Z!M:Y#>RN@7UN Z=KX @-*!UIX'8-7*$!/[KJ!E[7P!,;6",- M_*Z!+W9I[#@LN@8+H0$9RT#,UR-GM@HZ'/)6+T%69]>79?%BE$T\YS4_M*)K MVW.9Y+MF?-S6)?]KSMO5U\MB5Q6;?)W5;&W?H&,E]UJ3X?4M&15%^X\EE9MGF*U3?C MO[^R[1TK_V?<.W MY5W^;-Y(GW=9;+>\S/T09AOC2Y:O+_*=LMRGS?%N*O;,7RYZS9>@TQT1._LIJ?*ATKU;/^5?"M&S:; M\\%[','T.()IR[%'.)^S3;9;,2.K^2!=?3 L\HM!36JJ!NB!Y+2DYLSY?$V= MR_GSZ;"20\@P(M!VISF??ZSVV8I=S?@)NV+E,YM=&RI!@SB18J-LQQIV^D8. MLOR%:_G4&P;&4H5XP)Y!C+%*04RC&>*QR72-$C?O!DE?%;M?-:U_R^M'8E\4VKZJB_&[LBII5*LEI4YX_RI<@3@#BA"!.9$OU MP?.%FG1CRX.$DH4XWF)0EQ(0)U5UF[H+JJY[SE&ESONJ]+5BJM2J33UQ+"^1 ML )"Y&PR)'+O._ZO(0+*D8FC9&P! E+0;#!V'"/8\/5CHW!;)QK_HE/5>^+ MTEAEU:-*[EK:A.(,X@0@3@CB1*Y-4/=T M+C@0H'<4H'>. "N5 '5U5TN=6G>1L )"Y&PR)/KKME^"0)%)HV1L 0)2^7= MP:]M'-^RU8KVCXKVM8J^[>85)UIN;Z2T-XCY%*2=4AC[['M[:R';K8ULM2J; MV'Q7,]ZT5NE=FW-"X05Q A G!'$B7[ZF]VQ7$+8O5UY"'&K;0ND%=2H!<5)Y MXWB_O<58[5T']>A^^+GC,8;;2-%;Z&=JD$\HT"A2@0"$*%'4@ MH9H)^NZ"3H_\A105H_J4H$ I #04](DM1]Y9T+IBKD\^M9I#:0&4%G:T@?)$ MSR-2!)'#EZAC9-]B*"V!TE(4;2C_WM,B>E/K]4;&Y4&A>.YWBN6+=!G4I0H%39<8^.33-ZRXWH M/;>S9:DMODC#: FE!5!:"*5%1/8*N63Y/RK*%NH50FD)E):B:,/AT/N%1&\8 M+D^F&\?AD%4GXZ"9JK1#HW5BFN5\K#1*MFF7&^VSLOZN'"$HTQ %"E"@$ 6* MB&P<4KF RQ:<;]OBC908U:D$!4J5'7<78P6\]PZ)WCQ$*%9;VZ$&(I060&DA ME!81V404[]YVBH:ZB%!: J6E*-IPI/1.(CG+2AR.E/U3V9CO]>%:I\ M]V!D#R5K!X]Z3*!<1A0H0(%"%"@BLAW']2]J7[8:%_+RK1C5J00%2I4=/]V^ MH49[LY&=$#O79 MFY5$[U:.+%LG2KTN%&='8=&R(D9;8M+GXGLF]FFZUI$ M7"@:*R)5J]=588YKVY9-7%$!:J)G6W1$ K0W[:C>M/O!"G:E%*CL)*F6L"O" MY#7LBB!Y$;LBR+.$I8V1*H@?1]]SQ2MR_2Z9>OZ#TA(H+471AN+J#32J-]#> M93&[/N>$$R<*%*! (0H4=:#!HS:V(PX#V7&S>0$2QE6,ZE2" J7*CGL+:Z06 M]H87U1M>[[JJ79][ZE4-E!9 :2&4%E'91N)25ES50-/&4%H"I:4HVG"8] 8< M/<^ .W>!NQXWI6"#0 $*%*) 40<:6L&RQ!7NFVU*<3&J6PD*E"I[3D>7NM/> M_J+GV5]3%[OKL9/+,9(60&DAE!91V10BCG+).S1O#*4E4%J*H@V'0.^G4;V? M]CZKX_5)IU1M$"A @4(4*.I PWLBOC3/EGTUA]@V$1\=174K08%2Q?8YQ!NO MVKVQ1?7&UOLND]MF9>GWQR94?2 JKP:;A8Q%O9R)R1(F>C3U7%1N:-H;0$ M2DM1M.$ Z#TUJO?4WK1J7L^>4KI!H %"E&@B"J,2%MZJRF%7>I[GO@,*C1M M#*4E4%J*H@V'0^],6GIG4K MQD.! A0H1($B%.C&D@U+:IH+2WA"*OZ9A)KJ+&>]4*5- =LY5/3)>V7^S(-[ M_ JQR9*O1J8<*/,0!0I0H! %BBS9/'1=Z6:&I;#@FMM8TNT,5+\2%"A5=]T= M?;<6J[XML7RS'B2F!]CZ;4492=I]HP8HGO)GVC"+/I@BQ, M7WRF4Q&I6@JL"O,<0A;$M\2SMR+4HL0W+;(8J86]*6?I3;D?+ 56:T%E&2G> MS5H.4[R=M1PDGIM"18R\$EC5J>8X>HX8>J/?)9,+#-3(@M)2%.T@KOG)IUTT MG^'R:U8^Y+O*V+![CC<_>%RAY>%C40XOZF+??@#&75'7Q;;]\9%E:U8V ?SO M]T51O[YH/E/C^.$TU_\'4$L#!!0 ( '6$D58B:W%N*@< $D? 8 M>&PO=V]R:W-H965T&ULK5G;3U;7-EG]W)Q)7:ZXC6[ETCM-ALJ7VY9)9ZO9WAV>/"!/ZVU>3!?7&WI M$WM@^N/V7L*W>>>EY!M6*RYJ)-GJ>G:#+Y=A8@98BS\X>U9'GY&A\BC$)_/E M?7D]"PPB5K%"&Q<4_NS9DE65\00X_FZ=SKHYS<#CSP?O[RQY(/-(%5N*ZD]> MZO7U+)NADJWHKM(?Q/,OK"44&W^%J)3]'STWMBF9H6*GM-BT@P'!AM?-7_JY M#<31 )Q,#"#M '(Z()H8$+8#0DNT069IW5%-%U=2/"-IK,&;^6!C8T<#&UZ; M-#YH";]R&*<72U$K4?&2:E:B!PU_($=:(;%"2ZK6Z!WD6:$+]/'A#KWY]ONK MN89)S=!YT4YPVTQ )B; !/TJ:KU6Z*>Z9.70P1S0=I#) ?(M\7J\8\5;%.(? M$ D(<0!:?OUP[($3=A$,K;]PPM_O6R:IYO53LR2YYDQ=NN+4N(G<;LQVO51; M6K#K&>Q'Q>2>S1;??8.3X$<7QU=R-F <=8PCG_?%;U!=*J&4BV0S,K8C30G9 M+RYP%J51%L97\_TQ X=EB(,HRZ/.<( N[M#%WGS%6=L[!6N>UTA\;0;CU\S@*SD;Q"CI8I1X,WC'P&G!:5-)ZQ+1C9": M_],\8)]!)!1S1:!QFQPE+8F2').3W+K,LB@G[LRF'>K4B_J6EE"A'[4/8#J: M.8^B$W3>6=R11YZ@9QW\S O_08OBTX71G!(58F,HV'B[:&0C&E$]\ MYQ/).R*YE\@[RB7:TVK'C$P E0VW^PVI-86)$%=J!QR?N5[;?+D(YB.":9)G M)_P<1D&>!NY5A(->\H(S\+._=UR_'$!#8X1,J'C!G/6M=7V,"8<8YZ/<. SS MF,13X(_T&GO!WQSO5(!?"\U0R54A=I !LY>%Y$^\IE5#J?O-R0:/V> @P?B4 MC,,NBG">3+ A/1OB9;-GP4,7I(Z\@14X"Q $L($D< M):<4QI87$0[B=()"+__8J[6+GZF1$%,UC83LN%K;O6!)N-=^ZW )4S(L?*U MF!V&A.!DHH[B7L!QY-7()NS*Q)TJQ4 IS<(Y1'I*_K"W+3A7_U[+VS $?9> MO0*[N"GLKE"F06"PUAXKIY[XO7Q5C6WIQHY<3N2QEW'LU_%[R;:4EP=!;-(H M])I).#M(:=9ADU\GM;%*7Z1I/"ID8S,29I.%K!=S[%?S+@%;^F*BW_0A12%- M&3Y:BD[H8YDG21[FH[HUMKN(2#0I(;V48[^6W[0X>:T9Y-V]S<W:779"2:*)E)[TD$[\D MFR/%%WMR%W(REMF+),VR\+27/+QP?B5?9S MZ^=K>1NR[I6;^)7[7HJ"L5*AE10;!"7'MAL0"';H2KJ=[8S%6(ZCQ-'B.NQR M8S:Q@TDOV\0OVQ^@8SQ MN^R2?!)_+^'$?P@?QO\X]J8A!TK*'#=L4=W5W*T [13#[HDX2#CL2#*=A%Z$ MB5^$NVV_E6+/2XC\XPM:.?:3$_U84>,\=* ?VT'?E^-)^+W\$K_\&OB\+B2# M,QUZ4[+FT_>F?AE63M .T&9P0:A-B M6"\OC$HGU+%X9A#@T\;:889#6$432'N))7Z);9 RT]!X,(ZE0P! M]NI*5>"1U\U5.PBO6Q.\"GZV)KR2 MM^%%:*_BH5_%[8VQ;4C-,=K7&_D=G=%6OX*C(=E>]D/_0?R4+)1=AC3]["Y6 M?F?G$/[_CH:$>\4/B7>]_R;J"TOZ?;V'M-H"#;NS;W]NOG#_[6THSKX ?R5O MPV <7?K[VX>E@"!(=70)XS[('#:!O70^$F9G@,:]0HS3L: Y[*(\3*/,7='" MOJ<(_3W%D!0<+MOC0]-*? V#<:- 8D=7Y[ +S;\) GT_$?K[B=\/5U_VFKB[ M%0/(A:6FNGD M]WQ. 4I&+VY( *?OTXNT^=%+2>BMG^R[6H5L1IJ7?=W3[GWPC7T+>O+\%E\N MF[>ZO9OF)?.O5$*Z%:K8"EP&;U, )9OWMLT7+;;VU>>CT%IL[,Q&-OAJ5R=N:Y4L M^:%-=3(=C\].-E+71\^?\K4/]OE3TS:5KM4'*UR[V4A[^T)59O?L:'(4+WS4 MJW5#%TZ>/]W*E;I2S>?M!XMO)QV54F]4[;2IA57+9T<7D\%WS1:N>2 MSX(D61AS35_>E,^.QL20JE31$ 6)/S?J4E45$0(;7P/-HVY+>C#]'*F_9MDA MRT(Z=6FJ?^BR63\[>G@D2K64;=5\-+M?5)#GE.@5IG+\K]B%M>,C4;2N,9OP M,#C8Z-K_E=^"'G[F@6EX8,I\^XV8RY>RD<^?6K,3EE:#&GU@4?EI,*=K,LI5 M8W%7X[GF^7O9M%8)LQ0O6H=[S@E9E^+*VXBN7^E5K9>ZD'4C+HK"M'6CZY7X M8"I=:.6>GC1@@XB=%&'+%W[+Z0^VG$S%.U,W:R=>U:4JAP1.P'\GQ#0*\6)Z M)\67JAB)V207T_%T>@>]6:>4&=.;_8#>KW8E:_V[)+_)Q:6I'80MI7# M54[5C;\ %;W6M:P++2MQA8L*/MLX\;\7"]=8>-T_#ZG(,S _S !%XF.WE85Z M=K2EO>R-.GK^ES]-SL9/[A!OWHDWOXOZ_XW-[]SRL$#O3:.RB3@6_S%#Y$FF M-C)-#<>X'V\*8T6S5N(O?WHXG8Z?7)K-5M:W_&WRY('0 MM*O0-99*2A5BH<%@L:Y-95:WHO#+04$V8BT=8O\&.6VK2B%IZ3%G&FMJ761R MN[5&%FO1&&2NE:K!%)/5A.7\=Q\QVM-8M^!'+$QYR_R*Q 23\R=.U*8^UO6-=$'] M7J6Z^(XW"7/06"UV(GF.S&M$ZX6X>(IC7&ELHZ<3^ZS_NKX#K]S0>]7:-,66' MZT8[+F,P(W%K9>VHH+)2EEI5)2DT.H=8=!8D53NY!&\[):U<5/CTTTIB3RU5 MA74V:PZH^Y7WV(+#!0\BPYS/G\0_"6G=W(I?Z^QO<";RE.F44NUDGHM?)&15 M%H%HFR6"T2 ZO[;::;) %X!W!)U5A0)_I=A9W32JAO/7CO,G7*;2JB7%2(BF M&N]V&+)JZY,X4<56 MZEM!:0?+3L=_CL\VIH%68+J6@AS. 52#$*U+/)3=&'YV:W:0_P6LX3(\-B@- MOE9HE(9M%7E(:PF%;-%=P1[+KI"XOI $9F)L@US5EHJO29\*>N0< M;,(6M#L";JV1P&F)VFPK;. R2\GO]Z[L@["*1*KH$'4($@#_6*[*0^J'9O M2TII%'H[C5HF^S*][6/ U\*J8C]1V^ ').;G6M,W1E#,X,4&VB@D0A49!6&5 MH7:@/-*&E$0W\AKNU'%*5F!+;[VS4L) M7\B559Z5O"/,ULA"9D#RTP&R1)^[S3NW[)83+^A7E+4L/00"H_);<..1>->K MMR4?T11. O&LI3(U"ARGN?KVNPJ5:X4UWNLZ_P8TL PP75=8B!D#: 0IN/0 M,3D*@HK0"$QD?1[_[HE+Z=89%V5\$.0&$(9MDH(=LJ#F @"_ L>K-;RKTEA- M8MZ GK>C]TJHP>H5[%R!4<"BKE1 R6+C^Q*8J")AX&4+]=WFHP3OZQI@JF7Z M&7O<%J:#T[.'NW;Q&[E?RY2D3RV$+J(U"EA"-\)J=^VE< U?I@T/B>TU0B"B MA!<[CA>6:D=;[RCQH63>(&DBTP9%^#U4F8NOT#Y)2SSKAF%?2!8]-=YQ(V^Y M'N+[:U52N(J7?@72OVN1T@N5UHT.$KU^^>:RA].T%#F*$CZQ?M& 2J$V"Y@[ M]FHL)3Y,\D%R+HTB+-AP91=L8Y8[+=.TE_"T/:SMGJ$*T#TST%[H'%SVD5$' M1U?J2>SVG,JWJJ#B)N!7L":5.19THYJU\3'LPR'F:,#]&\T(C^Z5IETTR[;J M:F&L)CMDXWMB+-Y@/VW);2B&WYIZ=5PQ"KKP)25ER@+-J9T/QZI?&8H/;:<[ M:M@&^94 &?YA7& !=F6]\B6HB])"6Y0$@C(%WR'PO<#<(TJ>C\-_O.?X'[X6C-[3& ('R>=E.UZU%>W'Z#1H-:,?9+ M+*>!4LD-7[>\,,@"08DK2_"* 8!?&7JQ7KJ(#N4.S4[HQ8)DY#*$;-0W(J[R MK%9L2;C,4FGN"(-;DCFZQ\BUB"32(G"#S04#?*XDI%X"X5T%"X E9P"UW:(] M]2U*Q-X,M3UKY'JLT8RF(C0K.Z8A00BI$0%+%*3LD_RF]OT_U!TN5L- 8\D1 MH 7;'5:P0W$UU:Q:X,1G1;]6'QP'9V[3U\A"0XI^_J8-4)R2#Z"ITC$]C;4 M4G]CH9H=H6#?8,9RY?5 C Z #5R*[<'9A/&/(P@=H*ZD!,"A/38I4,1H99Q MYCC& V3T$2+FYV0/<9&J%[X'61JD&%7+(EK7,LZB+$-#%AJ&4//_C=-/X(;* MA,=]48T^AG'=&Z3AN4K*D>U5'8J^A_H4<>3L30.T,TPDP2TSF0 L2;"=JR// M?M3SQWD-2G3+C8A@8%E;Y6%0^9:LY30VZ&4Q[&]J5A$'UQ=2D^F2U* MUOE\W#4OE;0H7J&H)8"<%--2G]-(]&X$"1)3*I>ZHJ8V%B9 AX<4[50WUSC< M>PSXH![,%58OR,J1*&N*X)8+U;V,UN?\*YLPG>JL=V"CE%:V3X'' )PKC N[ MH54@W+=O9'^=)/2^I1!DM7=Y]+_&IX22NA9@2;8KB"&P$T$H "F,4':7R#1Y M!IT[UR.&D+ 7LN+G>5"?^X99.9\]D)UE%8*M-Q&;!*OT)B19W"ZU*Q!]E FZ MYEK[UGFOY\M*A6?1]9*LL22SKQ!3?1&D;!@[H3VQB%*?V+S')'Z12AUZ#;\- M,>?+>[H^&ZSGM3MJ *"+9>)N>=JR[8^K?%13FQ,SP4B\5TWVEDHVE"2NJ-/B M64S!Q:Z*-[@%XS0NJR)TPH."VJV.[L<)!5Y2^*$1$XASIE*35Y0TIJ-G=WSR M0W63'5A^ %AVCS\B4P6D<"P&]J*%.A5D:,BK! M 4?5A4HQ=O1R<8'U1D!Q !.-)NZ=*JB]@6.-LI=$& \,M)+*YGOGD"D\%1<= M 5U5QUA/-$G5>GD<-E9EQ,A=/QYHJF_*%IKF"[8'$I"./.80^1SM$T$3URL@ MY=?WTVPE7VM3R4NU:'I]!51$4V^.?48E6<]]8SEYW :X$O@G)-WQ]7W>G>7C MR32?3\9B>A;^YN/Q6)Q.9OGYK/\[G>937+[@X>#/]C^TP0U2-XM'?CZ0SD\' M?%Z6JY55*UK1(_5[XCP?SQ[E#V=3<9;/YV!L=BHF^>ST-)]-QOET/A-GLVE^ M_O!1/AF?B=< D]F7"";[WO9-W]LF9RY9F@L3')ID8!?/&4*RHG9U28U'LCXG MK [Y-#(B%8>EE1M%![@<()Y8-- 0[?H:FNVC"&]/B;8706B+]6V8W(=#C\! MF"4-N /V; :E$KDIV5*[T.$1WNT3ER_+?GB=(5$XA3 ABS JA SH*,I^V$]M M3I).O?7XT, ?Z,0I:0?<-M)>@]!66@]OPY2-6 FW$CRC>F2740%.$@.@>@!O98D$S<5^9>+IR7-&91C*^ MZDW%37-?W*A)&1A NC 3=8_%6Z*231[[;OUK:SCI!&U97838\(7"7P]M,O?R M-,H*,(S&/+T'C0+E::!L%M3D< AZ*J%9TS4: 7ZXK9,UX;(?.UJ*6&O-@B8D MOE($#M'+R;C3+.QT)QVJTW?2(J-^WP_NF[DSV4'#\D2I PQ=9?RW&,N&C$4, M&B(.GL%"BYD8(B1 1O&BDL7U\17JJXKI/D'5&U/B.1J=\'$D0JKC=2\]C XV MC@FOX-0<'O.S7.V9):2W.IT>V"DG T/5W>%/ MFNF8D_3XY9"9[@=M/^ *>E?I>2RNBC5ZE8I'_R^2C=\FF[Z+#1JT0@5#<,'( MDMKQ;E #@W[/E.*SO[.$9M]Z$(U.=O/TL]O8KQFOW;B99\36;/[(1<\".)F MT^X3!/]$IW?9R\[Z66_]>^(X_#\Y1UU\E(_/YH,O&3_\$^O^#05,_E\J8,8( M8?KH//W\G?@'5]WMPC%6_G,/'K;QPU%G\QF M^>SAF7AP:'&"PN^?/CS-'YZ>8Z$7**,AQX%AI[@_G^1C7O@C)B<#0Q_8]]4^ MD^-'^?GYHS_>>S+/Q].S_'1^]L/-I\-0.J3=_RI61@=/KUX8>^MAFK)/*%L59P[>9%#'?0#TF07%F\X4(A3 MZ^Q'IXU)+QAJ>7%G,>^7]^DC.;P=AO"7:*&7:@&'Y(9BN,N7COQ%3R1[;6SV M/YPR7OG6.W6IC%V*W"E[%8>L!"K$6$SPWQQ70[_J@?\],1Z-QW1*/IZ<^F]T M=CZ>]8_?F I,L#HFIS,Q.7L$5S_''F?]&C\ZH->FWAO %_HG^ZC=]?$2 #GK MQD+LQY/1V4S,1^D4S=[+ZCP'DX/?MN/4[MPXE ]/,#F_W6EBNZ M !#H)X04*#P2HO>! M;U(4EE5+Y]9>L6'/Q-+Q32$KF;G 3:Q8=S-R*'TD9NKU7<2&D[Y:?[@T3B?6K@?'!H=SCLPOV3@'L\*PJ@JFM4;H-MVT*CUG:'+Z#TU?P;K M#Z!(L]TU/V[V:>9:>4[ARKTX?\QH:,SW->BG.!RU(=MG6!G/XJE3/VQ=?Z#A MSY#]2"DDQL::JG^=HG<58J[W!"^*]V!26CB" -TX<\L\PU8M:=#_DPP-WU/R M8VM'HU7L>E#\ ]DR3^8$27',8CWA!MN90LOX0D$>6M@XTT-@FT%EZP8=OB14H5'1H)>!P 2EXLOJ)Q+1U;?MZ6W8M0*>10OJ21IU=5 MK.I\?I&^]F1J0ZDQ&8I]/Y;OY^4_?M2/G4@K]'9#)KM$D+C9P6QR\(SFT"OD M)\E/"#;*KOB'$IQYZL;_FJ"[VOT6X\+_!*%?[G_(\4[:%8V0*K7$H^/1^>F1 ML/['$?Y+8[;\@X2%:1JSX8]K)1%QM #WEP90+7RA#;I?J#S_%U!+ P04 M" !UA)%6:-4VWSL) !I%@ & 'AL+W=OO[9DC)E\22R2',X\S;QYUO;'NBU\K%<2WRM3^9K0.H;F:3GV^ M5I7T$]NH&B.E=94,>'2KJ6^WU_SNP=U>VS887:L' M)WQ;5=)MWREC-S>CV:A[\5&OUH%>3&^O&[E2CRK\LWEP>)KV5@I=J=IK6PNG MRIO1W>SJW1G-YPG_TFKC![\%1;*T]@L]_%SO7>FL^Z".N;T9N1*%0I6Q,^VLW?5(KGG.SE MUGC^*S9Q[MGE2.2M#[9*B^%!I>OX7WY+. P6O#D]LF">%LS9[[@1>WDO@[R] M=G8C',V&-?K!H?)J.*=K.I3'X#"JL2[G%V-Q$&8OGBV?D $'AH"'9BL:(VN! M[50=E-/U2N@Z6)'OK\[[U6$M Z;DIBV46*E:.6DPN\)@KO$31BHO9%V0B8(C M\6-1VZ!+G1KJYT"MR V$)MHG,X5&06O>87I?JV;AGS96=.UJ*P/(J<9 M<847M#BL%1YMT9*S-).PY5%V=:.$+4OE)N(?+792CIFTQGYV:?2*/?*9=$HH M'R1>H9@+L5DK4%8?-DAS66FR+YK6Y6OX(*PK,+ 7V(]PA$Q.Z %ZZW!Z+04C/*PIE M0+0..Y;\3&@C- 254")7TI:$JFSP'GC*H,375F*/H)5G5Y '9,'8%)]O5(YH M%9\&C73X_/#=F_GL\JWOTX;BFM+)[J'%<:2< 20N)OOOY&-,W+:QT;#'AKZ4 MW#JR& B,Y, 6.2KC\?!>8.P4YX'HL+-8*DR%3[5'$CC5!]4?+>7(6N=K$=#M MQ@1_+*Y:M'6?PM)DCAH,K8;;"@B+1FXIA6-B>6E4.DW\ZO*3TJK46#WF(=NZ MX0AR1TCD9DZ'L]QR0$@=V!2$1T@9G-O6 /$*Y!$R]NCI&%\VZ3<[ ^B(#1X"V"QARKF*&CI MJ3:#S88 Q]#Q!A''J$79.GH^ELD(QVZE"=NI07 0("""+D/@AS3>/G/9UMC= M@K@X,>,Y(D78C[;FPL7.*8")^+G.@'6=E D3'',$;7282O#V"0789X_"8(M1 M.K:PUJXX::0+6Y1X75CG.8W@,LFB6(,FA@8/D)%A0TG9HN!I,*[I8=K9QEZ, MJ*=@&+ .!;_FG%B2Y<8ZRA^26&+E+&8C!6KH2:@E[2E8MN(HM8X8ROZ$(0X) MJ'E-M-?98;(*1#V24K'.=8,>D-AAF*>I(7#!TMA+]LL0,^-;MJ;4)DX[G"$_ M^I\H)IL3:17Q )]M.!'W+9TG([Q5$IU+D3@2D#:J6L+U3MZP$_@Q2X?6YU6' M$0KI>S%;G(\7Y^?BG9ZCJD!L\!EC7=/MNG+B:6))VKNT!LI[D,)>%-K+ MU5]S6:F2@.B+;\Q9 !7^?X')-!YA(@B[ M&#?, S[AXJ_$(RXZ16L48?FXFY]@S=@J6.,PIW-%N.+^4*<9)\L\,L.A+++BN^[O/A$ MQ7Z4O ;)A1)AMR$%<8'!"X8\-=@\&V0R2OA7VRNM!CD#FN-FY#LPO5[5.VY" M>@6GEVVP:+CLT,OM-]09I8_E3HOJEL\1T:'%0G(EA5=D+VL9#GV6#L_@.[2^ MK'.BYH[W+#1)/G"90T26";2\1PV M5SID&@'68=4I.%A.VW7JU"N0,LF:HWWF$<"QC3ID?V^+%4O2CK[NFL9TRBYI MC+^VNF KF))4-R'L5)8ZF]\9%+_U!@]QU5#A=+WZJ)][LBFN/*H#,Q91SU5@ M!^\S]4,)@I:J_0N4>Q5 FC9V^Z%JLLL@=>V/B# _R1Z.J53*6.K@@X!4@'PH MH#YU_@7/L@PJZ?I]L1UU,9D<1T&!':( >9(F,G5;1WB(?@< 97LNA+[/8H6L MMZGY59-UI^.K4-\$GB7=+LVN+,5< 6'^5X#O,83-6VE3F*1+VW=\L6* MJ@1G5.%V ?E*5 %U"7.<8I@BD W@#=*%B"-^=&)GC"7U0(E!Y0M%B];ADS)' M?3=1Q,9CH*Z%*X5RP Z&\M90$:8+18\>LXY2_4M %)'3A/8KR*!L6Z2CK-AS M2J@.C"(*$9!'&Z%FM3ZX$\?",YPIO=!+Y1Y/WN_G.PNW@1;0?D]Y$IL5O[5\ MN])U5K8XA9TE. .-"?TFW78B'NA>1,!F'P!7H9D9B#_3/2+==7<"ON!F1C$, M&!UGV.E#_.R[NXCTE].,J'7;)7(0+,P9;$A$@FICI%#+)]3% :M)G^>RE/=, MQR76Q'M_!TWG.I\TNTXP%8I^W'T&I.XWW#13<2AKTG3P><_4..* M/W(2,R(]XY? _FW_'?4N?C[<38\?87^1;D6L:E2)I:>3R_-1;/7=0[ -?TQ< MV@ >YI]K)5$9- 'CI;6A>Z -^J_+MW\ 4$L#!!0 ( '6$D5;U:GFU8P, M *X' 8 >&PO=V]R:W-H965T&UL?57;CMLV$'W75PR4 M($_"ZFJON[$->"]) S3!8C=M411]H*6Q180B%9**=OOU'5*RZD76?I%XF3ES MSI S7/9*?S,UHH6G1DBS"FMKVZLX-F6-#3,7JD5).SNE&V9IJO>Q:36RRCLU M(LZ29!XWC,MPO?1K]WJ]5)T57.*]!M,U#=//URA4OPK3\+#PP/>U=0OQ>MFR M/3ZB_;V]US2+)Y2*-R@-5Q(T[E;A)KVZ+IR]-_B#8V^.QN"4;)7ZYB:?JE68 M.$(HL+0.@='O!]Z@$ Z(:'P?,<,II',\'A_0/WCMI&7+#-XH\2>O;+T*%R%4 MN&.=L ^J_Q5'/3.'5RIA_!?ZP7:6AU!VQJIF="8 ?#GSV->3AR6"0G'++1 M(?.\AT">Y2VS;+W4J@?MK G-#;Q4[TWDN'2'\F@U[7+RL^M[9E%:LXPM@;FE MN!P=KP?'[(1CFL%G)6UMX$Y66+T$B(G%1"4[4+G.SB+>8GD!>1I!EF39&;Q\ MDI9[O/P$WD>EJIX+ 4Q6\$E:)O=\*Q VQJ U<,M-*93I-,+?FZVQFB[(/Z_E M88A2O![%%'ZW9MTGKP_HZ&8-!3GT,\=SUG'UVE]41:# M'-Z]661I^AY&<,I-0+G'9HN:1M CE;Z%-,KFLZ@H"C_^)CS9FN$9V3: +H".J.7SH,YVO-B[F!]@M%8WGB6N\ZZ._R"["&. MQD&)55/>"8F2]E.PR!^4@>'@S,L4WTW!/@S!CD7!W1 L^,N)">Y^%D/6G;3N M)/))11+XNS)/%]$L+X*ORC+Q(H=.Y(UJ6B:?J7H=A8E7K._)66>KO?EC3@XK:&=#^3E&ACA,78'JBU_\! M4$L#!!0 ( '6$D5;@$T.B? < -<3 9 >&PO=V]R:W-H965T+N+%E!BO5I.-PF0)BVNA^MMD/3V/ASN M RW1-E%)]))4W-ROOV=(2782)^T6AP."F)(X,\_,/#,S%L*RKTW= MFK/)VMK-V^G4E&O1<'.L-J+%DZ72#;>XU*NIV6C!*R?4U-,DBF;3ALMV+)3Z0AI_RLJNSR;S":O$DG>U MO5';OXC>GYSTE:HV[C_;^KU),6%E9ZQJ>F$@:&3K?_G7/@Y[ O/H&8&D%T@< M;F_(H;SBEI^?:K5EFG9#&RV3,M>_)T73YX1CQ/V2;5V;=C[MA+50P538!D!)0.@=\F+&J]$>0L2/V0#F[,(%:,H1: M- NAQW SWE9/[N*_70O6/E#@BDG:>[;EAN%OJ6J4MWG+;M$UJJX6I-_;O/8B M@3- ^H*GUO<>.J%@M&/90JQDV\IVQ2"T$5JJBKUB19CDL_ DC;">A?,T#^.3 MV2-A:4PG*I;-\C"*(G:21_0;H-'86J"Q6.!HG6.C7Z_C61K.DQE[@V5]%Z#"FR2X&WE!%3*_ =+('%%&8SPM2 M7>3AW.%Q;.@5AZQ%RZ= QGD:)EGNU_,XC*'P8""!FTX!I$R+FI,G&Z[!@5/98NPBB#V1Y"E"-=R.OGM0C0=3M--*LXQ1S9VE&1 MHYB?8]ZG0>[*RSWFXN>MJ.^@WKU\[VDG*0T^<%=.2_ M+;[L+U6SX>W]D$$C[D0+ M1KUA2[+!R ;;:-7@N=+WO05+CA'25V/Q#;]QSN(YY=:(%U7(MJR["AG&HZ'Z MV%)07EU-N/N-[!I*;IS_[%H7Q\GX1;"54DB@5G>21H>0;=>R7+-5QS5OK2!\ M<&RMZ@K>\JJ2-!X@$68-2L'RG5)XE'VM/U^ZFZ M:[0(0CISC@^-%CKG_AA@E]B#H378"_(+U'M")]R4.$8>D D1>4"/@:+=1O6G MA!:5:#9N'EWIX[2RB0'/EZ6MJ.%'>] MBOV8^EZPSQ7NVN*!4$I#91O.HL(UHA_J%L8=L3BU6K&#XPY:3UM$!E&6&Y#) M<[4_=;,\S(H_W?#B[P09'VQI;FYGK^??W=+Z.6+\I9:&ON_96LS[/C?>B>G_ ML/&'@/+&;Z-[5NC&9$! SOOUH$II-F[6RQ?(ZF5?Q8O/;9]UR(%C[_E-$XS'$@QWGB,IG, M][O.GS.\WWG\/%#S?_-Q;\L#E8\&/W;]BO M^\[YL0U^*ZVB@"11G(;LKUU]3\LL9'L/,C<]7'0KO&_3=?ZH4;0X^1PF#FYI MZ2=*E,F=:Q4UWKD\:>$!>CUY\XKE?='WIQ@@SI(, -,GKH^-!9'!T)ZA2"Y* MG,3&G;=!/[.2+R! VW_-<,S8 _G+3_,D+GX%I7:BA/+C]0W%$$ZA1=/%6+>< M ICG/4@BI18!O[]<"O?1)OB(N0TS@64W%/%'M6F>/Y,HK4_,CJ$2@WY$J-?O&B8% 4,J*'7H MK7ZZ][$%?%VY3THT9X.6_KO+>'?\:G7A/];LMOM/7I^XQKNM8;580C0Z+O() MT_XSDK^P:N,^W2R4M:IQR[7@H YXO%;C47Y"!\5O>^7\!4$L#!!0 ( M '6$D58,9_:,APH !8@ 9 >&PO=V]R:W-H965T%OM 6[0M5)8\).4D M^^OW.R0E2XZ=2_.V*)+(]+GQ7+YS2/7TMI _U5((S>Y66:[..DNMU^].3M1L M*59<=8NUR/'-O) KKO%1+D[46@J>&*95=A(%P>!DQ=.\]8).]7"MW2QU+1PK,B4^D1>7&\W-O+B _(^_%VF^I[]>S)56B(C_K-ODU9$;[\(JI)W M:LUGXJR#,E!";D3G_(_?PD'P_A$#>[6!O<>DOS0>CPK;;^J70@NOSX[9(ZK8 M-6I#2"D2[T87LY_L7TOA71:K-<_OV9(KQDN]+&3Z7Y&POA\$ ?VP&R!&4F;" M*^9; \&R%3H;S)A(6U MML@H9F]8T V",&#'7L-H0\\N6-_2#FK"(&1A$#PDO60C0SF,1PU*6GI(>X5L M-,3]8)?V._)>I8N<:^P\]L=19 B/S;_M+AK>L9O_FGL?Q526P$4&'B@(8Y_I MI6 7!9<)@YNN4@DD*Z2B#_1-%8]&+#A@#HB9X$88=DHZ(E7BBX/U!#O-]^/ZMS]+<,E"%%#HRM-9L^.^%LDT*K84-AM-@$[L>( 0!I]#39VZ;.CZ0Y3, '4*>10;]7J[.L4&3$6J86.52)(FCS6^L3; E45%T6 M%*U)-%E:O]?FKNNH) 46\D*CWVT0&&AW8:BJ[C;52R>,-'I6HTVCSSS'2$M1 M\*I:=K&<<^RWN7V68W1-<\PCI8D:S9@U."RH$1(N F G-VA24< ^D@3;*3\+ MKDH;[6Y#)VUOEI6)4T)^USQG(B$ MM9HKV[@6'6=H8Y-?0L*H[JZA&?;J4:>J;E,%N4E]BK6MA2[[OH: ;#NP M6>7;SES)\?>W630_D9KR O05I?4^SUR9>DVT\#%KV>+ZE,.\M7;X'U ':.ZX MF,-%5KSIB@^-L:"WQABCRYQBW0"IO?W\RD)3\] DF)S;+VOK3JO8X#FH_ M@1,P0 !8@+>4\[YWNTRA YE84BHW;>1HB;_#*;J4^78^4#S#[@6V98ZP&8H2 M^ ,OPJ'W;"%YKAV2KVJ3X,,*"&W%P+=IU@@.^AC/,'^IMM)R;0[;I'(WOP^E M]\[NL2U08<;HUX-ZGW[,\T3OXV]!GH4G@^E6 M;62!604>$2)Q>^JRB?(>+66C!P&_I5^82>*@3_LA4+=E-B''(U&\Q+B$/>62 M=Z_UWO$^KUHY ^'PU=)B?V>L^TU4@:#.CU"/PX' M_OB5 G?S#<_C.'K=3AF! W*+!M7Z_!'V[)'NA2D1/CDU>Z)!J^6MNV#<>S'HI=/><3V,EQ@5%<[SV".HNEZF8&V 3!F- /T 28V9UKHQ!O8VZ9+4#JAT1%[D:%9F##<-X-CV#/0X>$?9 M.4;G*P$Z&JEWK/UQS%$(>A-&[:Y M\:;*B;C;"T@ T+II6)44SJR1T;]CTU/V1,8K*/C0ZJ,%TO:FTN?DT?%B/W\T MJ+BC;@\=I1M$].S3904EZ91GU3F%!EMWWG3Q;%Y('3A(',P85MV)NAR_;.2X M7UT83K;W9W3G*%LYQJYAFO+I@J!R&Z" #LG?Z%*AZ3O6],,V^3 *X\Q4I^4V M/ZT 6/A-T"L?DE 1N[]UI-P5+YU?#&S17+_[7?79,^:U:@/'R7EE=L-(NU(5 MCO>&]7OF]B;TA\CD7M=D8&O-?01IB,((,'L$)H>VG]RSMTW,.E==TKCU"M6J M!6^;9#5A*W7,Q[^XI!IXT T.HHI_X,18X:'I/08+;YUHS+B>>Z]6WXZ8"Z3Z MUJBB9#OSRG.@C0Y#Y@6"*>0IO?$NP9(-4DWP=+==A?@TBM$/^_(DJ=HI4W(W?6CR+67JJB M\Q0!V_<^\*3QKA9SV,*\D5889'! MZ]MZ]7ZI??$ONO=DMLWYI^Y7*1H-IF8 M@Q5%T._8>YGJ@R[6YLWOM-"Z6)G'I>#H%D2 [^=%H:L/I*#^KP#G_P-02P,$ M% @ =8215GA+[Q#9 P ^ @ !D !X;"]W;W)K&ULK59+;^,V$+[[5PRTQ9[4Z&'+=A+;0!Y;; _;-;+;]E#T0$LCBXA$ MJB0=Q_^^,Y2M:-O$6!0]V'S-?//-@QPM]MH\V@K1P7-3*[L,*N?:JRBR>86- ML!>Z144GI3:-<+0TV\BV!D7AE9HZ2N-X&C5"JF"U\'MKLUKHG:NEPK4!NVL: M80ZW6.O],DB"T\:#W%:.-Z+5HA5;_(+NUW9M:!7U*(5L4%FI%1@LE\%-]#[CWCT)V.\7-?6_\.^D\TF >0[ MZW1S5"8&C53=*)Z/<1@HS.,W%-*C0NIY=X8\RWOAQ&IA]!X,2Q,:3[RK7IO( M2<5)^>(,G4K2Z)IR?BM^E9Q'O,+V"<)@]?Y=,HVO MSY">]*0GY]#_O^R=-?.Z$[]HAZ,IO'\W3Y/D&OX3%?BL<(3/F._X;H(N2YFC M"4$K/*F_G#+FX(#>)2,81=1T(12](+17@JL0[G33"G6 2K#:UB"9=YHO*\D( M:+7Q+T(G+0WD)$_OC$<;[923->3"5E#2DP6R:8U^0GL!-Y95J/"PV1#0J?A" MSXQFM&;K&U$+E:-]P?> $8&H(]&H0?( G'61RFTXQFZ?PRG*89C.,XC.,8 MDEDW3B_#-)GUVRDI7&8Q3";A))Z>3N]W1JKMB"D<4%#D^*:]1G<8(FGMCJ32 MC($]N*T$Y7A$Y(EM0SSI#MG.ZRT75-FIO#$,]7P^S:PETEL80/ M??(^=ZFEU\U5%"] ZV3CZZ(4%*$G4>\X_Q2/+/,\1I1FX%(C-8I]YQQ\IW-O M&-?E:.B[*)XX40493>:ZEF"+1K3/UNW]9ONF[V(MY]$WP2 M9BOIF:BQ)-7X8I8%8+H^VRV<;GUOVVA'G=)/*_HT0<,"=%YJBLUQP0;ZCYW5 MWU!+ P04 " !UA)%6M\T"PI@% #8# &0 'AL+W=OLK",]TT *.+2'3MP7'212")Y#\\]]T'ZRB$:5'F9I^G%8265ZD\LX]M5-+FT3 MM#+TU0G?5)5TJQO2=G'5&_76 P]J7@8>&$XN:SFG1PJ_U5\=OH8;E$)59+RR M1CB:7?6N1^]E F1ICPP@L3CF6Y):P8" MC;\[S-YF2S;G6ZC]4$3WUPR(B_]OG<(A[O1^0J.?>US.FJAS+PY)ZI-_GP;O0Q MO3C ]WC#]_@0^G_&XZ#U?FY?;*#D5!R);6SQK:3DUE:U-"LQ4QHC:C.-:@N- M,QZY&$H12H)I(&>D%@_T3*8A\0ALE9/X\<.[LRQ++^X?'N/;Z.(G(4TAGJ53 MMO'"!QE(?&^<\H6*A>@' O6T.Y0H(Q:ERLNX.^@H,_="(E)PH\:SZ$<::\(* MP,WT.RI;!+M-G)8212(CJ)BNNNUY1C:AM$X%!4^9X(P*D;L=7 M)!WHLE0H='+@T:[WGD++C_N>7@D0J.$/YNU,&/12))H7N71N!<"%= 5PKCW/ M(L.IFI+;9'FD@Y?1KH^E+(2L:V>7"LV'L,E[,1[WTS3E/Y&=;5ZG-(=^$(*6 MM0(G?&3I.!4CS%TGCG)K0L\#>8!G6XO8 MW8;'(#$XZA7B%1>O567=FV#=JK-*8E;%6&SB-25L_383Q&DA(;+'N,;9X>,\ M;Q+#(H@[S@$US\4C3K"BT93 YT^S&<4#0&QUA & M/2Y&OXZRT2 5/ZR?R2-G7A+]Z,>, (FUZ90,S5001Z/!*9N<1HLOUAS=@3!H M3D&Z"X07HY/!1ZQJ86]+:>;$]?(L==.&5+(\TJ :3P@@55"FX7#C7N"Z0F/).3"R MLHV)GNZ!"B7$6]A&%V@O'H=F,G.V>DF? @8^J/P-@?W_RAQ'>FW#Q/*H&A<& M?^U1;K#3#TO.N\+6'/'H5YZS8\P2I$S!Y=SZDVOTN=GJ]2KFTP#6!;2'P$7P MFEYNYT;]$ZL*\B&9T5]C!^$N.CJ]0"-"'T->=D(0+D*A59H[>XZH<"-;(T5O M0HF9TNK8A"I62*LG;AR@:H2Q(9I+49'D4Y 16<.W9,MO'9>ML6N\@8 MXMKZCH%\0AX!:M,T$( I=>/LZM;Q,D IHG\^M;U#^=A6O6?H/A;F73 J7(+0 M?J$/.COZ4DD0&^$.? KL]3)&YA6SA=)<=S@V/,<$S)H:PUOG13_>[@KAK68T MV^9*H+PT*H&$\,FZ?W; _585H#+]INKR/)KNV[_=L.V<6,"^;YT^ _%K MXV"D51X/N3;E=5-P[D(!\C&&"2I*ZGB4M8D>=6[,5EKQYEV;\;OIMR[(07NH M=Y#B!3)PWP#$>Y&*?3>:X=9M$Z+,XYT:AQTG?WOQW(QNKNW7[6WU97E[Y_\L M'8XN+S3-8)H.3D]ZPK7WZ/8CV#K>7:;' MS.1?4$L#!!0 ( '6$D5;2MP)?_@( *8& 9 >&PO=V]R:W-H965T M(S[.ML0^N1"1XJI1V\Z@DJB_C MV*4E5L(-38V:W^3&5H)X:XO8U19%%I(J%2>CT5E<":FCQ2R#.UF4Y _BQ:P6!=XC?:UO+>_B'B63%6HGC0:+^3RZ M&E\NISX^!'R3N'4[:_!*UL8\^,W';!Z-/"%4F))'$/S8X J5\D!,X['#C/J2 M/G%W_8+^/FAG+6OA<&74=YE1.8\N(L@P%XVB.[/]@)V>4X^7&N7"+VS;V-,D M@K1Q9*HNF1E44K=/\=3U82?A8O1*0M(E)(%W6RBPO!8D%C-KMF!]-*/Y19 : MLIFUH2TRW5_$3]*EJT6*\XA'Q:'=8+0X.1Z?C=X> MD##M)4P/H?_[?W80;C_9SX;PZ +>P.%^?<)"J",>#D+KX$N)1QQ?"_T,TO&@ MKW_Q\ $92-$2.P0H'P^U-2EBQC!N -M2IB5(@M3PJ&<>Q[)[,$F?*+GLNG&\ M A7#DP.?#NP6J/M;\@ :(?$&I7$#7(5D3/#4(+'501#V$HJ.T*I M:30[A4\6Y!& HR3+0F JJ:G0%W--6NY7@)QB0>J,Z66-4.H9C#UBO1Y*%(7E M),*!;XHV!$H^((>PO%)L. !\)2L95V0;;@ "YKGOG&D1.CDGQQ?)^/RM@UQJ MP?WW/(R37LR #=(K"TUAQ[9!HO,LE'QL9";I>0C[[EZ\XQT5VB(XI L=H=9& M^M/>A*]:[_D3WCKXC;"%Y*(*&ULG55-;]LP#+WG5Q NT%-1?R1MLS8) MD+0;MD.'(D'7P["#8C.V4%GR)#EN__THV?52(#6&76)1XGM\%$5FUBC]; I$ M"R^ED&8>%-96UV%HT@)+9LY5A9).=DJ7S)*I\]!4&EGF0:4(DRBZ#$O&9;"8 M^;T'O9BIV@HN\4&#JG;&MVP>1$X0"DRM8V#TV>,M M"N&(2,;OCC/H0SK@X?J-_8O/G7+9,H.W2CSQS!;S8!I ACM6"[M6S5?L\KEP M?*D2QO]"T_J.+P)(:V-5V8%)0=QO(J[QCEBUF M6C6@G3>QN85/U:-)')>N*!NKZ903SBYNE4Q16LW<'9E9:(G3G81IAU^U^.0# M?)S O9*V,/!99IB])PA)3*\H>5.T2@89[S ]AW%\!DF4) -\XS[#L><;?\"W MYN;9 ),9/%*JVM)#M1P-_%QN#>6=VE_'LFXY)\QX -$W0E=[7F,A_9 M N$5F09T)04J")9;U'U1SJ!!*%@&ME%@>"[YCJ=,VNZ]HC;0%#PMJ.5254M+ M'#0]8#J!./K'&/%_QDBFD%S IJXJP8GM"4=,&$5$>P1&/#(7"$;5.D7O3RO8 M675W#L MZ80'K4W8W \P Q[9=GF_V\_(93L:_KJW _:>Z9Q3K07N"!J=7]%(TNW0:@VK M*C\HMLJ24+\L:,ZC=@YTOE/TACK#!>C_.19_ %!+ P04 " !UA)%6%/K& M=0 $ "N"0 &0 'AL+W=OVU*KKNP^D>G&1"K$WLK.U ^??.ID]VH^E97)NHG^^'%I]I_#(<:>/OL%& M$DGYS4YNDID76$*88VPL J-ABY>8YQ:(:'QO,+W6I34\_CZ@_^9BIU@BIO%2 MYE]Y8K*9=^9!@BFK+',M?N'7:T;3CR(*VUDT1@3@X*+>F1/ M31Z.#,Z"GQB$C4'H>->.',L5,VP^57('RFH3FOUPH3IK(L>%W92U4;3*R<[, MUU6D\7N%PL#5EO[UM&<(UB[VX@9B64.$/X'HAW KA+3D@H/ MI);AFX@KC+LPZ/L0!F'X!MZ@#7+@\ :_&B3\M8BT470D_GXMWAIM^#J:O2;G MNF0QSCRZ!QK5%KWYQP_]T^#B#:[#ENOP+?1?VY"W(?Z0!CO] $[@WX$_2SI& M B4:BPA5FVP?3(9P*8N2B3UPK2M,8.0'06!_, K>!7#JCQJ TX$_#MX'0N(# M2A@Z2N^"Z0?^I('I-^/DW6!#?T 8HPD%-O8#&L)@8D7O8T;QC?UP/(;_$=ZI M/Q@=]LH-=Z)SRU2<03AQ9H.79@2.BNRX(!<,(BX2+C;P!0W)0:9P0PIT?#Y] M_' 6AL'%E[L;]]6_^ QDH4LN2"L%3FN=E3#1-4]!.(]G"C&'Q%KBFXS0MVUE-_?*'AGNX93RPV$PE<9AQ3JU.@ MBCDYNDM3,*YLRSB&-QG7 M('"7[\$V1.)?A]/];YN%#INL&:RI?A#ZR8IK%N4D>D3*/!,G=SM!LW7!B.VR MTG3'M8;?Y1:5*"S3!RH]>4XN%AN%Z$0[;C)8Q"S!8M^YK;/@TPY2-25.":>2 MQR/R"VN9WE>Y1JI:X^'%#QNFK3*U79L8FTZV93QG$<_MMM&2#:0A"=?(>:#JUT$],;)T M'3F2AOJ[^\SH087**M!Z*JF"-Q/KH'VBS?\!4$L#!!0 ( '6$D5:=\*S] MI!$ ,0T 9 >&PO=V]R:W-H965T1V7WR),XD!Y[83()G-B9-9+ [. UMB=W.MEGI(R1WOKS]?%2F* M:LN:S.X^+ 83M]5BL>[U59%^N:_,K=TH58OOVZ*TKXXV=;U[<7)BLXW:2CNI M=JK$-ZO*;&6-7\WZQ.Z,DCDOVA8G\^GT_&0K=7ET]9*??397+ZNF+G2I/AMA MF^U6FOO7JJCVKXYF1^V#+WJ]J>G!R=7+G5RK&U5_VWTV^.TD4,GU5I565Z4P M:O7JZ'KVXO7LC!;P&[]JM;?19T&B+*OJEG[YD+\ZFA)'JE!9320D?MRI-ZHH MB!+X^,T3/0I[TL+X=UYM71\^/1*Y6LBGJ+]7^9^4% M8@:SJK#\K]C[=Z='(FML76W]8G"PU:7[*;][1?S(@KE?,&>^W4;,Y5M9RZN7 MIMH+0V^#&GU@47DUF-,E6>6F-OA68UU]]8NL&Z-$M1*O&XOOK!6RS,6-,Q(] MO]'K4J]T)LM:7&=9U92U+M?B[S1W:? MS<6GJJPW5KPK104]=DHJ\K:/8"VWNM2EIF6A;C!0P7_K:WX MW^NEK0T<\/^&5.08.!UF@*+RA=W)3+TZVM%>YDX=7?WY3[/SZ4\CXIT&\4[' MJ%^]EE9;XKLGAQ-,0XY=H?CKGN!#0HQN,RP$[YW\P;W%UXU*LO!$Y6(5-&X[ MC6-9O5%8NMW)\EZ 7-'DBI])Y\/\SKNO'U+QX;/XHFS5F S[?2AK94K>2A;X MKLPFJ;B^TW?2$R.7?U.9766<3R1_4S\K65R7>BL+ZU:X$*I6GYO"*O_HN@"# M42AIVBCS_ 6>:"$\I;22DQ8>(#A5H1'Y+*PN11:K8R)&G. L.,'9J!/\I:* MAIHSB#YDW-'EP\9EFHFG24:S*B$I65[:[O=MN)%W2BR5*@7([J"(7$B+ZD&K M8^/N-50+@W5.QW^ALPZ^H[:[ !C9!!2M\6),C@+!JU0_2 M%E_8E;,!?5UHN=2%KLGX, &]4E)-H'T;8SE_+MO\B5()%G;*Z J2504*7\LR M2>M]$XMB%21#*IB0XH*<&Q(MRYIM4[#2B@I,LQL_$1=GDYF83B[$8C$YQ8?S M,;\X#WYQ/NH7WYQ@[VP-WX;2AEQCE,*P:X!L$I/ED'8F#O88= CG_(1$=$UF MKS=MX)!^=UW26*M2&5D4'%AJYP.'#/"MU/0;YV96W?46=LHD ,9OC0:+R5:6 M0".TH:@K5-I;Q%_@E/R#?7#GHK/>R%K(U0H0P^66K0MC"%.9:-O?=W:F',5' M4E;8<"+>&'A=AG<[)N)D=B>+AHUD-P@0? ?F: NX(&E;9YYII[K20R%6'6\@ M=O)>+@MPOC;*L9(&PFR-Q*?2''JZDP2A0C3?0:?,#.9F&F: ]),0-X"@"H-!XFRQQ!Y&=J[G @:6,7L,5 M"^@2&)!"BDT-/Q!;!\K@107I&X&P5 \VGT1@1Y< . W33S@H=O NQ"4'H6V6 M_Z (:9B2='FYK+MHS^ LNA9&VULGA:WY\6-J15C0$R"7'(%F.:19JCUMO:>J M46AUAXJ#ZND5X?90>2I^@X.0M,2SKAN.9)=I.VJ\XU;>"_4]4_C]OV0)6EQ(=9VJML>84(09R*304O9ANSW"6S93F!T5["T68JW1HJGV%-3WLC M+O\\N/SS49>_;A'+%\@"RL@A0\X^2F38V5O*24>YY^:<-KA([U1&:$K Z>%J MA*O8"EM5;RJ7 UTZ::OOSE1WFMM)^BZOFF6]:HH OEJ=?2*F8UJZ#%JZ M'-72!["L#6<[F.IC5:Z/"V307%QS.AS2V"C!88UUNR1#N_2T9]0=-;:<=XON M38]_2"^ZXWF_02&]@Y_B'T;,1F0;6:X="@KI.-,&J 3%K,SXFYPLH5QQY.HG MC>&:YLICA+*>#88-V>C8+9" T/$&2;Q!S^6V2E(&M)R#\/J2^FVH/6*D[-ZL'(;J;-!V=W(O3*5TS&R[* MR6G",@H (HD2"(!M4D%.Z( -.0&,UP$JC^Q3[C1VNP+N!&]-6Z8 9;);SQH% M"-L]H?:?YD/'I%>?H<:M' UP9N,YQH&LK_+[,$(?7_Y(1F&:"=,\2!\>GS&H MZR=4-@D2,4 X!PV]0=4<9E><&: A'8/C%J3A>06ERJ@2]RD[')G4S(ZV[#L- M40@*]H%,OA#0J5=S*AJ$F_%F#]BT Z6]5=3A';A&*QOY5,:M6L,SLR'YJ,$$ M&C#W'G.Z+Y:JWE,?RVX<,)/3 PG *!K4R-_M03L:,>;@-K'CU864ZIM A_$# MVO: BA/O,1:0-TZ0<'Y,=A^PL7H1%)"E1H96I&L(KKCUHUNA2(Y\X@,)%5/8Y,IVJ//%VS3JF HK"NT17T\[!WRT1&C8BD MQILA&HA FB93@]8GGD/KYBH.7&Q;&6IT;A5)A9K':;[/S:07&=R=YQ4WF].'0AJ % ]>HL:5%-/0I**6NF1<&IE2V=@5-6I_+EZQK+$"H!>L-;!33 M2@XID#.[7$&XF7=#2TW-QZ&1W7.2T/F60I"5SN5E82N7$G+J[M'0L%U!#($= M"4(!2&$$U+)"IDD3Z-S:#AGZ2K*4!:_GJ7GJ)G'*NNR!LB$+'VR=B=@D>$MO M??;'U[FV&:*/,D&8VFDWDSN8VB2YPMHM$F_>(1KV%6*JPQ"4#=N)P8%81*E+ M;,YC(K^(I?8]N=N&F'/H*'X_Z;W/[^ZI488N5I&[I?%HP\O3>IR/:AH'M)E@ MO)[-NWHV'ZUGOR"/?R38!$V+&QIK#%:U42+#50V4DSYE03/HC$%"T7[!DQ2N M,K+(_*BM!T3"VVUT<+Z#$R-FT3@[ A1.U(KGFIP6%.YY[9Y/B0AO$,I=@UC# MC6"U2OP$IVIJ0M)YFQFX<7&S1#1]19.[@D$%IFA8_\X2OHQR#47*0>:7W-,T MW/EC1R<7 Q/G(ZA=8*+6Q+U5&8T X/>3Y"T1QH*>5F+9W C,)S)'Q;9^6A0= M8QW1J)+HU;'?6.5MJQ;&:IZF^JY,IFE,:#H !NG(H8?(I\(V!.ELIX"87S<6 M8RLY*!!+GJMEW>G+HTG -?ZI3PI\/2P+BW0ZFZ>G MLZF8G_N?Z70Z%6>S17JQZ'[.Y^DB(MTNKA,GR_FXCP]/05CBS,Q2Q=G9^EB-DWGIPMQOIBG%\\O MT]ET=*H\ZX[49J-'6E?O"&@6&:NW*R*VBPVD.:$>L=:A^5^,@27(( MRIS_2;'12!HFV\#][A'36U<=6P;\"+O''3K@NH<\D.JC+;7U@Q'J:[HZX% . M35^H5E2(-(0U>1"#;,B _I;+-A<]&JW*J#HY;P,>4X; 4W>:%7#P5II;$-I) MX[H%/]PG5OQ7$3Q4'5!.:,Y3=S2[D7 OZ$*-ZA5Z/O\!PK*#H^P _!R4I S= MTQ0!2OH..)ALL:2S2U?H>6)Z7*@[5413\\Y4/&OJL (UHST#2.L/B>P+\9&H M)+,7;LCU6U-QDO3:,CKSL>SJKGONAS8\ J,)ND>U-+KM/&CB*<\]Y6I)\<$I MPU'Q3;DNT5?QXJ:,WO&/W6F'H0QC3+6DJ:>K;)Y#].RRW6GA=QJE0[!GE!89 M]6'??VCF8+)!P_*4.."O4,G_$&-)G[$6TON(@V>PT&(A^H 3"%R\+F1V>WP# M/*#:\A0U*=LJQSJ:.#;6(>' ZT%ZF SVX8,25P.'3KU0L ?.S;/S:+(7?15T M.W"2E?0/W$,/[^W6G7RRCG?NE#]$93BDCS,= M2>+/']IX3?X:Q$N^1;(F3WTN>.;%3>;A$P3_6M58^S98/^FL_T0<^_]G%ZCC ME^GT_+3W2\*+?^"]/Z" V7^E A:,:.:7%_'G!^(/OC7NPFVL_/L>W)^*] ?# MP;N287]^TT4LD?AXR$5\IA<7E[^_]^PTG<[/T[/3\TS9N/WLSH3!?/>#V+C?^'^U9#Y_Z/-Q\Y46W1>E;EW?4A\$4=R-0YK M(W_@H6(2U6FZ!X":Y(:N'@4]@@3:KH^:,ZI"C.=HK-(5L,/!RG )=<[<+B]0=([?%) M\M@MC*BY]F C&T4;W>M=?HLNM?1SS*^MA=ZJ)2*&.Y[^+K\&\M<=D>1]99*_ M*I'P"XSN2)F$ZF4[K7-)V=N=_H MMM-TT2V_JPHPP>J8G2W$[/P2L7B!/*^$Y0XX!T '(\R(D!E:\BHKMI MU#4LM'^XFY*BO:D/+ZS058ZJN*-20N,]+C#M[!B9/VEOY/BCJ=;/!S;[1Y.O MZ0%0JIL(4Z#P")!NOE6F+7.IOW'$5^KZ)<=CXC%TGL0QF49\6/\&=RS6TJ.4 M!_Q1U5H5#=WG<8KU>T:6]CNB'63F/#=M21UG9"A]1&;J])VU'3']:MR-EO9P M)XQK77::'-S'X5,J^\CIY7#>@?DE=Q;MV9"?_;5F=08(V_8ZR:YUM4E9E,&EF5OE.(4K=^+\/J-^3 IS1\Y@6X[Q$P#.:/CN1N8QD[BX"> O/0WB6O([:Y"]*[3.E<2#[R()YUD MFLC0Y$XT%O7'D =>-KPD5W[)^*%!=X-Y-GZ%F>X*]?\^X8:&Z'0(_VV7/W9Y M]8>()B-$'XQZE2NV%(-%T>(-/DF++ZI6945).YHG/CP@ZDYN'E_J)G9D+[KL ME%0W8XB?ZP9*O,FO]\AE-B6;N_,0E/PY_H7+L_3.E>=W_? M\TF:-0W?"K7"TNGD KHW[D]FW"]UM>,_4UE6=5UM^>-&2:0">@'?KRI@2/\+ M;1#^<.GJ_P%02P,$% @ =8215@B"(S=Z!0 #P\ !D !X;"]W;W)K M&ULS5=;;]LV%'[GKR#'BRDNI>YP"& M/I2%T*>]W)CJ>##0:0XETWU9@< O\L.CX?6WDG\(7#2G?&U$8RD_+>OKS+3GNA=0@*2(W5 MP/!G"1=0%%81NO%WH[/7FK0+N^.U]KJ6XW.<6$WY=8H_,IQG9E^9*960.6W=L5H#>/QD8],=J':2-[7-O M.W[&=A33#U*87-,KD4'V5,$ VFCB=?1G,<[-5Y"VJ=)%- XC.,=^I(V.XG3 MESRC[Y-:,,'_819 ;V00F/4&?-XPC1=*] @C)_ 7+WE@HF4LX+>XB0@>(VF M?Y[-M%$(O[^VI<@[,-SN@*7DL:Y8"J>]RMI22^A-7[^*QN&;'>$-V_"&N[1/ M;Y'B65WX[6<%NH[[B>/WG,UXP8W=W@_ -"(DH\S0MXPK^H45-6R+9*>M[9'< MY4#FLL#*8"%E+)!HY7.JD6P;CTP.M.AXM>(FI[J#S%K(F57J5'!1U:A@[STL MH:#)/F5.":(#RAFH%B%N#W$0'=-U*LAWIX+8(7'#M83?=Y3ZUN)G)-F"_%9+ M QFY5MR:X:)+,M(=O\M0%0X+\JD-CWSNQ$I\D"3:;\(E<3O"P.^DP;67H/B2 MV?)'UDE\I+_0@^8_F@3)Z"@(Q\,G+\0M?H'<=R0@^E\F( F&PSB(CR;=\3?A M;Y6B.V@X:FDX>C$-+W(F%CXE%O/OO\9\MQIWTT#?.=I MB3V%4_$(3&D*]A#XEC)D.TE_,E%=2*S7/I*&^>1K)T+<\F& @V"$P,!.Q10. MXV3VB"W S%!XL(=BS75NI^E>E"1!!S3D9/T+O%[M773H9'P61R]-^VHV$0QN-@ M-!P_:SQ^6A]VL&+UL.--DY^D1. 1>R+)BXI'F>-@LU_XJ3&6SWX9[%LF2:RVQ MMQ)8 G5 5SE/S"*7^*$^G=6K9P*66&Q6@COBE[; .DIZ7G M!]%(\!I!_G"E#OM=:Z$+*>(@9>%$KAXJO+/@\6A E32D$?X-<194RC40EP^D M6]@/PZ%]1B/_%ME'LEF^E 4ZX=(1C1(:C8^0HA.T,=[(9'S)\8C--/TH!;@' MN>'Z_F"NP!8$= %+@L=QU!\G=-B?)-;.&!_)D8UI#MSGH-6PE?Z#SB6E!+5P M5S&[T8@'?U]I9]O;WIF_Y&S$_57Q U,++C0M8(Y+P_X$CSCEKU_^Q\V+-=#>@:?_ E!+ P04 " !UA)%65?2E-+4" M #Q!0 &0 'AL+W=OR@0)-V&8=B#8M,75)8R26F:OQ\E.VX&I-F+34KD MX2%%&R[TS*^,V4R"0&<5-DQ?R@T*NBFD:I@A596!WBADN7-J M>!"'X570L%KXZ=2=+50ZE5O#:X$+!7K;-$SMY\CE;N9'_N%@69>5L0=!.MVP M$E=HOFT6BK2@1\GK!H6NI0"%Q\!8YMT!$XT^'Z?.Q?$#_['*G7-9,XZWD/^K<5#/_VH<< M"[;E9BEW7[#+9V3Q,LFU^\*NM1V.?E4R1TH:TUH5G"I.F\B5PO[*"NCZ+8F/Y,N\0G%%F&)F2Q% M[2KU_H&M.>H/T\!0!&L79!W:O$6+7T&+8KB7PE0:/HD<\W\! J+6\XL/_.;Q M6<0[S"XAB080AW%\!B_I\TT<7O*?? LE&[@EKHKZ@FIN*KAUU48%OV[6VIW_ M/E6!%G]X&M_.T$1O6(8SGX9$HWI"/WWW)KH*/YYA/^S9#\^AIRN:R7S+$60! M*[E5&6HK=DF=8GL6[S1;ZG;/5 A[9$H#VH<$>@9LUE2;PU, $[D52+6V^H6, MZBJ\0X7 -!22T^3K"1S(>R?)>P[5(GH_;6#/=9!W".Q1X".3NUK16'N:49]> MP((S;>J,-HLJ40H]@%))K8'8C9,8QLD@"D?>4NX9-_N UYE=*J(<>(*V7A0E M@ZLX@0OO01K&O1.IO(4H&0V2T8BD%@Q./69P-(;41Z5;-AHRN16FGJ;(6&C@6Y!I>CD<^J';!M(J1&S?4:VFH:9U8T4Y&90WHOI#2 M'!0;H-_RZ5]02P,$% @ =8215O 6>\4+ P :0< !D !X;"]W;W)K M&ULC55M;]HP$/Z>7V%EU;1)4?-.&0,D^K956B74 M=INF:1],:ZXT"-_ M:'">6WMG\(W!6F^-BZ8RXQJN)#\.RO-O&-D]]4M3:R&KCC PJ)IH_?=Z[">187E)#QT,EUT19 M:T2S Y>J\T9R3%A1[HW"789^9CRE!H31Y-T#G7'0[X>A052[%Q8;A/,&(3F M$"?D5@JSU.1*E%#N H1(I^.4M)S.DZ.(EU"=DH]D^BD=!]E-\ M6((WEQQO)Q,+PC2A[0VUL5:;^L#:P)VBJ*N:XU)):"6587]I<[<,0=&@FH'J MA'.GC8-X0%KRW@MYSYG8;:_U]-!S:[FMS!.2!7D4!5$4;8^]+\C(.\@H#9(4 M;?,>28*\?Q;TLJQ%] 3VNA,2!TDO#[(L<^,/<1*D:'U$JKR3*G^U5%?:L,JQ MNZZ-K;#)-LFK9^RM&O8)>33$82&ABS=OXNT<"C3QL)DV)V9DIR_5ENY_(@:N M(#1I"D3O2OFJY+P?0)7V7&_8Q4?K6ABK>(H2]+(>BA#9:49Z<3_(T\Q[D(;R M':WVZ1-NM;\*U,(U>4T*"]]TPFZU>TH5NJ%DS8&ULC5;; M;N,V$'W75Q#JHM@ W.@NV:EM(-ETT0)-821I^U#T@9;&EA")5$DJWOQ]AY0L M>QW;7< PAY2HOH6'J6K3 <6(M9RS;P!/J/=BEQYHTH1=4 5Y7@1,)Z[MX&-W>).6\/_%G!5AW( MQ'BR$N+%3'XMYJYO"$$-N38(#(=7^ QU;8"0QK\#ICN:-(J'\@[]B_4=?5DQ M!9]%_5=5Z'+N3EQ2P)IUM7X4VU]@\,<2S$6M[#_9]F?CV"5YI[1H!F5DT%2\ M']G7(0X'"A/_C$(X*(26=V_(LKQGFBUF4FR)-*<1S0C65:N-Y"INDO*D)>Y6 MJ*<7OPL-BK3LC:UJ(!^?S:"N9IY&;'/"RP>1Q8O.XJTTN:]47@O522!_WZZ4 MEE@5_YSRML>*3V.93KE1+/%NU7\UR40_DV9V%:J]!O9 M,D7PMQ8U-K>Z(3OFSC%SQQHP>,Y[ZP>;5LD9[6BR@DW%><4W)A@MR$H4Y /) M:)BD=!KY**=T$B4TF*9'RI52'10D3A/J^SZ9)KX9';QF= UXK6CDP:UC^_(/ MTHA.PI1#RV5HPB$C.2\QLHY;!&=*A) M4&'* MN\#R-O:0A4^326:@LX1.+!^#O .FA..%;P(9)!$-XZ27)P$-$/!D()&W>0,P M91)J9CQIF<0:^$""(*2!;W(1A*F1S@)PP3\=:V?4C]'L0,%/,%V8UPMME(QM ME'QW&STPW4E3L7A)8OJ^I[$N@I]NK.<2G&9GJ>@M\8/^87CMG&N7_V'H/&^A M?D7X_I+%HL">H'AF#*AC EJAQA>;)>=9:%8[2Z:T4W1@&R4UZ;&!WJ*22XL6^QZ0PLV/[!&E?' MY_ZV?^7VQ_MOA02FA\0:U8XB<+2', M]]<"@SM,C('Q(VCQ'U!+ P04 " !UA)%6#\R8VST% #L$ &0 'AL M+W=O5CL RW1EE!)=$FJ;O;K=X:ZV&H%OA@DQFS.1B,=)2+G>B@WHL G*ZER;K"KUB.]48+'=E*> MC9CG348Y3XO!_-R.W:CYN2Q-EA;B1H$N\YRK^TN1R>W%P!\T [?I.C$T,)J? M;_A:W GS<7.CL#=JO<1I+@J=R@*46%T,%O[9Y8SLK<&G5&SU7AMH)4LIOU#G MM_ABX!$@D8G(D >.7]_$E<@R.:UER+:YD]CF- M37(QF T@%BM>9N96;G\5]7I"\A?)3-M/V-:VW@"B4AN9UY,109X6U3?_7N_# M,1-8/8%9W%4@B_*:&SX_5W(+BJS1&S7L4NUL!)<6E)0[H_!IBO/,_"[A2B0R MBX72KU[,F#]] ]=BE4:I@9\^\&4F].OSD<%(9#^*:J^7E5?VB%>?P3M9F$3# MVR(6<=?!""&V.%F#\Y+U>KP6T1 "WP7F,=;C+VC7'5A_P2/^WGXM4W,/?RZ6 MVBBDQE^'%EFY&!]V0>5RIC<\$A<#K 1[]0P/#>0C#^:/,ET+1$\LB#0\&;KAR/O&L%/![BAL>VD-?1\\#WOH>D5S*SE-)CM6=+00]MK M))8U#KT?;3\BA76Z+KC!E0?N*6/6\,3^]60Z;#,='IUIN['P?D/[I.%]:;3A M19P6ZT,Y[W5[..=5XN1FIXA4!:CM8!(!]X(K#8)*%D4@$I3-MN@ @5 #NRF2 M1>.L#"5=GW4X\N@"G&;LLQ5*W/FVL5BOE5CC]CK[]MP\P.#A]GO^V/5F59*" M*?C#R13;)\XOBA>4H!/JT9]SQ8L(U1['?F)NB P+,+>O[41_@A^3$(W>?A-@./;( 1Z6^\!"SW<#UL*: MV?@_8'H*#[.[PMRQ7\6C 8KVLHE7^R,Q/SR?39K9;#@.\<-CU':IQ'H(/FD) M/CF>X"0,)W2.QD#B@\>[%06WD8S%3H6H\%2'47"3\4*[L+R'9I-0E=)(P"TO MUN)0D?1">UP8ESRC+!%DGF6@+0A94UCN$D*%@#8/]O31(OG/-V&?+K"?^EV] M?1,*+UQM)>Y*LG* "&\%7>C(0V-\1?V "UY!C\^:_J.A=>1 SP0 M5@WL/9#52*,5SDL(QU@_X/ON%(MW/+1%UQFKNVCJHQ;@L3#Q;-GL>G7;V=5B M6YYUG=3C+.P6K;.KJ]:P4RVVVU,@T[9 ID<7R&>N2$6>%/]>CX=YO7#JJS?% M(;V/$LJW;KK;)G1<*DK1JP<][H^6HY;IOX; M)7:>PO]_4-*VJAH"5'2PRM4=:@CUE,%!"HWVWD!SH=;V/5M#),O"5"^C[6C[ M*K^HWF!WYM7O .^X6J=XR&9BA5.Q;O&:JZIWZZICY,:^SRZEP;=CVTP$QU.2 M#/#Y2DK3="A ^P/'_!]02P,$% @ =8215E8:2+H# P Q 8 !D !X M;"]W;W)K&ULE57;;M- $'W/5XR,0"#1^))>4$DB M]0*B#Z"J+?" >%C;XWC%>M?LCIOD[YE=)VXJI9&0HG@O<\ZJ8QM!/'4+F+76A1E #4JSI+D-&Z$U-%\ M&M9N[7QJ.E)2XZT%US6-L.M+5&8YB])HNW G%S7YA7@^;<4"[Y&^M[>69_' M4LH&M9-&@\5J%EVDYY?'/CX$_)"X=#MC\$YR8_[XR4TYBQ(O"!46Y!D$/Q[Q M"I7R1"SC[X8S&E)ZX.YXR_XY>&8<=@ ?DA< V0:0!=U]HJ#R6I"8 M3ZU9@O71S.8'P6I LSBI_4NY)\N[DG$TO]&%:1!(K-#!VP>1*W3OIC$QM0^( MBPW-94^3O4"39O#5:*H=?-(EEL\)8M8T",NVPBZS@XS76(QADKZ'+,FR WR3 MP>@D\$T.&WT0*[B6KE#&=1;AUT7NR')I_-[GN6<\WL_HK\NY:T6!LXCO@T/[ MB-'\S:OT-/EX0._QH/?X$/O\GJ]?V2D$4\&GJL)0O;#CXDX0PAT61A=22>%K M?)^'PUDN1O89@\]&-4)KS:,,%X_O/&PO=V]R:W-H965TWE)P64$K*2R1@/O'^":]QF!I!%?&5 MPD;NM)%)9<;Y=].YRR=>8$8$##)E$$1?UG +C!F2'L>/!NJU[S3"W?8+_6.5 MO$YF1B3<'L:_TF S9SYKWW]3OC_:\ M'T-VB>+P D5!%/7(;X^7ASUR?+P\Z,I];63K9M2Z&56\>"]OKN_DZ 9*W5+H M41N*,)49X\9!].U>/T9W"@KY?Y]7-3WIIYL2<"V7)(.)I^>X!+$&;_KGNS - M_NYSSB4,.X)U7(U;5V,;7;LJZ)J8^H!8\UG^ZG.OI@PJBJEWZVDXC >C($W& M_GK7F=>!<9)$T6C8CP!H9"].T!BAF(WCE@I9XZ!US"L"-8 MQ\VT=3-]T\J2NG35)0P[@G5<';:N#IU4%BNE?XRHSSA'''P&YZ!G5ZUG5^<5 M)JOL!),<I2QAV!.NX&0;;56KPIN6OP3LR MUBD-NZ)UK=W9 (1.:J =<\+\=@7"YX .&[==ZX?61>_^0FC7G>*4(Q ^!W38 MJ>WZ/;0OX/=7P]A:#>W8DV>M2QIV1>M:NMT=A,G;%D3K[N-D:UW2L"M:U]KM MOB6T;UR.+HB#8W=B/9']6S'[R,[-?+O'"*V+;4M%2X_=6O=$[DG5Z;K?WSD! M,^>5#T0\TU(B!G.-#RZ'>D"B/@*L.XHOJT.Q&5>*%U5S 20'80+T\SGGZJ5C MSMG:@]CI;U!+ P04 " !UA)%6;QP2?66:*F3-Q2 8K6G/S46[>0.?/R.*EDNOF MGVPZ7<\A::V-+#MC9% RT7[I71>'+0,_/F 0= ;!KD%TP"#L#,+&T999X]8U M-70^57)#E-5&-#MH8M-8HS=,V%-<&H6K#.W,?(EID=4/,,!1MF"G(DN6"K5A*A2&W0B8:U)HF:/M65+71Y/DU&,JX?D%.R>WR MFCQ_^F+J&B1IMW+3CM!52R@X0,@/R'LI3*')*Y%!]AC 1>]Z%X,'%Z^"HXC7 MD)Z1T#\A@1<$ X06?V[N'Z$3]A$/&[SP -X'E5/!?E";Q2=D(866G&6T36J1 MD1L%&H1I!7@JKYF@(F64DR4* 6\0AOK+9:*-PCOP=2C"+8%HF("M"Q>ZHBG, MG,KNI=;@S)\]\6/OY5!T_A'8HUA%?:RB8^@8>\76U%YTPKMLO#\A">1,""9R MO, <8P-#,6B!1PVP+67K>1A%07 ^GKKK;??V]2(\Z-&6WB/FHY[YZ"AS+'^& M=X>5W&-A20R!.X.D:Z8+*Q\BW6+&6V1.?>]\/#[?(3VD%X;A)!XF'?>DX_] M^BCFWV9;O._9:(*_ \&PO=V]R:W-H965T[#:!Y,,5+2<*]Y_H>GYB3N(-USI[Y'$"@ES3)^+ U%V)QX7D\FD-* M>#M?0":_F>4L)4*>LB>/+QB0N$Q*$P_[?L]+"MH+6ZX5[^C07Q05O-%B0)W@ \7EQQ^295Z/$-(6,TSQ##&;# MUF5P<1V6"67$(X4UWSI&12O3/'\N3F[C80) 62',>W M#6BKKEDD;A^_HM^4SHB7B: \AEZ)(R2J3P> MPQ0RL63 T55"HN??9%2>R+-'DBQ)2?\EEQ._* XY^C &06C"?QUX0@ZI /:B M3?FKJCS>4S[ :))G8L[1IRR&6 ?P9"]U0_BUH2ML11Q#U$9A\!%A'V/T^6&, M/OQL&MCUX3"!&48;7ECS'9:XX1[<&T)922.@"1 N.9;WA$"WV6(I.")9O,7Q MWQ#-,_IM*8G_\J?$0;<"4O[5Q')5M&,N6BP%%WQ!(ABVY+W.@:V@-?KEIZ#G M_VYBQA&8QD^GYJ=C0Q_)>W,&M-2>J4]KLGEHR-3BC^-HW77K[KK6[MY,^4?T MZ64A5S2(Y6RS%'V90#H%]A7]BR8TH^E273+18:W6=-H=@6G$]&IB>J>X+7HN M^7$$IO'3K_GI6X53JT1(E9@ZM:?[*"U765-;]LR@RK2T<%:W<.9.^^3E7>U; MJS6=6T=@&C'G-3'GI]#^N4M^'(%I_ 2^\BC^CZG_G7RCB*O&WLGL&&\TSEVA::S@Q4[^!2WP::J*XXD<*?,86+V7 M=*6,KDCQX(,2:=5I0L5WE"JVC 14D(70)6;Q6+<:^6W?[PR\E=;:)B[0XX(Z M3!^S,G2!W=$U4_T!"[^]7N,9=82FLZ,,8= ]B>J=.D-7:#I'RAL&5FMUG.I[ M1M4'W5W5]XRJ#_>H7OFUP.Z;#*K_JWQ<1H]Y(GLI>VBZW%M+-IY41V@Z0=(&U3YP">RJWSSF*\F4FJAW6^FJ]17]9;DSO7+\*+JZK MC78%4^W[3PA[HAE'" 9 >&PO M=V]R:W-H965T?G(M41XW MD4KCF,J?5Q")[<4 #W8//K'56ML'P_EY0E=P M _I++2\& MCNT11!!H"T'-OPTL((HLDNG'CP)TL&_3.AY>[]#_S((WP=Q2!0L1?65+O;X8 M3 =H"2%-(_U);-]"$=#(X@4B4ME?M"ULG0$*4J5%7#B;'L2,Y__I74'$0QQ( MX4!J#MB[Q\$M'-R'.GB%@Y2\>!33>?G4FR1M-8&S5YD9&;>)GS&[;C? M:&G>,N.GYQ^H3B4@$:*K5)EW2B'*E^@F3P/[_(:M. M90+E&ET$@4JX97Z%K M$;& @4*O?-"410I]H%)2.XJOT1_HRXV/7OWV^GRH32=M4\.@Z-!5WB%R3X
  •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end

    •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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 212 292 1 false 86 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://endonovo.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://endonovo.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://endonovo.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://endonovo.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Shareholders' Deficit Sheet http://endonovo.com/role/StatementOfShareholdersDeficit Consolidated Statement of Shareholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://endonovo.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business and Summary of Significant Accounting Policies Sheet http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies Nature of Business and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Revenue Recognition Sheet http://endonovo.com/role/RevenueRecognition Revenue Recognition Notes 8 false false R9.htm 00000009 - Disclosure - Patents Sheet http://endonovo.com/role/Patents Patents Notes 9 false false R10.htm 00000010 - Disclosure - Notes payable Notes http://endonovo.com/role/NotesPayable Notes payable Notes 10 false false R11.htm 00000011 - Disclosure - Shareholders??? Deficit Sheet http://endonovo.com/role/ShareholdersDeficit Shareholders??? Deficit Notes 11 false false R12.htm 00000012 - Disclosure - Related Party and former Related Parties Transactions Sheet http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions Related Party and former Related Parties Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Income taxes Sheet http://endonovo.com/role/IncomeTaxes Income taxes Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://endonovo.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Concentrations Sheet http://endonovo.com/role/Concentrations Concentrations Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://endonovo.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies) Sheet http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies Nature of Business and Summary of Significant Accounting Policies (Policies) Policies http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables) Sheet http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables Nature of Business and Summary of Significant Accounting Policies (Tables) Tables http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Revenue Recognition (Tables) Sheet http://endonovo.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://endonovo.com/role/RevenueRecognition 19 false false R20.htm 00000020 - Disclosure - Patents (Tables) Sheet http://endonovo.com/role/PatentsTables Patents (Tables) Tables http://endonovo.com/role/Patents 20 false false R21.htm 00000021 - Disclosure - Notes payable (Tables) Notes http://endonovo.com/role/NotesPayableTables Notes payable (Tables) Tables http://endonovo.com/role/NotesPayable 21 false false R22.htm 00000022 - Disclosure - Shareholders??? Deficit (Tables) Sheet http://endonovo.com/role/ShareholdersDeficitTables Shareholders??? Deficit (Tables) Tables http://endonovo.com/role/ShareholdersDeficit 22 false false R23.htm 00000023 - Disclosure - Income taxes (Tables) Sheet http://endonovo.com/role/IncomeTaxesTables Income taxes (Tables) Tables http://endonovo.com/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - Schedule of Balances of Liabilities Measured at Fair Value (Details) Sheet http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails Schedule of Balances of Liabilities Measured at Fair Value (Details) Details 24 false false R25.htm 00000025 - Disclosure - Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) Sheet http://endonovo.com/role/ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) Details 25 false false R26.htm 00000026 - Disclosure - Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details) Sheet http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details) Details 26 false false R27.htm 00000027 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Details Narrative) Sheet http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Nature of Business and Summary of Significant Accounting Policies (Details Narrative) Details http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - Schedule of Sources of Revenue (Details) Sheet http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails Schedule of Sources of Revenue (Details) Details 28 false false R29.htm 00000029 - Disclosure - Revenue Recognition (Details Narrative) Sheet http://endonovo.com/role/RevenueRecognitionDetailsNarrative Revenue Recognition (Details Narrative) Details http://endonovo.com/role/RevenueRecognitionTables 29 false false R30.htm 00000030 - Disclosure - Schedule of Patents (Details) Sheet http://endonovo.com/role/ScheduleOfPatentsDetails Schedule of Patents (Details) Details 30 false false R31.htm 00000031 - Disclosure - Schedule of Estimated Future Amortization Expense (Details) Sheet http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails Schedule of Estimated Future Amortization Expense (Details) Details 31 false false R32.htm 00000032 - Disclosure - Patents (Details Narrative) Sheet http://endonovo.com/role/PatentsDetailsNarrative Patents (Details Narrative) Details http://endonovo.com/role/PatentsTables 32 false false R33.htm 00000033 - Disclosure - Schedule of Notes Payable (Details) Notes http://endonovo.com/role/ScheduleOfNotesPayableDetails Schedule of Notes Payable (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Maturity Dates of Notes Payable (Details) Notes http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails Schedule of Maturity Dates of Notes Payable (Details) Details 34 false false R35.htm 00000035 - Disclosure - Notes payable (Details Narrative) Notes http://endonovo.com/role/NotesPayableDetailsNarrative Notes payable (Details Narrative) Details http://endonovo.com/role/NotesPayableTables 35 false false R36.htm 00000036 - Disclosure - Schedule of Preferred Stock (Details) Sheet http://endonovo.com/role/ScheduleOfPreferredStockDetails Schedule of Preferred Stock (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Stock Options Outstanding (Details) Sheet http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails Schedule of Stock Options Outstanding (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) Sheet http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Warrants Outstanding (Details) Sheet http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails Schedule of Warrants Outstanding (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Warrants Exercise Price Range (Details) Sheet http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails Schedule of Warrants Exercise Price Range (Details) Details 40 false false R41.htm 00000041 - Disclosure - Shareholders??? Deficit (Details Narrative) Sheet http://endonovo.com/role/ShareholdersDeficitDetailsNarrative Shareholders??? Deficit (Details Narrative) Details http://endonovo.com/role/ShareholdersDeficitTables 41 false false R42.htm 00000042 - Disclosure - Related Party and former Related Parties Transactions (Details Narrative) Sheet http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative Related Party and former Related Parties Transactions (Details Narrative) Details http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions 42 false false R43.htm 00000043 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 43 false false R44.htm 00000044 - Disclosure - Income taxes (Details Narrative) Sheet http://endonovo.com/role/IncomeTaxesDetailsNarrative Income taxes (Details Narrative) Details http://endonovo.com/role/IncomeTaxesTables 44 false false R45.htm 00000045 - Disclosure - Concentrations (Details Narrative) Sheet http://endonovo.com/role/ConcentrationsDetailsNarrative Concentrations (Details Narrative) Details http://endonovo.com/role/Concentrations 45 false false R46.htm 00000046 - Disclosure - Subsequent Events (Details Narrative) Sheet http://endonovo.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://endonovo.com/role/SubsequentEvents 46 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToOfficersOrStockholdersCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 200, 7838 [dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 7 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 4870, 4871, 7020, 7022, 7038, 7845 [dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 6855, 6856 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 7818 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent - form10-k.htm 200 form10-k.htm endv-20221231.xsd endv-20221231_cal.xml endv-20221231_def.xml endv-20221231_lab.xml endv-20221231_pre.xml ex31-1.htm ex32-1.htm form10-k_001.jpg form10-k_002.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 756, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 212, "dts": { "calculationLink": { "local": [ "endv-20221231_cal.xml" ] }, "definitionLink": { "local": [ "endv-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "endv-20221231_lab.xml" ] }, "presentationLink": { "local": [ "endv-20221231_pre.xml" ] }, "schema": { "local": [ "endv-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 496, "entityCount": 1, "hidden": { "http://endonovo.com/20221231": 44, "http://fasb.org/us-gaap/2022": 132, "http://xbrl.sec.gov/dei/2022": 3, "total": 179 }, "keyCustom": 57, "keyStandard": 235, "memberCustom": 56, "memberStandard": 28, "nsprefix": "ENDV", "nsuri": "http://endonovo.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://endonovo.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Notes payable", "menuCat": "Notes", "order": "10", "role": "http://endonovo.com/role/NotesPayable", "shortName": "Notes payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Shareholders\u2019 Deficit", "menuCat": "Notes", "order": "11", "role": "http://endonovo.com/role/ShareholdersDeficit", "shortName": "Shareholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Related Party and former Related Parties Transactions", "menuCat": "Notes", "order": "12", "role": "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions", "shortName": "Related Party and former Related Parties Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Income taxes", "menuCat": "Notes", "order": "13", "role": "http://endonovo.com/role/IncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://endonovo.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Concentrations", "menuCat": "Notes", "order": "15", "role": "http://endonovo.com/role/Concentrations", "shortName": "Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "16", "role": "http://endonovo.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "17", "role": "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Nature of Business and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "18", "role": "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Nature of Business and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfSourceOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "19", "role": "http://endonovo.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfSourceOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://endonovo.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Patents (Tables)", "menuCat": "Tables", "order": "20", "role": "http://endonovo.com/role/PatentsTables", "shortName": "Patents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Notes payable (Tables)", "menuCat": "Tables", "order": "21", "role": "http://endonovo.com/role/NotesPayableTables", "shortName": "Notes payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfPreferredStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Shareholders\u2019 Deficit (Tables)", "menuCat": "Tables", "order": "22", "role": "http://endonovo.com/role/ShareholdersDeficitTables", "shortName": "Shareholders\u2019 Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfPreferredStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Income taxes (Tables)", "menuCat": "Tables", "order": "23", "role": "http://endonovo.com/role/IncomeTaxesTables", "shortName": "Income taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Schedule of Balances of Liabilities Measured at Fair Value (Details)", "menuCat": "Details", "order": "24", "role": "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails", "shortName": "Schedule of Balances of Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details)", "menuCat": "Details", "order": "25", "role": "http://endonovo.com/role/ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails", "shortName": "Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativesPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditDerivativeTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details)", "menuCat": "Details", "order": "26", "role": "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails", "shortName": "Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativesPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditDerivativeTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Nature of Business and Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-5", "lang": null, "name": "ENDV:WorkingCapitalDeficiency", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Sources of Revenue (Details)", "menuCat": "Details", "order": "28", "role": "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails", "shortName": "Schedule of Sources of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ENDV:ScheduleOfSourceOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_DirectSalesMedicalCareProvidersGrossMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Revenue Recognition (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "shortName": "Revenue Recognition (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://endonovo.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Patents (Details)", "menuCat": "Details", "order": "30", "role": "http://endonovo.com/role/ScheduleOfPatentsDetails", "shortName": "Schedule of Patents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Estimated Future Amortization Expense (Details)", "menuCat": "Details", "order": "31", "role": "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails", "shortName": "Schedule of Estimated Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Patents (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://endonovo.com/role/PatentsDetailsNarrative", "shortName": "Patents (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Notes Payable (Details)", "menuCat": "Details", "order": "33", "role": "http://endonovo.com/role/ScheduleOfNotesPayableDetails", "shortName": "Schedule of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "ENDV:NotesPayableIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "ENDV:LongTermDebtPastMaturity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Maturity Dates of Notes Payable (Details)", "menuCat": "Details", "order": "34", "role": "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "shortName": "Schedule of Maturity Dates of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "ENDV:LongTermDebtPastMaturity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Notes payable (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://endonovo.com/role/NotesPayableDetailsNarrative", "shortName": "Notes payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "ENDV:ScheduleOfPreferredStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_PreferredStockDesignatedMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Preferred Stock (Details)", "menuCat": "Details", "order": "36", "role": "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "shortName": "Schedule of Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ENDV:ScheduleOfPreferredStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_PreferredStockDesignatedMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Stock Options Outstanding (Details)", "menuCat": "Details", "order": "37", "role": "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "shortName": "Schedule of Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_us-gaap_WarrantMember", "decimals": null, "lang": "en-US", "name": "ENDV:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_StockOptionsMember11991953", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details)", "menuCat": "Details", "order": "38", "role": "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "shortName": "Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_StockOptionsMember11991953", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Warrants Outstanding (Details)", "menuCat": "Details", "order": "39", "role": "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "shortName": "Schedule of Warrants Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "ENDV:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://endonovo.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Warrants Exercise Price Range (Details)", "menuCat": "Details", "order": "40", "role": "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "shortName": "Schedule of Warrants Exercise Price Range (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ENDV:ScheduleOfShareBasedCompensationSharesAuthorizedUnderWarrantPlansByExercisePriceRangeTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember", "decimals": null, "lang": "en-US", "name": "ENDV:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-09-27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Shareholders\u2019 Deficit (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "shortName": "Shareholders\u2019 Deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-09-27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Related Party and former Related Parties Transactions (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "shortName": "Related Party and former Related Parties Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember", "decimals": "0", "lang": null, "name": "us-gaap:DeferredCompensationEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "menuCat": "Details", "order": "43", "role": "http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Income taxes (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://endonovo.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneSignificantCustomersMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Concentrations (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://endonovo.com/role/ConcentrationsDetailsNarrative", "shortName": "Concentrations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneSignificantCustomersMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://endonovo.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-01-012023-04-17_us-gaap_SubsequentEventMember_us-gaap_SeriesDPreferredStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Shareholders' Deficit", "menuCat": "Statements", "order": "5", "role": "http://endonovo.com/role/StatementOfShareholdersDeficit", "shortName": "Consolidated Statement of Shareholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://endonovo.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Nature of Business and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "7", "role": "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies", "shortName": "Nature of Business and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "8", "role": "http://endonovo.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Patents", "menuCat": "Notes", "order": "9", "role": "http://endonovo.com/role/Patents", "shortName": "Patents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 86, "tag": { "ENDV_AccrualOfDeferredCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual of deferred compensation.", "label": "Accrual of deferred compensation" } } }, "localname": "AccrualOfDeferredCompensation", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_AccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Principal interest convertible" } } }, "localname": "AccruedInterest", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENDV_AcquisitionPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition Payable.", "label": "Acquisition payable" } } }, "localname": "AcquisitionPayable", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_BlueRidgeConsultingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Blue Ridge Consulting LLC [Membe]", "label": "Blue Ridge Consulting LLC [Membe]" } } }, "localname": "BlueRidgeConsultingLLCMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_CertainFixedPercentageOfCashPremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain fixed percentage of cash premium", "label": "Percentage of cash premium" } } }, "localname": "CertainFixedPercentageOfCashPremium", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "ENDV_ChangeInRightsDueToAmendmendAndRestatedCertificateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in rights due to amendmend and restated certificate, description.", "label": "Change in rights due to amendment and restated certificate, description" } } }, "localname": "ChangeInRightsDueToAmendmendAndRestatedCertificateDescription", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "ENDV_CommonSharesIssuedPursuantToConsultingAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common Shares Issued Pursuant To Consulting Agreement.", "label": "Common shares issued pursuant to consulting agreements" } } }, "localname": "CommonSharesIssuedPursuantToConsultingAgreement", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "ENDV_CommonSharesIssuedPursuantToConsultingAgreementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares issued pursuant to consulting agreement shares.", "label": "Common shares issued pursuant to consulting agreements, shares" } } }, "localname": "CommonSharesIssuedPursuantToConsultingAgreementShares", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "ENDV_CommonStockShareSubscribedButUnissuedSubscriptionReceivable": { "auth_ref": [], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "CommonStockShareSubscribedButUnissuedSubscriptionReceivable", "negatedLabel": "Stock subscriptions" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionReceivable", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ENDV_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement [Member]", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ConversionOfPreferredCStockToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion Of Preferred C Stock To Common Stock", "label": "Conversion of Preferred stock to common stock" } } }, "localname": "ConversionOfPreferredCStockToCommonStock", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_ConversionOfSeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of Series C Preferred Stock [Member]", "label": "Conversion of Series C Preferred Stock [Member]" } } }, "localname": "ConversionOfSeriesCPreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ConversionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price percentage.", "label": "Conversion price" } } }, "localname": "ConversionPricePercentage", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ConvertiblePreferredStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock shares issued.", "label": "Convertible preferred stock shares issued" } } }, "localname": "ConvertiblePreferredStockSharesIssued", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENDV_ConvertiblePreferredStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock shares outstanding.", "label": "Convertible preferred stock, shares outstanding" } } }, "localname": "ConvertiblePreferredStockSharesOutstanding", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENDV_DirectSalesMedicalCareProvidersGrossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Direct Sales Medical Care Providers Gross [Member]" } } }, "localname": "DirectSalesMedicalCareProvidersGrossMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails" ], "xbrltype": "domainItemType" }, "ENDV_EightFixedPromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eight Fixed Promissory Notes [Member]", "label": "Eight Fixed Promissory Notes [Member]" } } }, "localname": "EightFixedPromissoryNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_EighteenFixedRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eighteen Fixed Rate [Member]", "label": "Eighteen Fixed Rate [Member]" } } }, "localname": "EighteenFixedRateMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive Officer Former Executive and Former Operational Manager [Member]", "label": "Executive Officer Former Executive and Former Operational Manager [Member]" } } }, "localname": "ExecutiveOfficerFormerExecutiveAndFormerOperationalManagerMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsByDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation settlements by debt conversion.", "label": "Settlements by debt extinguishment" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsByDebtConversion", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_FairValueOfCommitmentSharesIssuedWithDebt": { "auth_ref": [], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of commitment shares issued with debt", "label": "Fair value of commitment shares issued with debt" } } }, "localname": "FairValueOfCommitmentSharesIssuedWithDebt", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_FixedRatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed Rated Notes [Member]", "label": "Fixed Rated Notes [Member]" } } }, "localname": "FixedRatedNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_FormerPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former President [Member]", "label": "Former President [Member]" } } }, "localname": "FormerPresidentMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_FormerRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Related Party [Member]", "label": "Former Related Party [Member]" } } }, "localname": "FormerRelatedPartyMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_HanoverPortfolioAcquisitionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hanover Portfolio Acquisitions Inc [Member]", "label": "Hanover Portfolio Acquisitions Inc [Member]" } } }, "localname": "HanoverPortfolioAcquisitionsIncMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_IndependentContractorAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Independent Contractor Agreement [Member]", "label": "Independent Contractor Agreement [Member]" } } }, "localname": "IndependentContractorAgreementMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_IndependentContractorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Independent Contractor [Member]", "label": "Independent Contractor [Member]" } } }, "localname": "IndependentContractorMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_InducementLossRelatedToConversionOfPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Inducement loss related to conversion of preferred stock.", "label": "Inducement loss related to conversion of preferred stock", "verboseLabel": "Inducement loss" } } }, "localname": "InducementLossRelatedToConversionOfPreferredStock", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "ENDV_IntellectualPropertyRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intellectual Property Rights [Member]", "label": "Intellectual Property Rights [Member]" } } }, "localname": "IntellectualPropertyRightsMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_IssuanceOfCommonStockToSettleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock to settle debt", "label": "Issuance of common stock to settle debt" } } }, "localname": "IssuanceOfCommonStockToSettleDebt", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_LongTermDebtPastMaturity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term debt past maturity.", "label": "Past due" } } }, "localname": "LongTermDebtPastMaturity", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_LongtermAcquisitionPayableForCostsNotPaidAtClosing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-term acquisition payable for costs not paid at closing.", "label": "Long-term acquisition payable for costs not paid at closing" } } }, "localname": "LongtermAcquisitionPayableForCostsNotPaidAtClosing", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_NineFixedRatePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nine Fixed Rate Promissory Notes [Member]", "label": "Nine Fixed Rate Promissory Notes [Member]" } } }, "localname": "NineFixedRatePromissoryNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_NonRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Related Parties [Member]", "label": "Non Related Parties [Member]" } } }, "localname": "NonRelatedPartiesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "ENDV_NotesPayableIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable issued to non-related parties.", "label": "Notes payable issued" } } }, "localname": "NotesPayableIssued", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_NotesPayableIssuedToNonrelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable issued to non-related parties.", "label": "Notes payable issued to non-related parties", "periodEndLabel": "Notes payable issued to non-related party" } } }, "localname": "NotesPayableIssuedToNonrelatedParties", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_NotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable [Member]", "label": "Notes Payable [Member]" } } }, "localname": "NotesPayableMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OneInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Investor [Member]", "label": "One Investor [Member]" } } }, "localname": "OneInvestorMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OneOfficerAndExecutiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Officer and Executive [Member]", "label": "One Officer and Executive [Member]" } } }, "localname": "OneOfficerAndExecutiveMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OnePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Promissory Notes [Member]", "label": "One Promissory Notes [Member]" } } }, "localname": "OnePromissoryNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OneSignificantCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Significant Customers [Member]", "label": "One Significant Customers [Member]" } } }, "localname": "OneSignificantCustomersMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OneVariableNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Variable Note [Member]", "label": "One Variable Note [Member]" } } }, "localname": "OneVariableNoteMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OriginalDebtDiscountOnConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Original debt discount on convertible notes.", "label": "Original debt discount on convertible notes" } } }, "localname": "OriginalDebtDiscountOnConvertibleNotes", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_PastMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Past Maturity [Member]", "label": "Past Maturity [Member]" } } }, "localname": "PastMaturityMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PatentsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents expiration period.", "label": "Patents expiration period" } } }, "localname": "PatentsExpirationPeriod", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "gYearItemType" }, "ENDV_PaymentToLicensingCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to licensing cost.", "label": "Payment to licensing cost" } } }, "localname": "PaymentToLicensingCost", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_PercentageOfDebtProvision": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of debt provision.", "label": "Percentage of debt provision" } } }, "localname": "PercentageOfDebtProvision", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_PercentageOfProceedsFromAnyPrivatePlacementOrGrossProfits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of proceeds from any private placement or gross profits.", "label": "Percentage of proceeds from any private placement or gross profits" } } }, "localname": "PercentageOfProceedsFromAnyPrivatePlacementOrGrossProfits", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_PreferredSeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series B [Member]", "label": "Preferred Series B [Member]" } } }, "localname": "PreferredSeriesBMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PreferredSeriesCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series C [Member]", "label": "Preferred Series C [Member]" } } }, "localname": "PreferredSeriesCMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PreferredSeriesDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series D [Member]", "label": "Preferred Series D [Member]" } } }, "localname": "PreferredSeriesDMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PreferredStockDesignatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Designated [Member]", "label": "Preferred Stock Designated [Member]" } } }, "localname": "PreferredStockDesignatedMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PrepaymentPenalty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Prepayment Penalty", "label": "Prepayment penalty" } } }, "localname": "PrepaymentPenalty", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_PriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price Range One [Member]", "label": "Price Range One [Member]" } } }, "localname": "PriceRangeOneMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "ENDV_PriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price Range Three [Member]", "label": "Price Range Three [Member]" } } }, "localname": "PriceRangeThreeMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "ENDV_PriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price Range Two [Member]", "label": "Price Range Two [Member]" } } }, "localname": "PriceRangeTwoMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "ENDV_PromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Notes [Member]", "label": "Promissory Notes [Member]" } } }, "localname": "PromissoryNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement [Member]", "label": "Purchase Agreement [Member]" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_RealizedProfitPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Realized profit, percentage", "label": "Realized profit, percentage" } } }, "localname": "RealizedProfitPercentage", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party [Member]", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_RepaymentsOfDeferredCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of deferred compensation.", "label": "Cash repayments of deferred compensation" } } }, "localname": "RepaymentsOfDeferredCompensation", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_RioGrandeNeurosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rio Grande Neurosciences Inc [Member]", "label": "Rio Grande Neurosciences Inc [Member]" } } }, "localname": "RioGrandeNeurosciencesIncMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ScheduleOfPreferredStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of preferred stock [Table text block].", "label": "Schedule of Preferred Stock" } } }, "localname": "ScheduleOfPreferredStockTableTextBlock", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "ENDV_ScheduleOfShareBasedCompensationSharesAuthorizedUnderWarrantPlansByExercisePriceRangeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Share Based Compensation Shares Authorized Under Warrant Plans By Exercise Price Range Table [TextBlock]", "label": "Schedule of Warrants Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderWarrantPlansByExercisePriceRangeTableTextBlock", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "ENDV_ScheduleOfSourceOfRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Source Of Revenue [Table TextBlock]", "label": "Schedule of Sources of Revenue" } } }, "localname": "ScheduleOfSourceOfRevenueTableTextBlock", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "ENDV_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SeriesAAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series AA [Member]", "label": "Series AA [Member]" } } }, "localname": "SeriesAAMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_SeriesAAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series AA Preferred Stock [Member]", "label": "Series AA Preferred Stock [Member]" } } }, "localname": "SeriesAAPreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SeriesCConvertibleRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Redeemable Preferred Stock [Member]", "label": "Series C Convertible Redeemable Preferred Stock [Member]" } } }, "localname": "SeriesCConvertibleRedeemablePreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Preferred Stock [Member]", "label": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Agreement [Member]", "label": "Settlement Agreement [Member]" } } }, "localname": "SettlementAgreementMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SettlementOfDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement of Debt [Member]", "label": "Settlement of Debt [Member]" } } }, "localname": "SettlementOfDebtMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SettlementsOnNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlements on note payable.", "label": "Settlements on note payable" } } }, "localname": "SettlementsOnNotePayable", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_SevenFixedRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seven Fixed Rate [Member]", "label": "Seven Fixed Rate [Member]" } } }, "localname": "SevenFixedRateMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable number.", "label": "Number of warrants exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercises in period weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "verboseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning", "verboseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "durationItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregated intrinsic value, outstanding, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueCancelled", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregated intrinsic value, outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueExercised", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding aggregate intrinsic value granted.", "label": "Aggregated intrinsic value, outstanding, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueGranted", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option exercised in period weighted average exercise price.", "label": "Weighted-average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option forfeited or expired in period weighted average exercise price.", "label": "10. Stock Options and Warrants", "verboseLabel": "Weighted average exercise price, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option grand in period weighted average exercise price.", "label": "Weighted-average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option outstanding weighted average number of share.", "label": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare", "periodEndLabel": "Weighted-average exercise price, exercisable ending balance", "periodStartLabel": "Weighted-average exercise price, exercisable ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareExercisePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share exercise percentage.", "label": "Share exercise price" } } }, "localname": "ShareExercisePercentage", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term (years), beginning outstanding.", "label": "Weighted Average Remaining Contractual Term (years), Outstanding Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Term (years), Granted.", "label": "Weighted average remaining contractual term (years), granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Exercisable Term 2.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2", "verboseLabel": "Weighted average remaining contractual term (years), outstanding beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term cancelled.", "label": "Weighted average remaining contractual term (years), cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term exercised.", "label": "Weighted average remaining contractual term (years), exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SixteenFixedRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixteen Fixed Rate [Member]", "label": "Sixteen Fixed Rate [Member]" } } }, "localname": "SixteenFixedRateMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_StockIssuedDuringPeriodFairValuesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period fair values issued for services.", "label": "Shares issued for common stock for services, value" } } }, "localname": "StockIssuedDuringPeriodFairValuesIssuedForServices", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_StockIssuedDuringPeriodFairValuesSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period fair values shares issued for services.", "label": "Shares issued for common stock for services, shares" } } }, "localname": "StockIssuedDuringPeriodFairValuesSharesIssuedForServices", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENDV_StockIssuedDuringPeriodSharesConnectionWithPromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares connection with promissory notes.", "label": "Issuance of Commitment shares in connection with promissory notes, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConnectionWithPromissoryNotes", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "ENDV_StockIssuedDuringPeriodSharesSettlementOfDebtWithFormerRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares settlement of debt with former related party.", "label": "Common shares issued as settlement of debt with former related party, shares" } } }, "localname": "StockIssuedDuringPeriodSharesSettlementOfDebtWithFormerRelatedParty", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "ENDV_StockIssuedDuringPeriodValueConnectionWithPromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value connection with promissory notes.", "label": "Issuance of Commitment shares in connection with promissory notes" } } }, "localname": "StockIssuedDuringPeriodValueConnectionWithPromissoryNotes", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "ENDV_StockIssuedDuringPeriodValueSettlementOfDebtWithFormerRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued as settlement of debt with former related party.", "label": "Common shares issued as settlement of debt with former related party" } } }, "localname": "StockIssuedDuringPeriodValueSettlementOfDebtWithFormerRelatedParty", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "ENDV_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ENDV_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Receivable [Member]", "label": "Subscription Receivable [Member]" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SuperAASuperVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Super AA Super Voting Preferred Stock [Member]", "label": "Super AA Super Voting Preferred Stock [Member]" } } }, "localname": "SuperAASuperVotingPreferredStockMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ENDV_SupplierMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier [Member]", "label": "Supplier [Member]" } } }, "localname": "SupplierMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ThirteenFixedRatePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thirteen Fixed Rate Promissory Notes [Member]", "label": "Thirteen Fixed Rate Promissory Notes [Member]" } } }, "localname": "ThirteenFixedRatePromissoryNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers [Member]", "label": "Two Customers [Member]" } } }, "localname": "TwoCustomersMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_TwoPromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Promissory Notes [Member]", "label": "Two Promissory Notes [Member]" } } }, "localname": "TwoPromissoryNotesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_TwoSignificantCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Significant Customers [Member]", "label": "Two Significant Customers [Member]" } } }, "localname": "TwoSignificantCustomersMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_UndesignatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated [Member]", "label": "Undesignated [Member]" } } }, "localname": "UndesignatedMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_UnrelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrelated Parties [Member]", "label": "Unrelated Parties [Member]" } } }, "localname": "UnrelatedPartiesMember", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_WarrantTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant term.", "label": "Warrants term" } } }, "localname": "WarrantTerm", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "ENDV_WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price per share exercise price warrant exercisable.", "label": "Weighted average exerice price" } } }, "localname": "WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "ENDV_WorkingCapitalDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficiency.", "label": "Working capital" } } }, "localname": "WorkingCapitalDeficiency", "nsuri": "http://endonovo.com/20221231", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r522", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r522", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r522", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r522", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r522", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r253", "r496", "r562", "r583" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r279", "r280", "r281", "r282", "r359", "r451", "r471", "r482", "r483", "r493", "r506", "r510", "r558", "r576", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r279", "r280", "r281", "r282", "r359", "r451", "r471", "r482", "r483", "r493", "r506", "r510", "r558", "r576", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r253", "r496", "r562", "r583" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r251", "r452", "r494", "r509", "r553", "r554", "r562", "r582" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r251", "r452", "r494", "r509", "r553", "r554", "r562", "r582" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r279", "r280", "r281", "r282", "r351", "r359", "r386", "r387", "r388", "r450", "r451", "r471", "r482", "r483", "r493", "r506", "r510", "r552", "r558", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r279", "r280", "r281", "r282", "r351", "r359", "r386", "r387", "r388", "r450", "r451", "r471", "r482", "r483", "r493", "r506", "r510", "r552", "r558", "r577", "r578", "r579", "r580", "r581" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r218", "r360", "r532", "r547" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r218", "r360", "r532", "r533", "r547" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r550", "r572" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r508" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r254", "r255" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r188", "r189", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r508" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r391", "r392", "r393", "r544", "r545", "r546", "r569" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r390" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r182", "r258", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Provision for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r32", "r42", "r140", "r316" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of note discount and original issue discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r42", "r63", "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r147", "r160", "r178", "r200", "r242", "r245", "r249", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r417", "r419", "r428", "r508", "r556", "r557", "r574" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r175", "r183", "r200", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r417", "r419", "r428", "r508", "r556", "r557", "r574" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r416", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r118", "r119", "r416", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.", "label": "Acquisitions description" } } }, "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r478", "r479", "r508", "r534" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r38", "r44", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, end of year", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r38", "r139" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r179", "r180", "r181", "r200", "r220", "r221", "r223", "r225", "r232", "r233", "r260", "r283", "r286", "r287", "r288", "r292", "r293", "r322", "r323", "r326", "r330", "r337", "r428", "r484", "r531", "r540", "r548" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r154", "r164" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES, note 8" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r71", "r277", "r278", "r481", "r555" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r544", "r545", "r569" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r508" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 2,500,000,000 shares authorized; and 213,227,538 and 74,498,761 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common stock, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r55", "r56", "r136", "r137", "r253", "r480" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r55", "r56", "r136", "r137", "r253", "r477", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r55", "r56", "r136", "r137", "r253", "r480", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r55", "r56", "r136", "r137", "r253" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r53", "r55", "r56", "r57", "r136", "r138", "r480" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r55", "r56", "r136", "r137", "r253", "r480" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "negatedLabel": "Less amounts converted to stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion of notes payable", "verboseLabel": "Conversion of stock amount issued" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r47", "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r47", "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Share conversion" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r47", "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion of notes payable, shares", "verboseLabel": "Conversion of stock shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r4", "r149", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible note", "verboseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r29", "r200", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r428", "r556" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditDerivativeTerm1": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Term of the credit risk derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "CreditDerivativeTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r54", "r253" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r47", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion of notes payable and accrued interest" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r47", "r49" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Shares issued for conversion of notes payable and accrued interest, shares", "terseLabel": "Debt conversion, stock issued", "verboseLabel": "Principal interest convertible" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r47", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion, stock issued" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r75", "r197", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r310", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r148", "r149", "r159", "r204", "r294", "r295", "r296", "r297", "r298", "r300", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r436", "r488", "r489", "r490", "r491", "r492", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r141", "r142", "r294", "r436", "r489", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r19", "r141", "r321", "r436" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r295" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt instrument description" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r204", "r294", "r295", "r296", "r297", "r298", "r300", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r436", "r488", "r489", "r490", "r491", "r492", "r541" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r20", "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt instrument periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r140", "r142", "r559" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedPeriodEndLabel": "Less debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r140", "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Discounts on notes payable current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r25", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred Compensation Equity", "verboseLabel": "Deferred compensation" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r90", "r91" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r42", "r240" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r568" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of derivative liability", "negatedLabel": "Change in fair value of derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r184" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability measurement" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r123", "r124", "r125", "r126", "r128", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Liability" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r348", "r494", "r495", "r496", "r497", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent": { "auth_ref": [ "r143", "r152", "r166", "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.", "label": "Due to officer" } } }, "localname": "DueToOfficersOrStockholdersCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r151", "r166", "r285", "r286", "r287", "r291", "r292", "r293", "r441", "r543" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related parties current and noncurrent" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r191", "r210", "r211", "r212", "r213", "r214", "r219", "r220", "r223", "r224", "r225", "r229", "r423", "r424", "r467", "r469", "r485" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r226", "r227", "r228", "r230" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r201", "r399", "r410" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Income tax computed at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Non-Deductible expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective income tax rate reconciliation, other adjustments, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "negatedLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r80", "r173", "r188", "r189", "r190", "r205", "r206", "r207", "r209", "r215", "r217", "r231", "r261", "r338", "r391", "r392", "r393", "r406", "r407", "r422", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r472", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Variable Debentures Black-Scholes Valuation Assumptions" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r308", "r352", "r353", "r354", "r355", "r356", "r357", "r425", "r447", "r448", "r449", "r489", "r490", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r308", "r352", "r357", "r425", "r447", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r308", "r352", "r357", "r425", "r448", "r489", "r490", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r308", "r352", "r353", "r354", "r355", "r356", "r357", "r425", "r449", "r489", "r490", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Schedule of Balances of Liabilities Measured at Fair Value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r133", "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Schedule of Changes in the Liabilities with Significant Unobservable Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in estimated fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r134" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Settlements by debt extinguishment" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Total", "periodEndLabel": "Derivative liability,ending balance", "periodStartLabel": "Derivative liability, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails", "http://endonovo.com/role/ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r308", "r352", "r353", "r354", "r355", "r356", "r357", "r447", "r448", "r449", "r489", "r490", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r177", "r266" ], "calculation": { "http://endonovo.com/role/ScheduleOfPatentsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r68" ], "calculation": { "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Schedule of Estimated Future Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r68" ], "calculation": { "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r264", "r265", "r266", "r267", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r66", "r453" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://endonovo.com/role/ScheduleOfPatentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents, net", "totalLabel": "Patents net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails", "http://endonovo.com/role/ScheduleOfPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r66" ], "calculation": { "http://endonovo.com/role/ScheduleOfPatentsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Finite-Lived Patents, Gross", "verboseLabel": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing gain (loss) on derivative instruments.", "label": "Gain (Loss) on Derivative Instruments [Member]" } } }, "localname": "GainLossOnDerivativeInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r42", "r73", "r74" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment of debt", "negatedLabel": "Gain on extinguishment of debt", "verboseLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r28", "r200", "r242", "r244", "r248", "r250", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r428", "r487", "r556" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r26", "r146", "r155", "r168", "r242", "r244", "r248", "r250", "r468", "r487" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r269", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r201", "r400", "r401", "r404", "r408", "r411", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income tax examination, description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Interest and penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r202", "r216", "r217", "r241", "r398", "r409", "r412", "r470" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r187", "r396", "r397", "r401", "r402", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective income tax rate reconciliation at federal statutory income tax rate, amount" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r39", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r41" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r41" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r41" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "verboseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r41" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "verboseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r41" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Patents" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/Patents" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r157" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r193", "r195", "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest", "verboseLabel": "Interest payable current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r153", "r165" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r42" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Fair value of equity issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r200", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r418", "r419", "r420", "r428", "r486", "r556", "r574", "r575" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r150", "r163", "r508", "r542", "r551", "r571" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r176", "r200", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r418", "r419", "r420", "r428", "r508", "r556", "r574", "r575" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r4", "r149", "r161", "r307", "r320", "r489", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "verboseLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r72", "r204", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "December 31, 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputOptionVolatilityMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.", "label": "Measurement Input, Option Volatility [Member]" } } }, "localname": "MeasurementInputOptionVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r194" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r38", "r40", "r43" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Cash flow from operations", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r43", "r156", "r167", "r174", "r185", "r186", "r190", "r200", "r208", "r210", "r211", "r212", "r213", "r216", "r217", "r222", "r242", "r244", "r248", "r250", "r260", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r424", "r428", "r487", "r556" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://endonovo.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standard Updates" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansPayable": { "auth_ref": [ "r4", "r149", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Notes and Loans Payable", "periodEndLabel": "Note payable, net" } } }, "localname": "NotesAndLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Conversion of notes payable and accrued interest to common stock" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r4", "r149", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "periodEndLabel": "Notes payable at end of period", "periodStartLabel": "Notes payable at beginning of period" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable, net of discounts of $10,587 and $75,800 as of December 31, 2022 and 2021, respectively", "verboseLabel": "Note payable outstanding" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r12", "r144", "r543" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable \u2013 former related party", "terseLabel": "Notes payable - related parties", "verboseLabel": "Note payable related parties" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r143", "r166", "r543" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes Payable, Related Parties", "periodEndLabel": "Notes payable issued to former related party" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r242", "r244", "r248", "r250", "r487" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r76", "r129" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Vesting strike price" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r51", "r61", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Nature of Business and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r51", "r52", "r61", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Acquisition of patents" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred stock, dividend per share" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r5", "r81", "r82", "r540", "r560" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Liquidation value of preferred stock, per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r198", "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Liquidation value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r322" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r322" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Number of shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r508" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r5", "r81" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r537" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r35" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock and units" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Debt and equity financing" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r36" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from the issuance of notes payable", "verboseLabel": "Proceeds from issuance of note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r192", "r263" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r358", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r145", "r440" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Stock issued during period value new issues" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r358", "r440", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r438", "r439", "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party and former Related Parties Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r539" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Principal payment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayments of notes payable in cash" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r37" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of related party", "negatedLabel": "Repayments on former related party advances" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r87", "r162", "r475", "r476", "r508" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated losses" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r173", "r205", "r206", "r207", "r209", "r215", "r217", "r261", "r391", "r392", "r393", "r406", "r407", "r422", "r472", "r474" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r238", "r239", "r243", "r246", "r247", "r251", "r252", "r253", "r347", "r348", "r452" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "terseLabel": "Recognized net revenues", "verboseLabel": "Total sources of revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfSourcesOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r253", "r549" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Notes Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r92", "r93", "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfBalancesOfLiabilitiesMeasuredAtFairValueDetails", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Patents" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturity Dates of Notes Payable" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r99", "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r77", "r78", "r79", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r179", "r180", "r181", "r232", "r322", "r323", "r324", "r326", "r330", "r335", "r337", "r493", "r531", "r540" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r88", "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r535", "r536", "r561" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r535", "r536", "r561" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Stated value dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Shares, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Shares, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Shares, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r100", "r102" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Number of warrants outstanding", "periodEndLabel": "Shares outstanding, ending balance", "periodStartLabel": "Shares outstanding, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Stock options, exercisable", "periodEndLabel": "Stock option outstanding, exercisable ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Stock option cancelled", "negatedLabel": "Stock option outstanding, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Stock option outstanding, granted", "verboseLabel": "Stock option to officers" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Stock options, outstanding", "periodEndLabel": "Stock option outstanding, ending balance", "periodStartLabel": "Stock option outstanding, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, beginning balance", "periodStartLabel": "Weighted average exercise price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregated intrinsic value, exercisable ending", "periodStartLabel": "Aggregated intrinsic value, outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Stock option vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price, cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r364", "r383", "r384", "r385", "r386", "r389", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices. upper limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Number of exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Number of outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregated intrinsic value, exercisable ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual term (years), outstanding beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Weighted average exercise price exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Weighted average exercise price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Number of shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r179", "r180", "r181", "r200", "r220", "r221", "r223", "r225", "r232", "r233", "r260", "r283", "r286", "r287", "r288", "r292", "r293", "r322", "r323", "r326", "r330", "r337", "r428", "r484", "r531", "r540", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r80", "r173", "r188", "r189", "r190", "r205", "r206", "r207", "r209", "r215", "r217", "r231", "r261", "r338", "r391", "r392", "r393", "r406", "r407", "r422", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r472", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfShare-basedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/PatentsDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r205", "r206", "r207", "r231", "r452" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/PatentsDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Forfeitures" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfVariableDebenturesBlack-scholesValuationAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Number of stock issued, value" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r23", "r80", "r81", "r87", "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares issued for conversion of Preferred Series D to common share, shares", "verboseLabel": "Issuance of conversion of convertible securities, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r5", "r6", "r80", "r81", "r87" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common Shares issued from debt settlement, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common Shares issued for services, shares", "verboseLabel": "Issuance of common stock services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r80", "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for cash, shares", "terseLabel": "Issuance of common stock, shares", "verboseLabel": "Shares as extingusihment" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r80", "r87" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Number of shares issued for debt" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r80", "r87", "r370" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock option outstanding, exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r80", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Shares issued for conversion of Preferred Series D to common share", "verboseLabel": "Issuance of conversion of convertible securities value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r24", "r80", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common Shares issued from debt settlement" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common Shares issued for services", "verboseLabel": "Issuance of common stock value services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r80", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common Stock issued for cash", "terseLabel": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r62", "r508", "r542", "r551", "r571" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r89", "r199", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r338", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Shareholders\u2019 Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r435", "r445" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r435", "r445" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r435", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r435", "r445" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r170", "r171", "r172", "r256", "r257", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r58", "r59", "r60", "r234", "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "http://endonovo.com/role/ScheduleOfWarrantsExercisePriceRangeDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common share outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r219", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 65 0001493152-23-012553-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-012553-xbrl.zip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